Non-Hodgkin Lymphoma Clinical Trial Landscape
Data updated: May 20, 2026
3,837 clinical trials tracked since 2008
Non-Hodgkin Lymphoma (NHL) is a cancer that begins in the lymphatic system, affecting white blood cells called lymphocytes. Understanding the clinical trial landscape is crucial for tracking advancements in NHL treatment. Since 2008, 3,810 NHL trials have been registered, with 1,589 currently active, encompassing studies that are recruiting, enrolling, or active but not recruiting. A significant portion of ongoing research is focused on early-stage trials, with 685 active Phase 1 trials out of 1871 total and 1012 active Phase 2 trials out of 2235 total. Phase 3 trials are less prevalent, with 177 active trials out of 340 total, while Phase 4 confirmatory trials represent a smaller fraction, with 24 active trials out of 52 total. Industry sponsorship is led by Roche, with 18 active trials, followed by Merck and Genmab, each with 15 active trials, AstraZeneca with 13 active trials, and Johnson & Johnson with 10 active trials. The high volume of Phase 1 and 2 trials suggests a strong emphasis on exploring novel therapeutic approaches and refining existing strategies in NHL.
1604 active
/
3837 total (since 2008)
682
Phase 1 Active
1876 total
1031
Phase 2 Active
2259 total
179
Phase 3 Active
342 total
22
Phase 4 Active
50 total
Top Industry Sponsors
Sorted by active Active Done Failed
Roche 17 45 13
Merck 15 10 4
Genmab 15 0 4
AstraZeneca 13 8 4
Johnson & Johnson 10 21 4
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT04269902 RECRUITING
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
National Cancer Institute (NCI) n=247
NCT03844048 ACTIVE NOT RECRUITING
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie n=165
NCT04759586 ACTIVE NOT RECRUITING
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
National Cancer Institute (NCI) n=244
NCT05602194 ACTIVE NOT RECRUITING
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
Children's Oncology Group n=440
NCT03701282 ACTIVE NOT RECRUITING
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
National Cancer Institute (NCI) n=720
+ 337 more Phase 3 trials — see full database below
Non-Hodgkin Lymphoma — Trials Started by Year (last 10 years)
2016 204
2017 208
2018 207
2019 201
2020 202
2021 239
2022 235
2023 251
2024 293
2025 306
2026 176
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Roche 75
Merck 29
Genmab 19
AstraZeneca 25
Johnson & Johnson 35
Bristol-Myers Squibb 68
Regeneron 10
BeOne Medicines 8
AbbVie 26
Eli Lilly 20
Active Trials by Phase
Phase 1 682
Phase 2 1,031
Phase 3 179
Phase 4 22
Enrollment Size Distribution
1-50 2,237
51-200 1,048
201-500 245
501-1k 83
1k+ 24
All Industry Sponsors
Sorted by active Active Done Failed
Roche 17 45 13
Merck 15 10 4
Genmab 15 0 4
AstraZeneca 13 8 4
Johnson & Johnson 10 21 4
Bristol-Myers Squibb 9 42 17
Regeneron 8 1 1
BeOne Medicines 8 0 0
AbbVie 7 14 5
Eli Lilly 7 12 1
Kite, A Gilead Company 7 10 3
Ono Pharmaceutical Co., Ltd. 7 0 0
Acerta Pharma BV 6 6 2
Guangzhou Lupeng Pharmaceutical Company LTD. 6 2 0
Loxo Oncology, Inc. 6 1 0
NCT04269902 RECRUITING
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
National Cancer Institute (NCI) n=247
NCT03844048 ACTIVE NOT RECRUITING
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie n=165
NCT04759586 ACTIVE NOT RECRUITING
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
National Cancer Institute (NCI) n=244
NCT05602194 ACTIVE NOT RECRUITING
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
Children's Oncology Group n=440
NCT03701282 ACTIVE NOT RECRUITING
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
National Cancer Institute (NCI) n=720
NCT07104032 RECRUITING
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Ono Pharmaceutical Co., Ltd. n=132
NCT03984448 ACTIVE NOT RECRUITING
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
National Cancer Institute (NCI) n=363
NCT04799275 ACTIVE NOT RECRUITING
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI) n=422
NCT06337318 RECRUITING
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
National Cancer Institute (NCI) n=600
NCT07479797 RECRUITING
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
Kite, A Gilead Company n=550
NCT06136559 RECRUITING
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Merck Sharp & Dohme LLC n=1,200
NCT06943872 RECRUITING
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Medicines n=630
NCT05018520 RECRUITING
The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
Ruijin Hospital n=640
NCT06230224 ACTIVE NOT RECRUITING
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
Regeneron Pharmaceuticals n=216
NCT05100862 RECRUITING
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
BeiGene n=780
NCT06970743 RECRUITING
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
BeOne Medicines n=150
NCT06973187 RECRUITING
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
BeOne Medicines n=500
NCT05947851 RECRUITING
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Merck Sharp & Dohme LLC n=735
NCT05139017 RECRUITING
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Merck Sharp & Dohme LLC n=290
NCT06742996 RECRUITING
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
BeOne Medicines n=300
NCT01804686 RECRUITING
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Janssen Research & Development, LLC n=700
NCT05976763 RECRUITING
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology n=421
NCT05171647 ACTIVE NOT RECRUITING
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche n=208
NCT06191744 RECRUITING
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Genmab n=1,095
NCT04442022 ACTIVE NOT RECRUITING
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Karyopharm Therapeutics Inc n=501
NCT07570823 NOT YET RECRUITING
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sinocelltech Ltd. n=101
NCT06717347 RECRUITING
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Merck Sharp & Dohme LLC n=1,046
NCT06149286 RECRUITING
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Regeneron Pharmaceuticals n=470
NCT04043494 RECRUITING
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
University Hospital Muenster n=683
NCT07226752 ACTIVE NOT RECRUITING
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
Genmab n=72
NCT06724237 RECRUITING
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Eastern Cooperative Oncology Group n=294
NCT03267433 ACTIVE NOT RECRUITING
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
ECOG-ACRIN Cancer Research Group n=689
NCT04628494 ACTIVE NOT RECRUITING
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Genmab n=484
NCT04712097 ACTIVE NOT RECRUITING
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
Hoffmann-La Roche n=478
NCT06765109 RECRUITING
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Nuvalent Inc. n=450
NCT05429268 ACTIVE NOT RECRUITING
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
Incyte Corporation n=82
NCT03959085 RECRUITING
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Children's Oncology Group n=5,951
NCT02112916 ACTIVE NOT RECRUITING
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
National Cancer Institute (NCI) n=847
NCT03914625 ACTIVE NOT RECRUITING
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
National Cancer Institute (NCI) n=6,720
NCT06084936 RECRUITING
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Hoffmann-La Roche n=182
NCT02443077 ACTIVE NOT RECRUITING
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
National Cancer Institute (NCI) n=94
NCT07562022 NOT YET RECRUITING
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Sinocelltech Ltd. n=93
NCT03737981 ACTIVE NOT RECRUITING
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI) n=465
NCT02048813 ACTIVE NOT RECRUITING
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI) n=529
NCT03206671 ACTIVE NOT RECRUITING
Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
University Hospital Muenster n=650
NCT07342478 RECRUITING
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Newave Pharmaceutical Inc n=306
NCT05045664 RECRUITING
Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody
Heidelberg University n=100
NCT04384484 ACTIVE NOT RECRUITING
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics S.A. n=440
NCT04666038 ACTIVE NOT RECRUITING
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Loxo Oncology, Inc. n=238
NCT03823534 RECRUITING
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
St. Louis University n=60
NCT07215585 RECRUITING
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
AstraZeneca n=420
NCT04094311 RECRUITING
Study of Out of Specification for Tisagenlecleucel
Novartis Pharmaceuticals n=200
NCT04224493 ACTIVE NOT RECRUITING
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Epizyme, Inc. n=555
NCT04404283 ACTIVE NOT RECRUITING
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Seagen, a wholly owned subsidiary of Pfizer n=239
NCT05254743 RECRUITING
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Loxo Oncology, Inc. n=662
NCT06549595 RECRUITING
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
AstraZeneca n=1,018
NCT05888493 ACTIVE NOT RECRUITING
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
Novartis Pharmaceuticals n=109
NCT05605899 ACTIVE NOT RECRUITING
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
Kite, A Gilead Company n=300
NCT05645107 RECRUITING
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Grifols Therapeutics LLC n=386
NCT07516093 NOT YET RECRUITING
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Nurix Therapeutics, Inc. n=620
NCT06561048 RECRUITING
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Corvus Pharmaceuticals, Inc. n=150
NCT06508658 ACTIVE NOT RECRUITING
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Genmab n=379
NCT04408638 ACTIVE NOT RECRUITING
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche n=270
NCT06522737 RECRUITING
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
SecuraBio n=124
NCT07511114 NOT YET RECRUITING
A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping
Ruijin Hospital n=156
NCT07509151 NOT YET RECRUITING
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
AstraZeneca n=420
NCT06470451 RECRUITING
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
Soligenix n=80
NCT04824092 ACTIVE NOT RECRUITING
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
Incyte Corporation n=899
NCT05735834 ACTIVE NOT RECRUITING
Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients
International Extranodal Lymphoma Study Group (IELSG) n=122
NCT07409428 RECRUITING
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Hutchmed n=240
NCT04529772 ACTIVE NOT RECRUITING
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
Acerta Pharma BV n=611
NCT07300514 RECRUITING
Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
Fudan University n=136
NCT01190930 ACTIVE NOT RECRUITING
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Children's Oncology Group n=9,350
NCT07502118 RECRUITING
NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
Health Institutes of Turkey n=40
NCT07493109 RECRUITING
Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
Ou Bai, MD/PHD n=200
NCT04881838 ACTIVE NOT RECRUITING
CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL
Children's Cancer Group, China n=172
NCT05681260 RECRUITING
Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)
Children's Cancer Group, China n=200
NCT02405676 ACTIVE NOT RECRUITING
BNHL-2015 for Children or Adolescents in China
Children's Cancer Group, China n=200
NCT02845882 ACTIVE NOT RECRUITING
LBL-2016 for Children or Adolescents in China
Children's Cancer Group, China n=150
NCT06047080 ACTIVE NOT RECRUITING
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Hoffmann-La Roche n=1,130
NCT04931368 ACTIVE NOT RECRUITING
OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma
Klinikum Stuttgart n=331
NCT05624554 ACTIVE NOT RECRUITING
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Merck Sharp & Dohme LLC n=300
NCT06091254 RECRUITING
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Regeneron Pharmaceuticals n=822
NCT03336333 ACTIVE NOT RECRUITING
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
BeiGene n=590
NCT07188558 RECRUITING
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Lyell Immunopharma, Inc. n=400
NCT07414758 RECRUITING
Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine n=68
NCT05991388 RECRUITING
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
University of Birmingham n=210
NCT03480360 ACTIVE NOT RECRUITING
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center n=21
NCT02972840 ACTIVE NOT RECRUITING
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Acerta Pharma BV n=635
NCT07029217 RECRUITING
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
Memorial Sloan Kettering Cancer Center n=375
NCT06356129 ACTIVE NOT RECRUITING
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
Celgene n=850
NCT07402876 RECRUITING
A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma
Aldeyra Therapeutics, Inc. n=20
NCT07377578 RECRUITING
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD. n=394
NCT06097364 ACTIVE NOT RECRUITING
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
Regeneron Pharmaceuticals n=733
NCT07389616 RECRUITING
A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine n=40
NCT05700448 NOT YET RECRUITING
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
CStone Pharmaceuticals n=150
NCT06091865 RECRUITING
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Regeneron Pharmaceuticals n=904
NCT04965493 ACTIVE NOT RECRUITING
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Loxo Oncology, Inc. n=600
NCT07355283 NOT YET RECRUITING
IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. n=198
NCT05023980 ACTIVE NOT RECRUITING
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Loxo Oncology, Inc. n=309
NCT07348575 ENROLLING BY INVITATION
A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma
Second Affiliated Hospital of Nanchang University n=80
NCT05006482 RECRUITING
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
University of Rochester n=668
NCT06776952 RECRUITING
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Evopoint Biosciences Inc. n=120
NCT06220032 RECRUITING
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
Stichting Hemato-Oncologie voor Volwassenen Nederland n=324
NCT07072585 NOT YET RECRUITING
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
Children's Oncology Group n=1,708
NCT05929222 RECRUITING
Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi
Fondazione Italiana Linfomi - ETS n=190
NCT04680052 ACTIVE NOT RECRUITING
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
Incyte Corporation n=654
NCT06006117 RECRUITING
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
The Lymphoma Academic Research Organisation n=260
NCT01046825 ACTIVE NOT RECRUITING
Mature B-Cell Lymphoma And Leukemia Study III
St. Jude Children's Research Hospital n=128
NCT03117751 ACTIVE NOT RECRUITING
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital n=790
NCT06911502 RECRUITING
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Celgene n=400
NCT06520163 RECRUITING
Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
The Affiliated People's Hospital of Ningbo University n=99
NCT02390869 ACTIVE NOT RECRUITING
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients
Fondazione Italiana Linfomi - ETS n=128
NCT07258680 ENROLLING BY INVITATION
BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas
N.N. Petrov National Medical Research Center of Oncology n=114
NCT07084662 RECRUITING
Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma
Sun Yat-sen University n=80
NCT05770037 RECRUITING
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
Cancer Research UK n=30
NCT07234162 RECRUITING
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Dizal Pharmaceuticals n=218
NCT06929624 RECRUITING
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=280
NCT07220187 NOT YET RECRUITING
Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial
SWOG Cancer Research Network n=102
NCT06072131 RECRUITING
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Acrotech Biopharma Inc. n=504
NCT04459416 ACTIVE NOT RECRUITING
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
Memorial Sloan Kettering Cancer Center n=299
NCT05371093 ACTIVE NOT RECRUITING
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
Kite, A Gilead Company n=231
NCT07202052 RECRUITING
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)
Monash University n=900
NCT07202091 RECRUITING
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)
Monash University n=900
NCT07202078 RECRUITING
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)
Monash University n=900
NCT07202065 RECRUITING
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)
Monash University n=900
NCT03057054 ACTIVE NOT RECRUITING
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Children's Oncology Group n=173
NCT05556720 ACTIVE NOT RECRUITING
Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial
Monash University n=960
NCT04833114 ACTIVE NOT RECRUITING
Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)
GWT-TUD GmbH n=306
NCT04002297 ACTIVE NOT RECRUITING
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
BeOne Medicines n=510
NCT07187960 NOT YET RECRUITING
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. n=228
NCT07185373 NOT YET RECRUITING
Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
Huashan Hospital n=215
NCT07011056 RECRUITING
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Chengdu Zenitar Biomedical Technology Co., Ltd n=390
NCT07178457 NOT YET RECRUITING
Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance
Assistance Publique - Hôpitaux de Paris n=84
NCT06082102 RECRUITING
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd. n=324
NCT06947967 RECRUITING
Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
Chipscreen Biosciences, Ltd. n=224
NCT07168980 RECRUITING
Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents
Children's Cancer Group, China n=87
NCT05058404 ACTIVE NOT RECRUITING
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma
Fondazione Italiana Linfomi - ETS n=605
NCT05409066 ACTIVE NOT RECRUITING
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Genmab n=549
NCT04212013 ACTIVE NOT RECRUITING
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
Memorial Sloan Kettering Cancer Center n=23
NCT04668690 ACTIVE NOT RECRUITING
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=193
NCT04662255 ACTIVE NOT RECRUITING
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
Loxo Oncology, Inc. n=500
NCT06953739 NOT YET RECRUITING
A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL.
The First Affiliated Hospital with Nanjing Medical University n=60
NCT04365036 RECRUITING
A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)
Sun Yat-sen University n=207
NCT06830421 RECRUITING
Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients
University Hospital Freiburg n=340
NCT06792253 RECRUITING
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc n=416
NCT05578976 ACTIVE NOT RECRUITING
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Genmab n=900
NCT06756152 RECRUITING
Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=50
NCT06363994 RECRUITING
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
InnoCare Pharma Inc. n=476
NCT04834024 RECRUITING
MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
Beijing Mabworks Biotech Co., Ltd. n=168
NCT06284122 RECRUITING
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
The Lymphoma Academic Research Organisation n=790
NCT04332822 RECRUITING
A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
Nordic Lymphoma Group n=300
NCT06573645 NOT YET RECRUITING
A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL
Xia Yi n=428
NCT06475820 ACTIVE NOT RECRUITING
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=150
NCT00877214 ACTIVE NOT RECRUITING
Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas
Jurgen Barth n=1,272
NCT06548347 NOT YET RECRUITING
A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma
Shanghai YingLi Pharmaceutical Co. Ltd. n=606
NCT06522555 RECRUITING
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
Ruijin Hospital n=100
NCT06521255 RECRUITING
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd. n=244
NCT06510530 NOT YET RECRUITING
Astragalus for Symptomatic Alleviation in High-grade Lymphoma
Bnai Zion Medical Center n=60
NCT06496308 RECRUITING
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
Ruijin Hospital n=78
NCT03703375 ACTIVE NOT RECRUITING
Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
Celgene n=93
NCT06434467 NOT YET RECRUITING
The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=83
NCT06255795 NOT YET RECRUITING
The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma
Ruijin Hospital n=142
NCT06188676 RECRUITING
Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL
National Research Center for Hematology, Russia n=100
NCT05328258 RECRUITING
Use of GnRHa During Chemotherapy for Fertility Protection
Kenny Rodriguez-Wallberg n=500
NCT05515029 ACTIVE NOT RECRUITING
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=56
NCT05820841 RECRUITING
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
Universität des Saarlandes n=330
NCT05931263 RECRUITING
A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
The First Affiliated Hospital with Nanjing Medical University n=104
NCT05775705 NOT YET RECRUITING
L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH
Beijing Friendship Hospital n=25
NCT05678933 ENROLLING BY INVITATION
AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH
Tianjin Medical University Cancer Institute and Hospital n=200
NCT04442412 RECRUITING
Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy
Fondazione Italiana Linfomi - ETS n=430
NCT05205902 NOT YET RECRUITING
TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides
Assistance Publique - Hôpitaux de Paris n=78
NCT04670029 RECRUITING
Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line
Weprom n=186
NCT02836158 RECRUITING
Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL
Navy General Hospital, Beijing n=100
NCT02657785 RECRUITING
Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy
Navy General Hospital, Beijing n=100
NCT03647072 RECRUITING
PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy
Sherief Abd-Elsalam n=60
NCT02858258 RECRUITING
ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma
Prof. Dr. M. Dreyling (co-chairman) n=870
NCT03274492 COMPLETED
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche n=1,000
NCT01231412 COMPLETED
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center n=174
NCT06125028 TERMINATED
[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma
Pentixapharm AG n=8
NCT03593018 COMPLETED
Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL
The Lymphoma Academic Research Organisation n=86
NCT03570892 COMPLETED
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
Novartis Pharmaceuticals n=330
NCT04231448 COMPLETED
Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL
Chipscreen Biosciences, Ltd. n=423
NCT05051891 COMPLETED
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd. n=3
NCT06313996 WITHDRAWN
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT02947347 COMPLETED
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Pharmacyclics LLC. n=445
NCT02730299 COMPLETED
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
Gamida Cell ltd n=125
NCT04214444 COMPLETED
Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab
University Hospital, Tours n=26
NCT01516580 COMPLETED
Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients
Gustave Roussy, Cancer Campus, Grand Paris n=482
NCT04182204 COMPLETED
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche n=270
NCT02881086 COMPLETED
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
Goethe University n=1,023
NCT03391466 COMPLETED
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Kite, A Gilead Company n=359
NCT02367040 COMPLETED
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Bayer n=458
NCT01650701 COMPLETED
A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma
The Lymphoma Academic Research Organisation n=1,030
NCT03575351 COMPLETED
A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas
Celgene n=184
NCT03112174 COMPLETED
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
Pharmacyclics LLC. n=366
NCT02763319 COMPLETED
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Incyte Corporation n=453
NCT01996865 COMPLETED
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Celgene n=503
NCT02320292 TERMINATED
Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma
Mayo Clinic n=20
NCT01776840 COMPLETED
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
Janssen Research & Development, LLC n=523
NCT01974440 COMPLETED
A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma
Janssen Research & Development, LLC n=403
NCT01476787 COMPLETED
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Celgene n=1,030
NCT01303887 COMPLETED
A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients
University of Liverpool n=680
NCT03734016 COMPLETED
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
BeiGene n=652
NCT01865110 COMPLETED
R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL
The Lymphoma Academic Research Organisation n=623
NCT05664217 TERMINATED
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Nektar Therapeutics n=15
NCT01855750 COMPLETED
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Janssen Research & Development, LLC n=838
NCT05181540 TERMINATED
A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation
Angiocrine Bioscience n=130
NCT03366272 COMPLETED
Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients
Universität des Saarlandes n=348
NCT03263026 COMPLETED
Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™
Denovo Biopharma LLC n=256
NCT01478542 COMPLETED
OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients with CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine
Universität des Saarlandes n=1,152
NCT02626455 TERMINATED
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Bayer n=551
NCT02406092 COMPLETED
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
Hoffmann-La Roche n=139
NCT01871727 COMPLETED
A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
Eisai Inc. n=112
NCT04745832 TERMINATED
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
MEI Pharma, Inc. n=82
NCT03595800 COMPLETED
Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen
Institut Paoli-Calmettes n=9
NCT01724346 COMPLETED
Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Pharmacyclics LLC. n=269
NCT03078855 COMPLETED
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
Jonathan Friedberg n=211
NCT03406156 COMPLETED
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
AbbVie n=120
NCT00678327 COMPLETED
Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma
University College, London n=1,202
NCT01728805 COMPLETED
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Kyowa Kirin, Inc. n=372
NCT03801525 TERMINATED
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
TG Therapeutics, Inc. n=277
NCT03959241 COMPLETED
TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)
Medical College of Wisconsin n=431
NCT03265574 COMPLETED
PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma?
South Tees Hospitals NHS Foundation Trust n=111
NCT03976102 COMPLETED
Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma
Dr. Reddy's Laboratories Limited n=317
NCT04361279 COMPLETED
A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL
Shanghai Institute Of Biological Products n=421
NCT02204982 TERMINATED
Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
SecuraBio n=13
NCT02049515 COMPLETED
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07
SecuraBio n=99
NCT02004522 COMPLETED
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
SecuraBio n=319
NCT01951885 COMPLETED
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Case Comprehensive Cancer Center n=101
NCT02536300 TERMINATED
Dose Optimization Study of Idelalisib in Follicular Lymphoma
Gilead Sciences n=96
NCT02285062 COMPLETED
Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
Celgene n=570
NCT01596621 COMPLETED
A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment
Teva Branded Pharmaceutical Products R&D, Inc. n=102
NCT05431179 WITHDRAWN
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Oncternal Therapeutics, Inc
NCT03372837 COMPLETED
Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma
SymBio Pharmaceuticals n=40
NCT02942173 COMPLETED
CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=150
NCT04236141 TERMINATED
A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).
Hoffmann-La Roche n=42
NCT01938001 COMPLETED
Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Celgene n=358
NCT04021082 WITHDRAWN
CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
Portola Pharmaceuticals
NCT01796002 COMPLETED
Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
The Lymphoma Academic Research Organisation n=421
NCT02303119 COMPLETED
Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)
The Lymphoma Academic Research Organisation n=221
NCT02703272 TERMINATED
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC n=72
NCT02811783 TERMINATED
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
Elorac, Inc. n=59
NCT02747043 COMPLETED
Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab
Amgen n=256
NCT01332968 COMPLETED
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Hoffmann-La Roche n=1,401
NCT02793583 TERMINATED
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
TG Therapeutics, Inc. n=710
NCT04796922 WITHDRAWN
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
Incyte Corporation
NCT02063685 COMPLETED
Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma
Fondazione Italiana Linfomi - ETS n=807
NCT01805557 COMPLETED
Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.
Fondazione Italiana Linfomi - ETS n=108
NCT01239797 COMPLETED
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb n=646
NCT02787239 COMPLETED
Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL
Shanghai Henlius Biotech n=407
NCT04849715 WITHDRAWN
A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
Incyte Corporation
NCT02448381 COMPLETED
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Soligenix n=169
NCT02566395 COMPLETED
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies
Northwell Health n=10
NCT02369653 COMPLETED
A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
Bristol-Myers Squibb n=512
NCT01510184 TERMINATED
Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy
Spectrum Pharmaceuticals, Inc n=79
NCT01597778 COMPLETED
Double Cord Versus Haploidentical (BMT CTN 1101)
Medical College of Wisconsin n=368
NCT01777152 COMPLETED
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Seagen Inc. n=452
NCT01321541 COMPLETED
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
CTI BioPharma n=312
NCT01420679 TERMINATED
Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients
Spectrum Pharmaceuticals, Inc n=21
NCT01662102 TERMINATED
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
Spectrum Pharmaceuticals, Inc n=1
NCT01122472 COMPLETED
Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP
The Lymphoma Academic Research Organisation n=650
NCT00967343 TERMINATED
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
Kiadis Pharma n=40
NCT01419665 COMPLETED
GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)
Sandoz n=629
NCT02128061 COMPLETED
Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+
The Lymphoma Academic Research Organisation n=250
NCT02260804 COMPLETED
To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma
Celltrion n=258
NCT02576275 WITHDRAWN
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
SecuraBio
NCT02910063 COMPLETED
Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
Amgen n=41
NCT01578499 COMPLETED
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
Millennium Pharmaceuticals, Inc. n=131
NCT04671420 WITHDRAWN
Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma.
Shanghai Henlius Biotech
NCT02951156 TERMINATED
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Pfizer n=29
NCT02809053 COMPLETED
A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma
Archigen Biotech Limited n=315
NCT02264574 COMPLETED
A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Pharmacyclics LLC. n=229
NCT01889069 COMPLETED
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
Hoffmann-La Roche n=159
NCT02867566 COMPLETED
A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
Innovent Biologics (Suzhou) Co. Ltd. n=420
NCT00750009 COMPLETED
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial
Case Comprehensive Cancer Center n=583
NCT01285765 COMPLETED
Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients
The Lymphoma Academic Research Organisation n=650
NCT01854567 COMPLETED
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
Mesoblast, Ltd. n=49
NCT01077518 TERMINATED
Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy
Novartis Pharmaceuticals n=346
NCT01611090 COMPLETED
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Janssen Research & Development, LLC n=578
NCT02162771 COMPLETED
To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan
Celltrion n=140
NCT01059630 COMPLETED
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Genentech, Inc. n=413
NCT03670901 TERMINATED
A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
JHL Biotech, Inc. n=8
NCT01578707 COMPLETED
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Pharmacyclics LLC. n=391
NCT01197560 COMPLETED
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Celgene n=111
NCT01021423 TERMINATED
A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).
Celgene n=9
NCT03349333 COMPLETED
A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL
Mundipharma (China) Pharmaceutical Co. Ltd n=85
NCT02268045 COMPLETED
Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma
mAbxience Research S.L. n=272
NCT01305200 COMPLETED
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
Children's Oncology Group n=226
NCT01461928 COMPLETED
A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab
Hoffmann-La Roche n=692
NCT02213263 COMPLETED
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
Pfizer n=394
NCT01287741 TERMINATED
A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Hoffmann-La Roche n=1,418
NCT00928018 COMPLETED
Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma
Dana-Farber Cancer Institute n=139
NCT01232556 TERMINATED
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Pfizer n=338
NCT01987505 COMPLETED
MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma
Hoffmann-La Roche n=140
NCT03355768 WITHDRAWN
Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL
Jennifer Amengual
NCT01200758 COMPLETED
A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma
Hoffmann-La Roche n=410
NCT01289223 TERMINATED
A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.
Mundipharma Research Limited n=88
NCT01482962 COMPLETED
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Millennium Pharmaceuticals, Inc. n=271
NCT01973387 COMPLETED
A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma
Janssen Research & Development, LLC n=160
NCT00722137 COMPLETED
Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma
Millennium Pharmaceuticals, Inc. n=487
NCT01098656 TERMINATED
Lenalidomide Maintenance Post-debulking in Advanced CTCL
European Organisation for Research and Treatment of Cancer - EORTC n=21
NCT01200589 TERMINATED
Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy
Novartis Pharmaceuticals n=438
NCT02359162 TERMINATED
Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage
Sun Yat-sen University n=50
NCT00921414 COMPLETED
Mantel Cell Lymphoma Efficacy of Rituximab Maintenance
French Innovative Leukemia Organisation n=299
NCT02366663 TERMINATED
BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL
City of Hope Medical Center n=3
NCT01659099 TERMINATED
GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma
The Lymphoma Academic Research Organisation n=671
NCT00877006 COMPLETED
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
Teva Branded Pharmaceutical Products R&D, Inc. n=447
NCT01724021 COMPLETED
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a
Hoffmann-La Roche n=743
NCT01646021 COMPLETED
Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
Janssen Research & Development, LLC n=280
NCT01722487 COMPLETED
Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL
Pharmacyclics LLC. n=269
NCT01701232 COMPLETED
Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma
Biocad n=174
NCT01649856 COMPLETED
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche n=572
NCT00516503 COMPLETED
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
Alliance for Clinical Trials in Oncology n=208
NCT01500083 COMPLETED
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia
Lundbeck Canada Inc. n=90
NCT00714259 TERMINATED
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
University of Alabama at Birmingham n=5
NCT00790036 COMPLETED
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Novartis Pharmaceuticals n=742
NCT00719472 COMPLETED
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)
Genentech, Inc. n=451
NCT00755040 COMPLETED
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Vanderbilt-Ingram Cancer Center n=164
NCT00719563 COMPLETED
American Ginseng in Treating Patients With Fatigue Caused by Cancer
Alliance for Clinical Trials in Oncology n=364
NCT02417129 TERMINATED
BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma
Boehringer Ingelheim n=2
NCT00920153 TERMINATED
Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
French Innovative Leukemia Organisation n=442
NCT02735876 WITHDRAWN
A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Acerta Pharma BV
NCT01324596 COMPLETED
A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib
University Hospital Southampton NHS Foundation Trust n=1,132
NCT01014208 COMPLETED
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
GlaxoSmithKline n=447
NCT00838357 COMPLETED
A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).
Genzyme, a Sanofi Company n=118
NCT01767714 COMPLETED
Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation
Sanofi n=100
NCT00854568 COMPLETED
Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL
Fudan University n=398
NCT01073163 COMPLETED
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
Cephalon n=54
NCT01355783 WITHDRAWN
A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma
Eisai Inc.
NCT01110824 COMPLETED
Prevention of Left Ventricular Dysfunction During Chemotherapy
Hospital Clinic of Barcelona n=90
NCT00799461 COMPLETED
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium n=1,337
NCT00782145 COMPLETED
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
Tufts Medical Center n=198
NCT01016548 COMPLETED
Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy
University Health Network, Toronto n=42
NCT06649812 RECRUITING
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
National Cancer Institute (NCI)
NCT02465060 ACTIVE NOT RECRUITING
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
NCT05886036 RECRUITING
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
National Cancer Institute (NCI)
NCT04840602 RECRUITING
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
NCT07299149 RECRUITING
Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
NCT07517705 NOT YET RECRUITING
MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma
University of Nebraska
NCT07583810 NOT YET RECRUITING
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
City of Hope Medical Center
NCT07069699 RECRUITING
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
National Cancer Institute (NCI)
NCT07259070 RECRUITING
Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
NCT07387471 RECRUITING
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
AbbVie
NCT07584889 RECRUITING
Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
Shenzhen University General Hospital
NCT06504199 ACTIVE NOT RECRUITING
Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
NCT07061951 RECRUITING
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
NCT06390865 ACTIVE NOT RECRUITING
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)
National Cancer Institute (NCI)
NCT06400225 ACTIVE NOT RECRUITING
Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)
National Cancer Institute (NCI)
NCT07003295 RECRUITING
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
National Cancer Institute (NCI)
NCT06385496 ACTIVE NOT RECRUITING
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)
National Cancer Institute (NCI)
NCT02978625 ACTIVE NOT RECRUITING
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
NCT03269669 ACTIVE NOT RECRUITING
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Cancer Institute (NCI)
NCT03213652 ACTIVE NOT RECRUITING
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT03504644 ACTIVE NOT RECRUITING
Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
ECOG-ACRIN Cancer Research Group
NCT07261163 RECRUITING
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
NCT07524530 NOT YET RECRUITING
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
National Cancer Institute (NCI)
NCT06514794 RECRUITING
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Wugen, Inc.
NCT01703949 ACTIVE NOT RECRUITING
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
University of Washington
NCT06588478 RECRUITING
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
NCT03210714 ACTIVE NOT RECRUITING
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT07582159 NOT YET RECRUITING
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
City of Hope Medical Center
NCT03038672 ACTIVE NOT RECRUITING
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
National Cancer Institute (NCI)
NCT04728893 RECRUITING
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Merck Sharp & Dohme LLC
NCT05006716 RECRUITING
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
BeOne Medicines
NCT05453396 RECRUITING
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
University of Washington
NCT07554898 RECRUITING
Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma
Zhejiang Cancer Hospital
NCT02506933 ACTIVE NOT RECRUITING
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
City of Hope Medical Center
NCT05672251 RECRUITING
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
NCT06634589 RECRUITING
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
BeOne Medicines
NCT06400251 ACTIVE NOT RECRUITING
Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)
National Cancer Institute (NCI)
NCT07578077 NOT YET RECRUITING
Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
City of Hope Medical Center
NCT07225985 RECRUITING
Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
NCT04439110 ACTIVE NOT RECRUITING
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
National Cancer Institute (NCI)
NCT05421663 RECRUITING
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
NCT06890884 RECRUITING
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Merck Sharp & Dohme LLC
NCT06768905 RECRUITING
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
University of Texas Southwestern Medical Center
NCT05718869 ACTIVE NOT RECRUITING
Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study
City of Hope Medical Center
NCT07123454 RECRUITING
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
AstraZeneca
NCT07514169 RECRUITING
The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL
Ruijin Hospital
NCT05963074 RECRUITING
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
Janssen Research & Development, LLC
NCT03258567 RECRUITING
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
National Cancer Institute (NCI)
NCT07572175 NOT YET RECRUITING
Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity
Icahn School of Medicine at Mount Sinai
NCT06242834 ACTIVE NOT RECRUITING
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Northwestern University
NCT04439279 ACTIVE NOT RECRUITING
Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)
National Cancer Institute (NCI)
NCT07029737 RECRUITING
A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
AstraZeneca
NCT04439266 ACTIVE NOT RECRUITING
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
National Cancer Institute (NCI)
NCT05826535 RECRUITING
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma, Inc.
NCT06874946 RECRUITING
Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
Peking University People's Hospital
NCT04439331 ACTIVE NOT RECRUITING
Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)
National Cancer Institute (NCI)
NCT04439344 ACTIVE NOT RECRUITING
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
National Cancer Institute (NCI)
NCT03474744 ACTIVE NOT RECRUITING
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients
Christian Buske
NCT06043323 RECRUITING
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
NCT07164469 NOT YET RECRUITING
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
M.D. Anderson Cancer Center
NCT06500273 RECRUITING
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Allogene Therapeutics
NCT07567014 NOT YET RECRUITING
Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS
NYU Langone Health
NCT05092451 RECRUITING
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
NCT02227251 ACTIVE NOT RECRUITING
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
NCT07569965 NOT YET RECRUITING
Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL
Miltenyi Biomedicine GmbH
NCT05852717 RECRUITING
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Dipenkumar Modi
NCT05283720 RECRUITING
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
NCT06784726 RECRUITING
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
University of Washington
NCT06045247 RECRUITING
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
M.D. Anderson Cancer Center
NCT06357988 ACTIVE NOT RECRUITING
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
National Cancer Institute (NCI)
NCT04439175 ACTIVE NOT RECRUITING
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
National Cancer Institute (NCI)
NCT04439123 ACTIVE NOT RECRUITING
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
National Cancer Institute (NCI)
NCT06400238 ACTIVE NOT RECRUITING
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)
National Cancer Institute (NCI)
NCT05660967 ACTIVE NOT RECRUITING
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
Genmab
NCT06564038 RECRUITING
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
AstraZeneca
NCT06112847 ACTIVE NOT RECRUITING
Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma
City of Hope Medical Center
NCT05490771 ACTIVE NOT RECRUITING
Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
National Cancer Institute (NCI)
NCT04663347 ACTIVE NOT RECRUITING
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Genmab
NCT07566377 RECRUITING
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Memorial Sloan Kettering Cancer Center
NCT04623541 ACTIVE NOT RECRUITING
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Genmab
NCT05529069 RECRUITING
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
M.D. Anderson Cancer Center
NCT04870944 RECRUITING
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Children's Oncology Group
NCT05956041 RECRUITING
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
University of Michigan Rogel Cancer Center
NCT03625037 ACTIVE NOT RECRUITING
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Genmab
NCT04115631 ACTIVE NOT RECRUITING
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
ECOG-ACRIN Cancer Research Group
NCT04542824 ACTIVE NOT RECRUITING
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
Genmab
NCT02029443 ACTIVE NOT RECRUITING
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Acerta Pharma BV
NCT04284774 ACTIVE NOT RECRUITING
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
NCT05952024 RECRUITING
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
AstraZeneca
NCT05848765 RECRUITING
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
University of Birmingham
NCT02332668 RECRUITING
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Merck Sharp & Dohme LLC
NCT04978584 ACTIVE NOT RECRUITING
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
M.D. Anderson Cancer Center
NCT03155620 ACTIVE NOT RECRUITING
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
NCT01318317 ACTIVE NOT RECRUITING
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT04851119 RECRUITING
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Oncology Group
NCT06390852 ACTIVE NOT RECRUITING
Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)
National Cancer Institute (NCI)
NCT04439227 ACTIVE NOT RECRUITING
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
National Cancer Institute (NCI)
NCT07555431 NOT YET RECRUITING
Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection
Carlos Brites
NCT05533775 RECRUITING
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
NCT04195555 ACTIVE NOT RECRUITING
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT02981628 RECRUITING
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Children's Oncology Group
NCT04320888 ACTIVE NOT RECRUITING
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
NCT07249905 RECRUITING
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
ModeX Therapeutics, An OPKO Health Company
NCT06364423 RECRUITING
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
National Cancer Institute (NCI)
NCT06360575 ACTIVE NOT RECRUITING
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)
National Cancer Institute (NCI)
NCT05907759 RECRUITING
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
National Cancer Institute (NCI)
NCT05182957 RECRUITING
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
The First Affiliated Hospital of Soochow University
NCT06390319 RECRUITING
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
St. Jude Children's Research Hospital
NCT06533748 RECRUITING
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
NCT07283679 RECRUITING
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
NCT01856192 ACTIVE NOT RECRUITING
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI)
NCT06594939 NOT YET RECRUITING
Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
Medical College of Wisconsin
NCT03075696 ACTIVE NOT RECRUITING
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Hoffmann-La Roche
NCT03964090 ACTIVE NOT RECRUITING
Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
National Cancer Institute (NCI)
NCT06765317 RECRUITING
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT04546620 ACTIVE NOT RECRUITING
Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)
University Hospital Southampton NHS Foundation Trust
NCT01849263 ACTIVE NOT RECRUITING
Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma
National Cancer Institute (NCI)
NCT04844866 RECRUITING
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Miltenyi Biomedicine GmbH
NCT04439136 ACTIVE NOT RECRUITING
Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)
National Cancer Institute (NCI)
NCT07075328 RECRUITING
A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma
Otsuka Medical Devices Co., Ltd. Japan
NCT07557056 NOT YET RECRUITING
Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Jennifer Woyach
NCT04439253 ACTIVE NOT RECRUITING
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
National Cancer Institute (NCI)
NCT07555470 NOT YET RECRUITING
Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
NCT04002947 RECRUITING
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
National Cancer Institute (NCI)
NCT06390826 ACTIVE NOT RECRUITING
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
National Cancer Institute (NCI)
NCT00972478 ACTIVE NOT RECRUITING
Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
NCT03863184 ACTIVE NOT RECRUITING
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
Weill Medical College of Cornell University
NCT01500733 ACTIVE NOT RECRUITING
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Heart, Lung, and Blood Institute (NHLBI)
NCT07302347 RECRUITING
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
Merck Sharp & Dohme LLC
NCT07554482 NOT YET RECRUITING
Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma
Beijing Tongren Hospital
NCT07082686 RECRUITING
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Beijing InnoCare Pharma Tech Co., Ltd.
NCT04570423 RECRUITING
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Spectrum Pharmaceuticals, Inc
NCT06806033 RECRUITING
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
NCT07552324 NOT YET RECRUITING
Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP
Ruijin Hospital
NCT04989803 RECRUITING
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
Kite, A Gilead Company
NCT05253118 ACTIVE NOT RECRUITING
Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)
Seoul National University Hospital
NCT07550855 NOT YET RECRUITING
Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma
Sun Yat-sen University
NCT06249191 RECRUITING
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
OHSU Knight Cancer Institute
NCT00840047 ACTIVE NOT RECRUITING
Methionine PET/CT Studies In Patients With Cancer
St. Jude Children's Research Hospital
NCT04414163 ACTIVE NOT RECRUITING
A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
ImmuneOncia Therapeutics Inc.
NCT06050694 RECRUITING
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
University Health Network, Toronto
NCT07365306 RECRUITING
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
NCT04627753 RECRUITING
Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.
Kim, Seok Jin
NCT06385483 ACTIVE NOT RECRUITING
Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)
National Cancer Institute (NCI)
NCT06552559 RECRUITING
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma
Samsung Medical Center
NCT04989621 RECRUITING
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
Sun Yat-sen University
NCT06263491 RECRUITING
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
M.D. Anderson Cancer Center
NCT05245656 RECRUITING
A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma
Kim, Seok Jin
NCT03213704 ACTIVE NOT RECRUITING
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT07097363 RECRUITING
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
University of Washington
NCT03698994 ACTIVE NOT RECRUITING
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT05463263 RECRUITING
A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
Step Pharma, SAS
NCT02974647 RECRUITING
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT06839053 RECRUITING
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Fred Hutchinson Cancer Center
NCT07461831 ACTIVE NOT RECRUITING
CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma
Beijing Tongren Hospital
NCT03523975 RECRUITING
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
City of Hope Medical Center
NCT06948786 RECRUITING
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
University of Washington
NCT06386315 RECRUITING
Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma
Mayo Clinic
NCT07545603 RECRUITING
Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma
Evopoint Biosciences Inc.
NCT05507541 ACTIVE NOT RECRUITING
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Mayo Clinic
NCT06137144 RECRUITING
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
AstraZeneca
NCT07542678 NOT YET RECRUITING
Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With a Glofitamab-based Induction and Consolidation Concept
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NCT04939272 ACTIVE NOT RECRUITING
Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
City of Hope Medical Center
NCT05969860 RECRUITING
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
NCT02436707 ACTIVE NOT RECRUITING
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Canadian Cancer Trials Group
NCT05909059 RECRUITING
CAR T-cell Therapy in Patients With Renal Dysfunction
Northside Hospital, Inc.
NCT03223610 RECRUITING
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
National Cancer Institute (NCI)
NCT07538180 ACTIVE NOT RECRUITING
Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL
Sun Yat-sen University
NCT04544592 RECRUITING
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
University of Colorado, Denver
NCT06252675 RECRUITING
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
University of California, San Francisco
NCT04984837 RECRUITING
Study of Lacutamab in Peripheral T-cell Lymphoma
The Lymphoma Academic Research Organisation
NCT03932331 ACTIVE NOT RECRUITING
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
AstraZeneca
NCT07535710 NOT YET RECRUITING
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
Shanghai Jiao Tong University School of Medicine
NCT03960840 ACTIVE NOT RECRUITING
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis Pharmaceuticals
NCT07162181 ACTIVE NOT RECRUITING
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Eli Lilly and Company
NCT05475925 RECRUITING
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Dren Bio
NCT07453095 NOT YET RECRUITING
Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy
Fondazione Italiana Linfomi - ETS
NCT05294731 RECRUITING
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
BeiGene
NCT07535762 NOT YET RECRUITING
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
Shanghai Jiao Tong University School of Medicine
NCT07224100 RECRUITING
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
University of Washington
NCT03934372 RECRUITING
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Biosciences International Sàrl
NCT03418038 RECRUITING
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
NCT04404088 ACTIVE NOT RECRUITING
Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma
M.D. Anderson Cancer Center
NCT06522386 ACTIVE NOT RECRUITING
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
M.D. Anderson Cancer Center
NCT04189757 ACTIVE NOT RECRUITING
Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma
M.D. Anderson Cancer Center
NCT06378190 RECRUITING
Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology
Instituto de Investigación Biomédica de Salamanca
NCT03328078 RECRUITING
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
NCT07523737 RECRUITING
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Beijing Tongren Hospital
NCT06839456 RECRUITING
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Children's Hospital of Philadelphia
NCT06218602 RECRUITING
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
M.D. Anderson Cancer Center
NCT04491370 RECRUITING
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
New York Medical College
NCT07356245 RECRUITING
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Jonathan Brammer
NCT02106988 ACTIVE NOT RECRUITING
Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma
M.D. Anderson Cancer Center
NCT05996185 RECRUITING
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Yale University
NCT03192397 ACTIVE NOT RECRUITING
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
NCT06698822 RECRUITING
A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA
M.D. Anderson Cancer Center
NCT06583083 RECRUITING
Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma
Sun Yat-sen University
NCT05998642 RECRUITING
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Canadian Cancer Trials Group
NCT07221500 RECRUITING
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Nurix Therapeutics, Inc.
NCT02514083 ACTIVE NOT RECRUITING
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
National Heart, Lung, and Blood Institute (NHLBI)
NCT04169737 RECRUITING
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
NCT06090539 RECRUITING
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Bristol-Myers Squibb
NCT06395103 RECRUITING
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Merck Sharp & Dohme LLC
NCT04439292 ACTIVE NOT RECRUITING
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
National Cancer Institute (NCI)
NCT01589302 ACTIVE NOT RECRUITING
PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
Kami Maddocks, MD
NCT06308822 ACTIVE NOT RECRUITING
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)
National Cancer Institute (NCI)
NCT04439201 ACTIVE NOT RECRUITING
Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
National Cancer Institute (NCI)
NCT04450173 ACTIVE NOT RECRUITING
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
University of California, Davis
NCT04439318 ACTIVE NOT RECRUITING
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
National Cancer Institute (NCI)
NCT07523555 RECRUITING
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Beijing Biotech
NCT07520006 NOT YET RECRUITING
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Nurix Therapeutics, Inc.
NCT07525466 RECRUITING
Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)
Beijing Tongren Hospital
NCT06362369 RECRUITING
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
NCT04560322 RECRUITING
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Massachusetts General Hospital
NCT06390839 ACTIVE NOT RECRUITING
Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)
National Cancer Institute (NCI)
NCT07526597 NOT YET RECRUITING
Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors
UNC Lineberger Comprehensive Cancer Center
NCT03849651 ACTIVE NOT RECRUITING
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
NCT06303167 ACTIVE NOT RECRUITING
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
National Cancer Institute (NCI)
NCT04439357 ACTIVE NOT RECRUITING
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
National Cancer Institute (NCI)
NCT07519772 RECRUITING
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Merck Sharp & Dohme LLC
NCT03478514 ACTIVE NOT RECRUITING
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
Alliance Foundation Trials, LLC.
NCT07319676 RECRUITING
Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas
National University Hospital, Singapore
NCT06314334 RECRUITING
Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma
Fudan University
NCT05183854 RECRUITING
Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial
University of Utah
NCT03697512 ACTIVE NOT RECRUITING
MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
International Extranodal Lymphoma Study Group (IELSG)
NCT01661881 ACTIVE NOT RECRUITING
Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma
Dana-Farber Cancer Institute
NCT05798156 ACTIVE NOT RECRUITING
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NCT04661020 RECRUITING
CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
Zhejiang University
NCT05303792 ACTIVE NOT RECRUITING
Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
Alliance for Clinical Trials in Oncology
NCT06756308 RECRUITING
A Study of Enasidenib in People With T-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT04417166 ACTIVE NOT RECRUITING
Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma
International Extranodal Lymphoma Study Group (IELSG)
NCT06108232 ACTIVE NOT RECRUITING
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
M.D. Anderson Cancer Center
NCT05735717 RECRUITING
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT04722172 ACTIVE NOT RECRUITING
A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL
Memorial Sloan Kettering Cancer Center
NCT04646395 ACTIVE NOT RECRUITING
Study of Acalabrutinib and Tafasitamab in MZL Patients
International Extranodal Lymphoma Study Group (IELSG)
NCT03533283 ACTIVE NOT RECRUITING
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
NCT03678883 ACTIVE NOT RECRUITING
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
NCT06760156 RECRUITING
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
H. Lee Moffitt Cancer Center and Research Institute
NCT07507318 NOT YET RECRUITING
Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
Rong Tao
NCT05994235 ACTIVE NOT RECRUITING
Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
Weill Medical College of Cornell University
NCT07284433 RECRUITING
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
AvenCell Therapeutics, Inc.
NCT02693535 RECRUITING
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
American Society of Clinical Oncology
NCT03703050 ACTIVE NOT RECRUITING
Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)
Gustave Roussy, Cancer Campus, Grand Paris
NCT07480863 ACTIVE NOT RECRUITING
Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT07506668 NOT YET RECRUITING
RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
Affiliated Hospital of Nantong University
NCT05257018 RECRUITING
R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
Fudan University
NCT04512534 RECRUITING
Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma
Fudan University
NCT07508605 RECRUITING
Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma
Shenzhen University General Hospital
NCT07451652 RECRUITING
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Hospital Universitario Dr. Jose E. Gonzalez
NCT07059650 RECRUITING
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
Dizal Pharmaceuticals
NCT06104592 RECRUITING
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
H. Lee Moffitt Cancer Center and Research Institute
NCT07502872 NOT YET RECRUITING
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Brown University
NCT07503353 NOT YET RECRUITING
A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies
Sheba Medical Center
NCT06687772 RECRUITING
CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
Washington University School of Medicine
NCT07502768 NOT YET RECRUITING
Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
Rong Tao
NCT05020015 ACTIVE NOT RECRUITING
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Takeda
NCT05757219 RECRUITING
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
H. Lee Moffitt Cancer Center and Research Institute
NCT06553872 RECRUITING
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
H. Lee Moffitt Cancer Center and Research Institute
NCT06533579 RECRUITING
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics Inc.
NCT06880913 RECRUITING
Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
Peking University People's Hospital
NCT04947319 ACTIVE NOT RECRUITING
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Ono Pharmaceutical Co., Ltd.
NCT07499271 RECRUITING
Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
The First Affiliated Hospital of Soochow University
NCT06915246 RECRUITING
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
VIVUS LLC
NCT03297606 RECRUITING
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Canadian Cancer Trials Group
NCT05702853 RECRUITING
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Medical University of South Carolina
NCT03793140 ACTIVE NOT RECRUITING
A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations
Memorial Sloan Kettering Cancer Center
NCT04531046 ACTIVE NOT RECRUITING
Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation
The Lymphoma Academic Research Organisation
NCT07494565 NOT YET RECRUITING
Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
Sun Yat-sen University
NCT02682641 ACTIVE NOT RECRUITING
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
NCT05147467 RECRUITING
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Ascentage Pharma Group Inc.
NCT05388006 RECRUITING
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
NCT07341191 RECRUITING
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
Canadian Cancer Trials Group
NCT07493148 RECRUITING
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Ou Bai, MD/PHD
NCT07015242 RECRUITING
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT06863402 RECRUITING
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Roswell Park Cancer Institute
NCT07489989 RECRUITING
Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.
Daihong Liu
NCT06519526 RECRUITING
Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
Fudan University
NCT04998669 RECRUITING
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
Juan P. Alderuccio, MD
NCT02503423 ACTIVE NOT RECRUITING
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Taiho Oncology, Inc.
NCT05025800 ACTIVE NOT RECRUITING
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
NCT07380984 RECRUITING
PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL
Ruijin Hospital
NCT03282396 ACTIVE NOT RECRUITING
Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma
M.D. Anderson Cancer Center
NCT06357975 ACTIVE NOT RECRUITING
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
National Cancer Institute (NCI)
NCT04246086 ACTIVE NOT RECRUITING
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
Hoffmann-La Roche
NCT07481669 RECRUITING
ASCT With TEAM Conditioning for Lymphoma With High Risk of CNS Relapse
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT04889716 RECRUITING
CAR-T Followed by Bispecific Antibodies
Abramson Cancer Center at Penn Medicine
NCT07480850 ACTIVE NOT RECRUITING
Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT02952508 ACTIVE NOT RECRUITING
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Cellectar Biosciences, Inc.
NCT04904588 ACTIVE NOT RECRUITING
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
NCT06207123 RECRUITING
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
University of Chicago
NCT07477366 NOT YET RECRUITING
Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma
ImmunityBio, Inc.
NCT07476066 NOT YET RECRUITING
Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory Aggressive B-Cell Lymphoma
Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd
NCT06859424 RECRUITING
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Center for International Blood and Marrow Transplant Research
NCT06918431 RECRUITING
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
City of Hope Medical Center
NCT05615636 RECRUITING
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
M.D. Anderson Cancer Center
NCT06931652 RECRUITING
Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
The Lymphoma Academic Research Organisation
NCT06561425 ACTIVE NOT RECRUITING
A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma
Galapagos NV
NCT07473167 RECRUITING
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
TICAROS Co., Ltd.
NCT05783596 ACTIVE NOT RECRUITING
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
Reid Merryman, MD
NCT06561074 RECRUITING
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
M.D. Anderson Cancer Center
NCT07459608 NOT YET RECRUITING
Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma
Henan Cancer Hospital
NCT06510309 RECRUITING
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
Gottfried von Keudell, MD PhD
NCT05683171 RECRUITING
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
NCT04644016 RECRUITING
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Memorial Sloan Kettering Cancer Center
NCT06572618 RECRUITING
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
City of Hope Medical Center
NCT06442475 RECRUITING
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
University of Washington
NCT06510361 RECRUITING
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Beth Israel Deaconess Medical Center
NCT07218510 RECRUITING
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
City of Hope Medical Center
NCT05458297 ACTIVE NOT RECRUITING
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
Merck Sharp & Dohme LLC
NCT05442515 RECRUITING
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Cancer Institute (NCI)
NCT05256641 RECRUITING
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Jonsson Comprehensive Cancer Center
NCT06059391 RECRUITING
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
NCT07460362 RECRUITING
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
Peking University Third Hospital
NCT02446457 ACTIVE NOT RECRUITING
Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
M.D. Anderson Cancer Center
NCT07350850 RECRUITING
A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)
Tongji Hospital
NCT07457177 NOT YET RECRUITING
Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL
LIANG WANG
NCT02629809 ACTIVE NOT RECRUITING
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT02568267 ACTIVE NOT RECRUITING
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Hoffmann-La Roche
NCT06067048 ACTIVE NOT RECRUITING
Zanubrutinib in Primary Cold Agglutinin Disease
Stichting Hemato-Oncologie voor Volwassenen Nederland
NCT05800366 RECRUITING
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Jennifer Crombie, MD
NCT07042438 RECRUITING
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
City of Hope Medical Center
NCT06416085 ACTIVE NOT RECRUITING
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer
University Health Network, Toronto
NCT06698003 RECRUITING
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Memorial Sloan Kettering Cancer Center
NCT05207670 ACTIVE NOT RECRUITING
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
Genentech, Inc.
NCT02339922 ACTIVE NOT RECRUITING
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
NCT07222631 RECRUITING
SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas
University of California, San Diego
NCT03331198 RECRUITING
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Juno Therapeutics, a Subsidiary of Celgene
NCT07294677 RECRUITING
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
University of Chicago
NCT07448324 RECRUITING
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
The First Affiliated Hospital with Nanjing Medical University
NCT07450391 RECRUITING
EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders
Daihong Liu
NCT05479994 ACTIVE NOT RECRUITING
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
BeiGene
NCT06539195 ACTIVE NOT RECRUITING
DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)
Dizal Pharmaceuticals
NCT04802590 ACTIVE NOT RECRUITING
Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
The Lymphoma Academic Research Organisation
NCT05950165 RECRUITING
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
Cho Pharma Inc.
NCT06486051 RECRUITING
A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma
Malaghan Institute of Medical Research
NCT04127227 ACTIVE NOT RECRUITING
Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type
Sun Yat-sen University
NCT07447726 NOT YET RECRUITING
Exploratory Clinical Study on the Safety and Efficacy of CD19X CAR-T Cell Injection in the Treatment of Relapsed/Refractory Large B-Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
NCT05681195 RECRUITING
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Baptist Health South Florida
NCT03789240 ACTIVE NOT RECRUITING
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
National Cancer Institute (NCI)
NCT05546268 ACTIVE NOT RECRUITING
Study of Oral MRT-2359 in Selected Cancer Patients
Monte Rosa Therapeutics, Inc
NCT05873712 RECRUITING
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
Aseel Alsouqi
NCT06919939 RECRUITING
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
University of Miami
NCT07441954 NOT YET RECRUITING
Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
NCT04077723 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
NCT07441993 RECRUITING
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
Institute of Hematology & Blood Diseases Hospital, China
NCT04195633 RECRUITING
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
NCT06504940 RECRUITING
Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)
First Affiliated Hospital of Zhejiang University
NCT01473628 ACTIVE NOT RECRUITING
Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma
M.D. Anderson Cancer Center
NCT07439653 NOT YET RECRUITING
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
TORL Biotherapeutics, LLC
NCT06583837 ACTIVE NOT RECRUITING
Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma
Fudan University
NCT04624633 ACTIVE NOT RECRUITING
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
Jennifer R. Brown, MD, PhD
NCT06526793 RECRUITING
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
AstraZeneca
NCT07432022 NOT YET RECRUITING
A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma
Shanghai EpimAb Biotherapeutics Co., Ltd.
NCT05589896 RECRUITING
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
NCT04186520 RECRUITING
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Medical College of Wisconsin
NCT06854003 RECRUITING
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
Christine Ryan
NCT01880567 ACTIVE NOT RECRUITING
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
NCT03198026 ACTIVE NOT RECRUITING
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT06536049 RECRUITING
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Yazeed Sawalha
NCT04745949 RECRUITING
PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy
M.D. Anderson Cancer Center
NCT05861050 RECRUITING
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
City of Hope Medical Center
NCT03930953 ACTIVE NOT RECRUITING
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
Celgene
NCT05336812 RECRUITING
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
NCT02756897 ACTIVE NOT RECRUITING
Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT06466122 RECRUITING
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
Kerry Rogers
NCT04842877 ACTIVE NOT RECRUITING
Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma
The Lymphoma Academic Research Organisation
NCT07416890 RECRUITING
Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
Zhejiang Cancer Hospital
NCT04571138 ACTIVE NOT RECRUITING
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma
Seattle Children's Hospital
NCT07418190 RECRUITING
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
The First Affiliated Hospital with Nanjing Medical University
NCT07410494 RECRUITING
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Essen Biotech
NCT04752826 RECRUITING
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
BioInvent International AB
NCT06630091 RECRUITING
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
M.D. Anderson Cancer Center
NCT05551936 ACTIVE NOT RECRUITING
A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
Vaishalee Kenkre
NCT03946878 ACTIVE NOT RECRUITING
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
NCT02846623 ACTIVE NOT RECRUITING
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
M.D. Anderson Cancer Center
NCT03136146 RECRUITING
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
M.D. Anderson Cancer Center
NCT07415980 NOT YET RECRUITING
Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL
Sun Yat-sen University
NCT02861417 ACTIVE NOT RECRUITING
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
NCT06723457 ACTIVE NOT RECRUITING
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
Northwestern University
NCT04980222 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
NCT05658562 ACTIVE NOT RECRUITING
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
Tanabe Pharma Corporation
NCT07410520 RECRUITING
PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.
The First Affiliated Hospital with Nanjing Medical University
NCT05144841 ACTIVE NOT RECRUITING
A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
Merck Sharp & Dohme LLC
NCT07405255 NOT YET RECRUITING
Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma
Ruijin Hospital
NCT06517511 RECRUITING
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
Sun Yat-sen University
NCT05677919 ACTIVE NOT RECRUITING
Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia
Mayo Clinic
NCT03710772 ACTIVE NOT RECRUITING
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
NCT04977024 ACTIVE NOT RECRUITING
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
GeoVax, Inc.
NCT07018752 RECRUITING
A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas
The Lymphoma Academic Research Organisation
NCT06558604 RECRUITING
Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma
The Lymphoma Academic Research Organisation
NCT02213926 ACTIVE NOT RECRUITING
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
Acerta Pharma BV
NCT06939283 ACTIVE NOT RECRUITING
A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma
Werewolf Therapeutics, Inc.
NCT06484920 RECRUITING
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
Rita Assi
NCT07398638 NOT YET RECRUITING
Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study
Sun Yat-sen University
NCT04883437 RECRUITING
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Emory University
NCT06504394 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
Merck Sharp & Dohme LLC
NCT03516617 RECRUITING
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
NCT03938987 RECRUITING
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
University of Alberta
NCT07397832 RECRUITING
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
Tianjin Medical University Cancer Institute and Hospital
NCT03758989 RECRUITING
A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
University of Rochester
NCT06485219 ACTIVE NOT RECRUITING
A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Chengdu Zenitar Biomedical Technology Co., Ltd
NCT03749018 ACTIVE NOT RECRUITING
Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
David Bond, MD
NCT06001385 ACTIVE NOT RECRUITING
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Center for International Blood and Marrow Transplant Research
NCT01574274 ACTIVE NOT RECRUITING
SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma
Dana-Farber Cancer Institute
NCT06350318 RECRUITING
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
H. Lee Moffitt Cancer Center and Research Institute
NCT07385989 NOT YET RECRUITING
Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma
WEI XU
NCT05563844 ACTIVE NOT RECRUITING
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Chengdu Zenitar Biomedical Technology Co., Ltd
NCT07387848 NOT YET RECRUITING
Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas
American University of Beirut Medical Center
NCT07381738 RECRUITING
Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders
Fudan University
NCT00882895 ACTIVE NOT RECRUITING
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Washington University School of Medicine
NCT05633615 RECRUITING
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
SWOG Cancer Research Network
NCT06829771 RECRUITING
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT06357676 RECRUITING
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
OHSU Knight Cancer Institute
NCT04669171 RECRUITING
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Enterome
NCT01511562 ACTIVE NOT RECRUITING
Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma
Alliance for Clinical Trials in Oncology
NCT04390737 RECRUITING
Evaluate the Safety and Clinical Activity of HH2853
Haihe Biopharma Co., Ltd.
NCT06909877 RECRUITING
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Haihe Biopharma Co., Ltd.
NCT05583149 ACTIVE NOT RECRUITING
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
Patrick C. Johnson, MD
NCT04745559 ACTIVE NOT RECRUITING
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
H. Lee Moffitt Cancer Center and Research Institute
NCT04419519 ACTIVE NOT RECRUITING
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
Memorial Sloan Kettering Cancer Center
NCT03943901 ACTIVE NOT RECRUITING
Split-Dose R-CHOP for Older Adults With DLBCL
University of Wisconsin, Madison
NCT07371923 RECRUITING
Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma
Beijing Tongren Hospital
NCT07180771 NOT YET RECRUITING
A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.
Boryung Pharmaceutical Co., Ltd
NCT06834373 RECRUITING
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Mayo Clinic
NCT07372352 RECRUITING
Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL
The First Affiliated Hospital of Soochow University
NCT07372365 RECRUITING
Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.
The First Affiliated Hospital of Soochow University
NCT05751798 RECRUITING
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
OSE Immunotherapeutics
NCT06492837 RECRUITING
Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients
Fondazione Italiana Linfomi - ETS
NCT01446133 ACTIVE NOT RECRUITING
Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)
M.D. Anderson Cancer Center
NCT03842696 ACTIVE NOT RECRUITING
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
University of Michigan Rogel Cancer Center
NCT06846463 RECRUITING
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Virginia Commonwealth University
NCT03642626 ACTIVE NOT RECRUITING
MT2017-45: CAR-T Cell Therapy for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT05071209 ACTIVE NOT RECRUITING
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
NCT07360288 NOT YET RECRUITING
Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma
TICAROS Co., Ltd.
NCT06013423 RECRUITING
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Fred Hutchinson Cancer Center
NCT06333262 RECRUITING
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Inhye Ahn
NCT07077512 RECRUITING
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
Sun Yat-sen University
NCT07024706 NOT YET RECRUITING
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
AstraZeneca
NCT06563505 RECRUITING
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
M.D. Anderson Cancer Center
NCT01352520 ACTIVE NOT RECRUITING
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
M.D. Anderson Cancer Center
NCT05222555 ACTIVE NOT RECRUITING
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
Incyte Corporation
NCT01808599 ACTIVE NOT RECRUITING
Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma
International Extranodal Lymphoma Study Group (IELSG)
NCT05716087 ACTIVE NOT RECRUITING
A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
NCT06647732 RECRUITING
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Sun Yat-sen University
NCT07098364 RECRUITING
ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
Fred Hutchinson Cancer Center
NCT07339527 NOT YET RECRUITING
EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas
Sun Yat-sen University
NCT06213311 RECRUITING
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
M.D. Anderson Cancer Center
NCT03829254 RECRUITING
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
NuCana plc
NCT05464719 RECRUITING
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
M.D. Anderson Cancer Center
NCT03278782 ACTIVE NOT RECRUITING
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
M.D. Anderson Cancer Center
NCT05929612 RECRUITING
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
M.D. Anderson Cancer Center
NCT06425302 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
Celgene
NCT07321301 RECRUITING
Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia
Daihong Liu
NCT02494700 ACTIVE NOT RECRUITING
Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma
M.D. Anderson Cancer Center
NCT05417165 RECRUITING
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
Seema Bhat
NCT01746849 ACTIVE NOT RECRUITING
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
NCT04572763 ACTIVE NOT RECRUITING
Copanlisib Plus Venetoclax in R/R DLBCL
Dana-Farber Cancer Institute
NCT06365671 RECRUITING
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
Ruijin Hospital
NCT07014917 RECRUITING
Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
Zulfa Omer
NCT02690545 ACTIVE NOT RECRUITING
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
UNC Lineberger Comprehensive Cancer Center
NCT03674411 ACTIVE NOT RECRUITING
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Masonic Cancer Center, University of Minnesota
NCT03463057 ACTIVE NOT RECRUITING
The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland
NCT06054776 RECRUITING
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
City of Hope Medical Center
NCT06883526 RECRUITING
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT03277729 ACTIVE NOT RECRUITING
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Fred Hutchinson Cancer Center
NCT05249959 RECRUITING
Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.
Fondazione Italiana Linfomi - ETS
NCT03961672 ACTIVE NOT RECRUITING
Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
City of Hope Medical Center
NCT06835530 RECRUITING
A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)
Fondazione Italiana Linfomi - ETS
NCT07138547 RECRUITING
GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma
Chinese PLA General Hospital
NCT05389293 RECRUITING
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
NCT07093710 RECRUITING
Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
Sun Yat-sen University
NCT05260957 RECRUITING
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
Lazaros Lekakis
NCT05800977 RECRUITING
A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
Shanghai AbelZeta Ltd.
NCT04604067 ACTIVE NOT RECRUITING
Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.
Swiss Cancer Institute
NCT04792502 RECRUITING
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Brown University
NCT05480449 RECRUITING
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
Stephan Grupp MD PhD
NCT04505254 RECRUITING
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT02966756 RECRUITING
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
AbbVie
NCT04915248 RECRUITING
Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.
Fondazione Italiana Linfomi - ETS
NCT03731234 ACTIVE NOT RECRUITING
Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance
Fondazione Italiana Linfomi - ETS
NCT04054167 RECRUITING
Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
NCT05783609 RECRUITING
Epcoritamab and Rituximab for First-line Follicular Lymphoma
Reid Merryman, MD
NCT07285044 RECRUITING
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
NCT07293403 NOT YET RECRUITING
Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
City of Hope Medical Center
NCT07165769 RECRUITING
Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial
Institute of Hematology & Blood Diseases Hospital, China
NCT06736613 RECRUITING
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT05455697 RECRUITING
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
University of Washington
NCT04661007 ACTIVE NOT RECRUITING
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
Incyte Biosciences Japan GK
NCT04068597 RECRUITING
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
NCT01371630 RECRUITING
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT04594798 ACTIVE NOT RECRUITING
A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
University of Rochester
NCT07288814 NOT YET RECRUITING
Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
Sun Yat-Sen University Cancer Center
NCT06387121 RECRUITING
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
Institute of Hematology & Blood Diseases Hospital, China
NCT03622788 ACTIVE NOT RECRUITING
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
M.D. Anderson Cancer Center
NCT07189065 RECRUITING
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
NCT06253663 ACTIVE NOT RECRUITING
Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Kite, A Gilead Company
NCT07285590 RECRUITING
Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
NCT05410418 ACTIVE NOT RECRUITING
Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
Washington University School of Medicine
NCT07153068 RECRUITING
SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Institute of Hematology & Blood Diseases Hospital, China
NCT07276737 NOT YET RECRUITING
Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT07276698 NOT YET RECRUITING
Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT04703192 ACTIVE NOT RECRUITING
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Daiichi Sankyo
NCT07272499 RECRUITING
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Ruijin Hospital
NCT07271121 RECRUITING
Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL
King Hussein Cancer Center
NCT06803693 RECRUITING
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Ruijin Hospital
NCT07269639 NOT YET RECRUITING
Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma
Seoul National University Hospital
NCT04925609 RECRUITING
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
Princess Maxima Center for Pediatric Oncology
NCT07188610 RECRUITING
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
NCT06986174 RECRUITING
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
Shayna Sarosiek, MD
NCT04827862 ACTIVE NOT RECRUITING
RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy
Abramson Cancer Center at Penn Medicine
NCT02932280 ACTIVE NOT RECRUITING
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Memorial Sloan Kettering Cancer Center
NCT06390956 RECRUITING
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
University of Utah
NCT05404048 ACTIVE NOT RECRUITING
PD-L1 PET-imaging During CAR T-cell Therapy
University Medical Center Groningen
NCT06300528 RECRUITING
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
University of Utah
NCT06788964 RECRUITING
Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)
University of Utah
NCT04787263 ACTIVE NOT RECRUITING
CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML
Bambino Gesù Hospital and Research Institute
NCT02223208 ACTIVE NOT RECRUITING
Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas
Fondazione Italiana Linfomi - ETS
NCT07255963 RECRUITING
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
The First Affiliated Hospital of Soochow University
NCT07188090 RECRUITING
Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Thomas Jefferson University
NCT07254754 RECRUITING
Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
NCT02570542 ACTIVE NOT RECRUITING
Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Memorial Sloan Kettering Cancer Center
NCT04484012 RECRUITING
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
City of Hope Medical Center
NCT05600686 RECRUITING
Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
Joseph Tuscano
NCT07247383 ACTIVE NOT RECRUITING
Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT07244380 NOT YET RECRUITING
Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.
Hebei Senlang Biotechnology Inc., Ltd.
NCT02427620 ACTIVE NOT RECRUITING
Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
NCT04439149 ACTIVE NOT RECRUITING
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)
National Cancer Institute (NCI)
NCT01351896 ACTIVE NOT RECRUITING
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
NCT07240194 RECRUITING
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
The First Affiliated Hospital with Nanjing Medical University
NCT05821088 RECRUITING
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
David Bond, MD
NCT04941716 RECRUITING
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
Fred Hutchinson Cancer Center
NCT04439188 ACTIVE NOT RECRUITING
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)
National Cancer Institute (NCI)
NCT07231250 NOT YET RECRUITING
Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Li Zhiming
NCT04094610 RECRUITING
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Turning Point Therapeutics, Inc.
NCT06464185 ACTIVE NOT RECRUITING
A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
NCT06716658 RECRUITING
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Institute of Hematology & Blood Diseases Hospital, China
NCT07231952 RECRUITING
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Memorial Sloan Kettering Cancer Center
NCT04060277 ACTIVE NOT RECRUITING
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
City of Hope Medical Center
NCT05643742 RECRUITING
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
CRISPR Therapeutics AG
NCT03113500 ACTIVE NOT RECRUITING
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
City of Hope Medical Center
NCT06550141 RECRUITING
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Marcela V. Maus, M.D.,Ph.D.
NCT03747757 ACTIVE NOT RECRUITING
Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue
M.D. Anderson Cancer Center
NCT04765111 ACTIVE NOT RECRUITING
Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
M.D. Anderson Cancer Center
NCT02877303 RECRUITING
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT02007044 ACTIVE NOT RECRUITING
Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT04245839 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
Celgene
NCT04148430 ACTIVE NOT RECRUITING
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
Memorial Sloan Kettering Cancer Center
NCT03125642 RECRUITING
Auto Stem Cell Transplant for Lymphoma Patients
Masonic Cancer Center, University of Minnesota
NCT04496349 RECRUITING
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Ascentage Pharma Group Inc.
NCT06569680 RECRUITING
Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma
Izidore Lossos, MD
NCT02323867 ACTIVE NOT RECRUITING
Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies
Children's Hospital of Philadelphia
NCT06796998 RECRUITING
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
Izidore Lossos, MD
NCT03728972 ACTIVE NOT RECRUITING
Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type
Memorial Sloan Kettering Cancer Center
NCT07013565 RECRUITING
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
New York Medical College
NCT05951959 ACTIVE NOT RECRUITING
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
AstraZeneca
NCT06828991 RECRUITING
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
Danielle Wallace
NCT05890352 RECRUITING
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
SWOG Cancer Research Network
NCT05565417 ACTIVE NOT RECRUITING
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Immunitas Therapeutics
NCT03779854 RECRUITING
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT03888105 ACTIVE NOT RECRUITING
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
Regeneron Pharmaceuticals
NCT02180711 ACTIVE NOT RECRUITING
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Acerta Pharma BV
NCT06520098 RECRUITING
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
VA Office of Research and Development
NCT04930653 RECRUITING
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
City of Hope Medical Center
NCT04257578 ACTIVE NOT RECRUITING
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
University of Washington
NCT07207785 NOT YET RECRUITING
PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma
Fondazione Italiana Linfomi - ETS
NCT07209163 NOT YET RECRUITING
Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma
Ruijin Hospital
NCT07208981 RECRUITING
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
The First Affiliated Hospital with Nanjing Medical University
NCT06052826 RECRUITING
Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
City of Hope Medical Center
NCT07206264 NOT YET RECRUITING
Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
Tianjin Medical University Cancer Institute and Hospital
NCT06066203 RECRUITING
A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
NCT07199296 RECRUITING
Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
Ruijin Hospital
NCT05296070 RECRUITING
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
University of Miami
NCT06925555 NOT YET RECRUITING
Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS
The First Affiliated Hospital with Nanjing Medical University
NCT06534437 RECRUITING
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
Ryvu Therapeutics SA
NCT06905509 RECRUITING
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Joseph Tuscano
NCT03147885 ACTIVE NOT RECRUITING
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute
NCT05623982 RECRUITING
A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd.
NCT07195799 RECRUITING
Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL
The First Affiliated Hospital with Nanjing Medical University
NCT03015896 ACTIVE NOT RECRUITING
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
David Bond, MD
NCT06854159 RECRUITING
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
Joseph Tuscano
NCT07197307 NOT YET RECRUITING
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Universität Münster
NCT06979076 NOT YET RECRUITING
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL
MingSight Pharmaceuticals, Inc
NCT04479267 ACTIVE NOT RECRUITING
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma
Barbara Ann Karmanos Cancer Institute
NCT05192486 ACTIVE NOT RECRUITING
A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05627856 ACTIVE NOT RECRUITING
A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05485753 ACTIVE NOT RECRUITING
A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Sichuan Baili Pharmaceutical Co., Ltd.
NCT04446962 ACTIVE NOT RECRUITING
LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)
Institut Curie
NCT06849713 RECRUITING
Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL
Massachusetts General Hospital
NCT06453044 RECRUITING
Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma
City of Hope Medical Center
NCT07191249 NOT YET RECRUITING
A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).
Tel-Aviv Sourasky Medical Center
NCT04083495 RECRUITING
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
NCT04975555 ACTIVE NOT RECRUITING
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
University of Alabama at Birmingham
NCT07184788 NOT YET RECRUITING
G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma
Navy General Hospital, Beijing
NCT04697940 ACTIVE NOT RECRUITING
Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL
Han weidong
NCT03011814 ACTIVE NOT RECRUITING
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
City of Hope Medical Center
NCT07107204 NOT YET RECRUITING
A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
Biotroy Therapeutics
NCT07175415 NOT YET RECRUITING
HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Princess Maxima Center for Pediatric Oncology
NCT06948981 RECRUITING
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Grit Biotechnology
NCT05745714 RECRUITING
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Princess Maxima Center for Pediatric Oncology
NCT05658640 RECRUITING
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
Princess Maxima Center for Pediatric Oncology
NCT05751044 RECRUITING
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Princess Maxima Center for Pediatric Oncology
NCT04533581 ACTIVE NOT RECRUITING
Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)
Kyowa Kirin Co., Ltd.
NCT07168317 RECRUITING
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL
The Affiliated Hospital of Xuzhou Medical University
NCT07162571 NOT YET RECRUITING
This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
NCT05471843 ACTIVE NOT RECRUITING
Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
BeiGene
NCT05884333 RECRUITING
Cord Blood Transplant in Adults With Blood Cancers
Memorial Sloan Kettering Cancer Center
NCT07159620 RECRUITING
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
The First Affiliated Hospital of Soochow University
NCT07159906 NOT YET RECRUITING
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
First Affiliated Hospital of Zhejiang University
NCT03162536 ACTIVE NOT RECRUITING
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCT06160843 RECRUITING
Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma
National Cancer Centre, Singapore
NCT04665765 ACTIVE NOT RECRUITING
Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
NCT07144657 NOT YET RECRUITING
Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma
National Taiwan University Hospital
NCT07139353 NOT YET RECRUITING
Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
Sun Yat-sen University
NCT06886139 NOT YET RECRUITING
A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.
Zhejiang Teruisi Pharmaceutical Inc.
NCT07035379 NOT YET RECRUITING
A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL
Zhejiang Teruisi Pharmaceutical Inc.
NCT07081022 RECRUITING
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
Shanghai Junshi Bioscience Co., Ltd.
NCT05788081 ACTIVE NOT RECRUITING
Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.
Olivia Newton-John Cancer Research Institute
NCT03505762 ACTIVE NOT RECRUITING
Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment
Wake Forest University Health Sciences
NCT07078500 RECRUITING
Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT07126236 RECRUITING
Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
NCT07124936 RECRUITING
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
NCT04315324 RECRUITING
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
SWOG Cancer Research Network
NCT07122609 NOT YET RECRUITING
Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Ruijin Hospital
NCT03765177 RECRUITING
CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
Ottawa Hospital Research Institute
NCT06978088 RECRUITING
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
Zulfa Omer
NCT06665217 NOT YET RECRUITING
G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
Navy General Hospital, Beijing
NCT05583071 RECRUITING
Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL
University of Cologne
NCT02734771 ACTIVE NOT RECRUITING
A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Patrick Reagan
NCT07117305 NOT YET RECRUITING
CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation
Zhengzhou University
NCT06375733 RECRUITING
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
Genfleet Therapeutics (Shanghai) Inc.
NCT02790515 ACTIVE NOT RECRUITING
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
St. Jude Children's Research Hospital
NCT06530550 RECRUITING
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Institute of Hematology & Blood Diseases Hospital, China
NCT06792825 RECRUITING
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Masonic Cancer Center, University of Minnesota
NCT02393157 RECRUITING
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
New York Medical College
NCT04099966 RECRUITING
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Mitchell Cairo
NCT03628612 ENROLLING BY INVITATION
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Autolus Limited
NCT06343311 RECRUITING
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Estrella Biopharma, Inc.
NCT05554939 RECRUITING
Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL
Chinese PLA General Hospital
NCT07106723 RECRUITING
Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL
Institute of Hematology & Blood Diseases Hospital, China
NCT03872180 ACTIVE NOT RECRUITING
Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Emory University
NCT06213636 RECRUITING
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Essen Biotech
NCT05660473 RECRUITING
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
NCT06556199 RECRUITING
A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT07097207 RECRUITING
Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma
Shenzhen University General Hospital
NCT06838832 RECRUITING
Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL
Chinese PLA General Hospital
NCT07094477 ACTIVE NOT RECRUITING
Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma
Daihong Liu
NCT02911142 ACTIVE NOT RECRUITING
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
National Cancer Institute (NCI)
NCT06045910 RECRUITING
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
Cancer Research UK
NCT06651853 RECRUITING
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
The First Affiliated Hospital of Xiamen University
NCT03179930 ACTIVE NOT RECRUITING
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
Memorial Sloan Kettering Cancer Center
NCT07081607 NOT YET RECRUITING
Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.
Ruijin Hospital
NCT06495723 RECRUITING
Polyspecific Antibodies in Lymphoproliferative T-cell Disorders
Xenothera SAS
NCT06220097 ACTIVE NOT RECRUITING
Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT06810778 RECRUITING
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Jonsson Comprehensive Cancer Center
NCT05673785 ACTIVE NOT RECRUITING
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
Takeda
NCT06682130 RECRUITING
Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL
The First Affiliated Hospital of Soochow University
NCT07058103 RECRUITING
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL
The Affiliated Hospital of Xuzhou Medical University
NCT03739502 RECRUITING
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
University of Rochester
NCT04416451 ACTIVE NOT RECRUITING
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
Memorial Sloan Kettering Cancer Center
NCT05805605 RECRUITING
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT03598998 ACTIVE NOT RECRUITING
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
City of Hope Medical Center
NCT07032532 NOT YET RECRUITING
Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)
Sun Yat-sen University
NCT07009002 RECRUITING
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
Chinese PLA General Hospital
NCT03314974 RECRUITING
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
NCT07034508 NOT YET RECRUITING
A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
Institute of Hematology & Blood Diseases Hospital, China
NCT07031700 NOT YET RECRUITING
A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL
Tianjin Medical University Cancer Institute and Hospital
NCT07001540 RECRUITING
Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation
Fudan University
NCT06167785 RECRUITING
A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T
University Health Network, Toronto
NCT03817320 ACTIVE NOT RECRUITING
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
NCT06996132 RECRUITING
Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
NCT06700798 RECRUITING
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial
Fei Li
NCT05800210 RECRUITING
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
University of Florida
NCT07022223 RECRUITING
Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT07020260 NOT YET RECRUITING
The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies
Princess Maxima Center for Pediatric Oncology
NCT05253495 RECRUITING
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
New York Medical College
NCT07014943 RECRUITING
High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma
Sichuan University
NCT07012980 NOT YET RECRUITING
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Shanghai Zhongshan Hospital
NCT05346809 RECRUITING
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
Divaya Bhutani
NCT03995147 ACTIVE NOT RECRUITING
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
University of Chicago
NCT06601504 ACTIVE NOT RECRUITING
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Hutchmed
NCT06793410 RECRUITING
Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
Vastra Gotaland Region
NCT06175000 RECRUITING
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
Providence Health & Services
NCT06414148 RECRUITING
MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
Peter MacCallum Cancer Centre, Australia
NCT06987916 RECRUITING
Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma
Shanghai Tongji Hospital, Tongji University School of Medicine
NCT06742502 RECRUITING
Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL
Sun Yat-sen University
NCT04548648 ACTIVE NOT RECRUITING
A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
UNC Lineberger Comprehensive Cancer Center
NCT06119685 RECRUITING
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Indapta Therapeutics, INC.
NCT06846489 RECRUITING
Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
Sun Yat-sen University
NCT07000617 RECRUITING
A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
Peking University Cancer Hospital & Institute
NCT06966154 RECRUITING
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL
Fudan University
NCT06014073 RECRUITING
TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL
Chinese PLA General Hospital
NCT06323525 RECRUITING
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
Chinese PLA General Hospital
NCT03114865 ACTIVE NOT RECRUITING
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06981988 NOT YET RECRUITING
A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL
Jiangsu HengRui Medicine Co., Ltd.
NCT06552572 ACTIVE NOT RECRUITING
Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy
Samsung Medical Center
NCT04104776 RECRUITING
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis Pharmaceuticals
NCT06594640 RECRUITING
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
NCT06244368 RECRUITING
GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
Institute of Hematology & Blood Diseases Hospital, China
NCT06971523 RECRUITING
A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
CytosinLab Therapeutics Co., Ltd.
NCT05294055 RECRUITING
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
NCT06967038 RECRUITING
Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome
Bangdong Gong
NCT05326243 RECRUITING
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
Pell Bio-Med Technology Co., Ltd.
NCT05891821 RECRUITING
Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)
Immune Oncology Research Institute
NCT06961500 NOT YET RECRUITING
Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A
Sun Yat-sen University
NCT06959732 RECRUITING
Zanubrutinib Combined With G-CVP in Previously Untreated FL
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT04460248 ACTIVE NOT RECRUITING
Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Ruijin Hospital
NCT06954805 RECRUITING
Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
Jennifer Amengual
NCT05908409 RECRUITING
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
IDP Discovery Pharma S.L.
NCT03571568 RECRUITING
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
BioInvent International AB
NCT04587687 RECRUITING
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
Joseph Tuscano
NCT04737889 RECRUITING
Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma
Henan Cancer Hospital
NCT05209620 RECRUITING
Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma
Henan Cancer Hospital
NCT06940791 RECRUITING
Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104)
Kyorin University
NCT02797470 ACTIVE NOT RECRUITING
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
AIDS Malignancy Consortium
NCT05635162 RECRUITING
Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma
University College, London
NCT04494503 RECRUITING
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Ascentage Pharma Group Inc.
NCT06918015 NOT YET RECRUITING
Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma
Zhejiang Cancer Hospital
NCT03934567 ACTIVE NOT RECRUITING
A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
Xynomic Pharmaceuticals, Inc.
NCT03600441 ACTIVE NOT RECRUITING
Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma
Xynomic Pharmaceuticals, Inc.
NCT03936153 RECRUITING
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Xynomic Pharmaceuticals, Inc.
NCT04024696 ACTIVE NOT RECRUITING
A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
Xynomic Pharmaceuticals, Inc.
NCT06921044 NOT YET RECRUITING
A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL
Xiaohui He
NCT05004064 RECRUITING
Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma
University College, London
NCT06918912 RECRUITING
Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure
Istituto Clinico Humanitas
NCT01415752 ACTIVE NOT RECRUITING
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Eastern Cooperative Oncology Group
NCT06911710 RECRUITING
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
Tianjin Medical University General Hospital
NCT06760039 RECRUITING
Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
Sun Yat-sen University
NCT06901999 NOT YET RECRUITING
Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients
Ruijin Hospital
NCT06902012 RECRUITING
Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma
Zhujiang Hospital
NCT06458439 RECRUITING
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
Abramson Cancer Center at Penn Medicine
NCT06890585 NOT YET RECRUITING
Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL
Li Zhiming
NCT06891157 RECRUITING
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
The First Affiliated Hospital with Nanjing Medical University
NCT06854445 RECRUITING
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
NCT04962126 ACTIVE NOT RECRUITING
Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy
Olivia Newton-John Cancer Research Institute
NCT05313243 RECRUITING
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
Yale University
NCT06764017 RECRUITING
CHiR Therapy for Elderly DLBCL Intolerant to Chemo
First Affiliated Hospital of Ningbo University
NCT06758037 RECRUITING
Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy
First Affiliated Hospital of Ningbo University
NCT06867536 RECRUITING
Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden
Liling Zhang
NCT06876688 RECRUITING
Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
Ruijin Hospital
NCT06560879 ENROLLING BY INVITATION
Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity in Children With Leukemia
National Institute of Pediatrics, Mexico
NCT05464433 ACTIVE NOT RECRUITING
Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma
Sun Yat-sen University
NCT06570447 RECRUITING
Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
Tianjin Medical University Cancer Institute and Hospital
NCT05833724 RECRUITING
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Great Novel Therapeutics Biotech & Medicals Corporation
NCT06871007 ENROLLING BY INVITATION
Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma
St. Petersburg State Pavlov Medical University
NCT05487170 RECRUITING
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Ranok Therapeutics (Hangzhou) Co., Ltd.
NCT06855823 RECRUITING
A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
Sun Yat-sen University
NCT05688241 NOT YET RECRUITING
EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases
University Hospital, Basel, Switzerland
NCT06021678 RECRUITING
Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Guangzhou Excelmab Inc.
NCT06845241 NOT YET RECRUITING
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.
NCT06299462 RECRUITING
PTCy and ATG for MSD and MUD Transplants
Instituto Nacional de Cancer, Brazil
NCT06151106 RECRUITING
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
The First Affiliated Hospital of Xiamen University
NCT06151080 RECRUITING
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
The First Affiliated Hospital of Xiamen University
NCT06158386 RECRUITING
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
The First Affiliated Hospital of Xiamen University
NCT06158399 RECRUITING
AZA Combined With RCHOP in P53-mutated DLBCL.
The First Affiliated Hospital of Xiamen University
NCT06834529 RECRUITING
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences
NCT04566887 RECRUITING
Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma
University Health Network, Toronto
NCT06824883 RECRUITING
Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
Peking Union Medical College Hospital
NCT06826118 RECRUITING
Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
The First Affiliated Hospital of Xiamen University
NCT06093841 ACTIVE NOT RECRUITING
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
Shanghai Ming Ju Biotechnology Co., Ltd.
NCT03264131 ACTIVE NOT RECRUITING
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
UNC Lineberger Comprehensive Cancer Center
NCT06733051 RECRUITING
Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
Sun Yat-sen University
NCT04586478 RECRUITING
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Juventas Cell Therapy Ltd.
NCT06530511 RECRUITING
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL
Affiliated Hospital of Nantong University
NCT05451810 ACTIVE NOT RECRUITING
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
Genmab
NCT06695013 RECRUITING
Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL
Ruijin Hospital
NCT06778902 NOT YET RECRUITING
AZA Combined with R-GemOx for Elderly DLBCL Patients
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
NCT05263583 ACTIVE NOT RECRUITING
Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma
Cothera Bioscience, Inc
NCT05885464 ACTIVE NOT RECRUITING
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Beam Therapeutics Inc.
NCT05281809 RECRUITING
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
John Lister
NCT06762431 ENROLLING BY INVITATION
Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.
Vitebsk Regional Clinical Cancer Centre
NCT05201248 ACTIVE NOT RECRUITING
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
Genmab
NCT06557330 NOT YET RECRUITING
MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma
Fox Chase Cancer Center
NCT06757894 NOT YET RECRUITING
Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma
Sun Yat-sen University
NCT06757387 NOT YET RECRUITING
Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma
Peking University Cancer Hospital & Institute
NCT05958719 RECRUITING
Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
NCT06750991 NOT YET RECRUITING
CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p)
Ruijin Hospital
NCT06071871 RECRUITING
A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma
University College, London
NCT06742463 RECRUITING
VHAG in Treating R/R T-ALL/LBL
First Affiliated Hospital of Zhejiang University
NCT06739265 RECRUITING
Golidocitinib Plus CHOP in Newly Diagnosed PTCL
Peking Union Medical College Hospital
NCT06737250 RECRUITING
NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL
NOBO Medicine
NCT05335018 ACTIVE NOT RECRUITING
GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma
Seoul National University Hospital
NCT06735495 RECRUITING
CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT05934513 RECRUITING
A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Genfleet Therapeutics (Shanghai) Inc.
NCT03385226 ACTIVE NOT RECRUITING
A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)
University College, London
NCT06101381 RECRUITING
CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma
University of Sao Paulo
NCT05221645 ACTIVE NOT RECRUITING
Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
University of Southampton
NCT04783415 ACTIVE NOT RECRUITING
Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
City of Hope Medical Center
NCT03671018 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
NCT06704555 RECRUITING
Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
Tianjin Medical University Cancer Institute and Hospital
NCT06702605 NOT YET RECRUITING
To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
Evopoint Biosciences Inc.
NCT06701344 NOT YET RECRUITING
Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients
Ruijin Hospital
NCT06698484 RECRUITING
To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)
National University of Malaysia
NCT05806099 RECRUITING
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL
Beijing Mabworks Biotech Co., Ltd.
NCT06566586 RECRUITING
A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT04110301 RECRUITING
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
Beijing Mabworks Biotech Co., Ltd.
NCT06656221 NOT YET RECRUITING
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
Ruijin Hospital
NCT03153202 ACTIVE NOT RECRUITING
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
Joshua Brody
NCT06674096 RECRUITING
RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL
Zhejiang Cancer Hospital
NCT05910801 RECRUITING
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Academic and Community Cancer Research United
NCT06683885 RECRUITING
A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma
Mingzhi Zhang
NCT06420076 RECRUITING
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
Essen Biotech
NCT04234061 ACTIVE NOT RECRUITING
Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma
Peter MacCallum Cancer Centre, Australia
NCT06646666 NOT YET RECRUITING
ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT
Ruijin Hospital
NCT06669143 NOT YET RECRUITING
Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission
Ruijin Hospital
NCT06544785 RECRUITING
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
PETHEMA Foundation
NCT05348213 RECRUITING
Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
Ruijin Hospital
NCT06589089 RECRUITING
Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy
Ruijin Hospital
NCT06652139 NOT YET RECRUITING
Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive
Ruijin Hospital
NCT06647940 RECRUITING
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）
Sun Yat-sen University
NCT06652165 NOT YET RECRUITING
Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL
Ruijin Hospital
NCT04624958 ACTIVE NOT RECRUITING
Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL
Sun Yat-sen University
NCT05961410 RECRUITING
Eltrombopag for Peripheral Blood Stem Cell Harvest
National Taiwan University Hospital
NCT06646211 NOT YET RECRUITING
High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)
Sun Yat-sen University
NCT05202782 ACTIVE NOT RECRUITING
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
Northwestern University
NCT06549335 NOT YET RECRUITING
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
Ruijin Hospital
NCT06271057 RECRUITING
Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
The Lymphoma Academic Research Organisation
NCT05406401 ACTIVE NOT RECRUITING
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
Merck Sharp & Dohme LLC
NCT04070040 RECRUITING
Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Beijing Sanbo Brain Hospital
NCT02889523 ACTIVE NOT RECRUITING
Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy
The Lymphoma Academic Research Organisation
NCT04974216 ACTIVE NOT RECRUITING
Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older
The Lymphoma Academic Research Organisation
NCT06238648 RECRUITING
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
Academic and Community Cancer Research United
NCT06598722 RECRUITING
BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT05641428 RECRUITING
Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL
University Medical Center Groningen
NCT06592170 RECRUITING
Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)
The First Hospital of Jilin University
NCT06594432 NOT YET RECRUITING
Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement
The First Affiliated Hospital with Nanjing Medical University
NCT06503263 RECRUITING
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
Navy General Hospital, Beijing
NCT06341556 RECRUITING
A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
Fudan University
NCT06553352 RECRUITING
Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
The First Affiliated Hospital of Xiamen University
NCT06550336 ACTIVE NOT RECRUITING
A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL).
The First Hospital of Jilin University
NCT06573151 NOT YET RECRUITING
Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL
Ruijin Hospital
NCT06573138 NOT YET RECRUITING
Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL
Ruijin Hospital
NCT06569485 RECRUITING
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients
Sun Yat-sen University
NCT06567366 NOT YET RECRUITING
CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors
Ruijin Hospital
NCT06566807 RECRUITING
Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
Huai'an First People's Hospital
NCT06479356 RECRUITING
CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
NCT06554600 RECRUITING
A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT05864742 ACTIVE NOT RECRUITING
Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma
Peter MacCallum Cancer Centre, Australia
NCT04914741 ACTIVE NOT RECRUITING
A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)
Peter MacCallum Cancer Centre, Australia
NCT05749549 ACTIVE NOT RECRUITING
Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers
Shanghai Blueray Biopharma Co., Ltd.
NCT06534762 RECRUITING
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
Zhejiang Provincial People's Hospital
NCT06468267 RECRUITING
RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.
Xianmin Song, MD
NCT06508099 RECRUITING
Vitamin A and D Supplementation in Allogeneic HCT
St. Petersburg State Pavlov Medical University
NCT03980171 ACTIVE NOT RECRUITING
Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma
Peter MacCallum Cancer Centre, Australia
NCT03676504 RECRUITING
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
University Hospital Heidelberg
NCT06516978 NOT YET RECRUITING
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
The First Affiliated Hospital with Nanjing Medical University
NCT06513234 RECRUITING
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
Institute of Hematology & Blood Diseases Hospital, China
NCT06287398 RECRUITING
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
Australasian Leukaemia and Lymphoma Group
NCT06503276 RECRUITING
The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NCT06471738 RECRUITING
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Chinese PLA General Hospital
NCT06503094 RECRUITING
CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT05880043 RECRUITING
GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies
GI Cell, Inc.
NCT06489808 RECRUITING
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
Institute of Hematology & Blood Diseases Hospital, China
NCT06430736 RECRUITING
PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)
Insel Gruppe AG, University Hospital Bern
NCT06486337 NOT YET RECRUITING
CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
NCT06482684 RECRUITING
CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma
Christian Schmidt, MD
NCT02628405 ACTIVE NOT RECRUITING
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
Academic and Community Cancer Research United
NCT06477549 RECRUITING
BeFluBu vs FluBuRux Conditioning in Haploidentical HCT
St. Petersburg State Pavlov Medical University
NCT06086197 RECRUITING
A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL
Zhejiang Cancer Hospital
NCT03293173 ACTIVE NOT RECRUITING
Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis
Nordic Lymphoma Group
NCT06454968 RECRUITING
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
Peking Union Medical College Hospital
NCT05422066 RECRUITING
Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma
Li Zhiming
NCT06462248 RECRUITING
Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies
Chi Kong Li
NCT06461182 RECRUITING
Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma
Koo Foundation Sun Yat-Sen Cancer Center
NCT02061800 ACTIVE NOT RECRUITING
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Diane George
NCT06441097 NOT YET RECRUITING
Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Ruijin Hospital
NCT05868395 RECRUITING
Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma
Medical University of Vienna
NCT05493800 ACTIVE NOT RECRUITING
Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT
MitoImmune Therapeutics
NCT06433362 RECRUITING
CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma
Tianjin Medical University Cancer Institute and Hospital
NCT06427213 NOT YET RECRUITING
This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma
Henan Cancer Hospital
NCT05189197 ACTIVE NOT RECRUITING
A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression
Fudan University
NCT05949944 RECRUITING
Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma
Sun Yat-sen University
NCT06415708 RECRUITING
Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
NCT05396118 ENROLLING BY INVITATION
Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients
Rigshospitalet, Denmark
NCT06412068 NOT YET RECRUITING
A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment
Sun Yat-sen University
NCT06173999 RECRUITING
A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma
Jiangsu HengRui Medicine Co., Ltd.
NCT06406556 RECRUITING
Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL
Sun Yat-sen University
NCT05453435 RECRUITING
Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody)
Sun Yat-sen University
NCT05869279 RECRUITING
Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
NCT06381830 RECRUITING
Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
NCT06376721 RECRUITING
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
Beijing Tongren Hospital
NCT06367374 NOT YET RECRUITING
MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL
Institute of Hematology & Blood Diseases Hospital, China
NCT06368167 NOT YET RECRUITING
A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
Jiangsu HengRui Medicine Co., Ltd.
NCT06206174 RECRUITING
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Shenzhen TargetRx Co., Ltd.
NCT04128072 RECRUITING
Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
NCT06347653 RECRUITING
Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)
Peking University
NCT05477264 RECRUITING
Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type
Won Seog Kim
NCT06321289 RECRUITING
Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL
Chinese PLA General Hospital
NCT06324994 NOT YET RECRUITING
Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.
Dalian Medical University
NCT04626791 RECRUITING
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Academic and Community Cancer Research United
NCT05387616 ACTIVE NOT RECRUITING
A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden
Ludwig-Maximilians - University of Munich
NCT06228963 RECRUITING
Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
Fudan University
NCT03620578 ACTIVE NOT RECRUITING
DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL
Stichting Hemato-Oncologie voor Volwassenen Nederland
NCT06255704 NOT YET RECRUITING
A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients
Shanxi Province Cancer Hospital
NCT05214183 ACTIVE NOT RECRUITING
Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma
Nordic Lymphoma Group
NCT05833763 RECRUITING
A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
Australasian Leukaemia and Lymphoma Group
NCT06104553 RECRUITING
A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT05694312 RECRUITING
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
Gruppo Italiano Malattie EMatologiche dell'Adulto
NCT06136351 RECRUITING
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
Ruijin Hospital
NCT04718883 ACTIVE NOT RECRUITING
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
NCT06062641 NOT YET RECRUITING
Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL
Ruijin Hospital
NCT05849857 RECRUITING
Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries
Oslo University Hospital
NCT05959694 RECRUITING
A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT05230680 RECRUITING
Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS)
Won Seog Kim
NCT06081478 RECRUITING
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
Beijing Tongren Hospital
NCT03616782 RECRUITING
Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)
Ho Sup Lee
NCT05992597 RECRUITING
ZR2 Sequential Immunochemotherapy for Newly Treated MCL
Zhejiang Cancer Hospital
NCT05768529 RECRUITING
Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
NCT06005870 RECRUITING
Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression
Huazhong University of Science and Technology
NCT05846750 RECRUITING
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
NCT05948033 RECRUITING
CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma
Chinese PLA General Hospital
NCT05941156 RECRUITING
Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia
The Affiliated Hospital of Xuzhou Medical University
NCT05931328 RECRUITING
The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.
The First Affiliated Hospital with Nanjing Medical University
NCT05909098 NOT YET RECRUITING
Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma
Xiangyang No.1 People's Hospital
NCT05901324 NOT YET RECRUITING
Efficacy of Lenalidomide Maintenance in Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma: a Phase II, Open-label, Single-arm Study
National Taiwan University Hospital
NCT05874778 NOT YET RECRUITING
A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission
Tianjin Medical University Cancer Institute and Hospital
NCT05842707 RECRUITING
Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
Aibin Liang，MD，Ph.D.
NCT05833893 RECRUITING
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Chinese PLA General Hospital
NCT04920617 RECRUITING
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
ImmunoVaccine Technologies, Inc. (IMV Inc.)
NCT03688451 ACTIVE NOT RECRUITING
Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma
Tahir Latif
NCT05648019 RECRUITING
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
KK Women's and Children's Hospital
NCT04935684 RECRUITING
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
University Hospital, Clermont-Ferrand
NCT03064867 ACTIVE NOT RECRUITING
Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Molly Gallogly
NCT05600660 RECRUITING
Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT04922567 RECRUITING
Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT05596097 NOT YET RECRUITING
Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission
LanZhou University
NCT03852407 RECRUITING
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
University of Liege
NCT05572983 RECRUITING
Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
Sun Yat-sen University
NCT05552937 RECRUITING
Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL
Beijing InnoCare Pharma Tech Co., Ltd.
NCT05549284 RECRUITING
Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)
Affiliated Hospital to Academy of Military Medical Sciences
NCT02859402 RECRUITING
Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas
Keimyung University Dongsan Medical Center
NCT01744223 ACTIVE NOT RECRUITING
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Bellicum Pharmaceuticals
NCT03301168 ACTIVE NOT RECRUITING
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
NCT05436223 RECRUITING
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
Hrain Biotechnology Co., Ltd.
NCT05425654 RECRUITING
RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL
National Research Center for Hematology, Russia
NCT05338931 RECRUITING
Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
AbClon
NCT05347641 NOT YET RECRUITING
Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma
The First Affiliated Hospital with Nanjing Medical University
NCT03161223 RECRUITING
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
University of Virginia
NCT05280626 NOT YET RECRUITING
First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP
Innovent Biologics (Suzhou) Co. Ltd.
NCT05260619 RECRUITING
Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma
Seoul National University Bundang Hospital
NCT05091541 NOT YET RECRUITING
A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Nanjing IASO Biotechnology Co., Ltd.
NCT05055791 NOT YET RECRUITING
A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NCT04913103 NOT YET RECRUITING
Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL
Czech Lymphoma Study Group
NCT04836507 RECRUITING
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients
Curocell Inc.
NCT04856137 NOT YET RECRUITING
A Phase I/II Study of Diffuse Large B-cell Lymphoma
National Health Research Institutes, Taiwan
NCT02194751 NOT YET RECRUITING
Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma
XEME Biopharma Inc.
NCT04771507 RECRUITING
A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)
Jeanette Lundin
NCT03356054 RECRUITING
Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse
Stichting Hemato-Oncologie voor Volwassenen Nederland
NCT04440436 RECRUITING
Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients
Beijing Immunochina Medical Science & Technology Co., Ltd.
NCT04432714 RECRUITING
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
The First Affiliated Hospital with Nanjing Medical University
NCT00863460 ACTIVE NOT RECRUITING
Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients
Institut Curie
NCT02259556 RECRUITING
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
Chinese PLA General Hospital
NCT02497898 NOT YET RECRUITING
Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma
The First People's Hospital of Changzhou
NCT07599423 NOT YET RECRUITING
A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Large B-Cell Lymphoma
The First Affiliated Hospital of Soochow University
NCT07594899 NOT YET RECRUITING
AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL
Ruijin Hospital
NCT07593482 NOT YET RECRUITING
Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.
Swiss Cancer Institute
NCT05976997 RECRUITING
Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
Liling Zhang
NCT07588698 NOT YET RECRUITING
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
Mwanasha Merrill, MD
NCT07585747 NOT YET RECRUITING
A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide
Institute of Hematology & Blood Diseases Hospital, China
NCT07587840 RECRUITING
CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
Liping Dou
NCT05169658 COMPLETED
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
University of Washington
NCT02362035 COMPLETED
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Acerta Pharma BV
NCT01208896 COMPLETED
Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma
University Hospital, Bordeaux
NCT04205409 COMPLETED
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
University of Washington
NCT03927105 COMPLETED
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
University of Michigan Rogel Cancer Center
NCT05896163 TERMINATED
A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.
Pfizer
NCT03349450 COMPLETED
DPX-Survivac and Checkpoint Inhibitor in DLBCL
Sunnybrook Health Sciences Centre
NCT04803201 SUSPENDED
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Alliance for Clinical Trials in Oncology
NCT04331119 TERMINATED
Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
Washington University School of Medicine
NCT03547700 TERMINATED
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
University of Michigan Rogel Cancer Center
NCT03035331 COMPLETED
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Mayo Clinic
NCT07316010 SUSPENDED
Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma
M.D. Anderson Cancer Center
NCT03902184 COMPLETED
IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
Innate Pharma
NCT04763616 COMPLETED
Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy
Won Seog Kim
NCT01820910 COMPLETED
Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment
International Extranodal Lymphoma Study Group (IELSG)
NCT02433795 COMPLETED
Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
Seoul National University Hospital
NCT03623373 COMPLETED
Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
Washington University School of Medicine
NCT03213678 COMPLETED
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT05189093 COMPLETED
Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma
Hangzhou Hanx Biopharmaceuticals, Ltd.
NCT03341520 COMPLETED
Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma
Heidelberg University
NCT05498220 TERMINATED
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
NCT03856216 TERMINATED
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
M.D. Anderson Cancer Center
NCT01384513 COMPLETED
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT06088654 TERMINATED
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
Innate Pharma
NCT04673266 COMPLETED
Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma
Memorial Sloan Kettering Cancer Center
NCT03213665 COMPLETED
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT06767956 WITHDRAWN
Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy
University of Pittsburgh
NCT02625480 COMPLETED
Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Kite, A Gilead Company
NCT04433156 COMPLETED
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
Henan Cancer Hospital
NCT01241734 COMPLETED
Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL
Hackensack Meridian Health
NCT07030699 WITHDRAWN
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT01679119 COMPLETED
Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy
University College, London
NCT02518555 COMPLETED
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Jennifer Woyach
NCT03526250 COMPLETED
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT06492304 COMPLETED
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
CRISPR Therapeutics
NCT02681302 TERMINATED
Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence
Hackensack Meridian Health
NCT04673617 COMPLETED
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Artiva Biotherapeutics, Inc.
NCT07493486 COMPLETED
IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study
Zhejiang Cancer Hospital
NCT05068440 COMPLETED
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
BeiGene
NCT04975698 COMPLETED
HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903
Catherine Bollard
NCT04661943 COMPLETED
Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma
Ou Bai, MD/PHD
NCT01011920 COMPLETED
Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
International Extranodal Lymphoma Study Group (IELSG)
NCT01315132 COMPLETED
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT02601313 COMPLETED
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)
Kite, A Gilead Company
NCT02135133 COMPLETED
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Dana-Farber Cancer Institute
NCT03590574 TERMINATED
Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma
Autolus Limited
NCT04703686 COMPLETED
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
The Lymphoma Academic Research Organisation
NCT04676360 TERMINATED
Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma
Jacob Soumerai, MD
NCT02213913 COMPLETED
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
University of Chicago
NCT02737046 COMPLETED
Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma
University of Miami
NCT03458260 COMPLETED
Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
The Lymphoma Academic Research Organisation
NCT05537766 TERMINATED
Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies
Kite, A Gilead Company
NCT05721222 TERMINATED
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
Genmab
NCT05714345 TERMINATED
Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
Allogene Therapeutics
NCT04268277 TERMINATED
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
University of Ulm
NCT04205838 TERMINATED
Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma
Jonsson Comprehensive Cancer Center
NCT03919175 TERMINATED
Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma
Massachusetts General Hospital
NCT04362007 TERMINATED
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
Otsuka Pharmaceutical Co., Ltd.
NCT05255601 COMPLETED
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Bristol-Myers Squibb
NCT05371054 COMPLETED
Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
National Cancer Institute (NCI)
NCT03990961 TERMINATED
Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
University of Chicago
NCT04282018 COMPLETED
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
BeiGene
NCT04569032 COMPLETED
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen, a wholly owned subsidiary of Pfizer
NCT03332017 COMPLETED
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
BeiGene
NCT02362997 COMPLETED
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Dana-Farber Cancer Institute
NCT01516567 COMPLETED
Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation
Gustave Roussy, Cancer Campus, Grand Paris
NCT06705530 COMPLETED
A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders
National Research Center for Hematology, Russia
NCT03581942 COMPLETED
Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
Memorial Sloan Kettering Cancer Center
NCT05872854 COMPLETED
Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light
Ellen Kim, MD
NCT04849416 COMPLETED
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Eli Lilly and Company
NCT03598608 COMPLETED
Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)
Merck Sharp & Dohme LLC
NCT06761677 SUSPENDED
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
SymBio Pharmaceuticals
NCT04809467 TERMINATED
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
Incyte Corporation
NCT02315326 COMPLETED
Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
Memorial Sloan Kettering Cancer Center
NCT05459571 COMPLETED
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
Kite, A Gilead Company
NCT06068881 WITHDRAWN
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation
Epizyme, Inc.
NCT00875056 COMPLETED
Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)
Merck Sharp & Dohme LLC
NCT04285268 WITHDRAWN
Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Rutgers, The State University of New Jersey
NCT04116437 COMPLETED
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
BeiGene
NCT04401774 COMPLETED
Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy
Memorial Sloan Kettering Cancer Center
NCT03740529 COMPLETED
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Loxo Oncology, Inc.
NCT06575686 SUSPENDED
Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
City of Hope Medical Center
NCT04855253 SUSPENDED
Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL
Masonic Cancer Center, University of Minnesota
NCT02896582 COMPLETED
Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance
The Lymphoma Academic Research Organisation
NCT03210662 COMPLETED
Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
NCT02264613 COMPLETED
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
Aileron Therapeutics, Inc.
NCT06558513 COMPLETED
To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors
Evopoint Biosciences Inc.
NCT02337829 COMPLETED
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Acerta Pharma BV
NCT07071909 WITHDRAWN
Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
UNC Lineberger Comprehensive Cancer Center
NCT04425070 TERMINATED
A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma
Antengene Corporation
NCT02490891 COMPLETED
Study of the Angiogenesis by PET/CT in Patients With Lymphoma
Centre Henri Becquerel
NCT06106841 TERMINATED
TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NCT04230304 TERMINATED
Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
Mayo Clinic
NCT06322342 COMPLETED
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Reveal Pharmaceuticals Inc.
NCT05179603 TERMINATED
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
Sanofi
NCT06511895 COMPLETED
AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)
Dizal Pharmaceuticals
NCT03105336 COMPLETED
A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Kite, A Gilead Company
NCT05120570 COMPLETED
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
Masonic Cancer Center, University of Minnesota
NCT01496976 COMPLETED
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL
H. Lee Moffitt Cancer Center and Research Institute
NCT03317899 COMPLETED
Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT05317936 TERMINATED
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax
M.D. Anderson Cancer Center
NCT02005289 COMPLETED
Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
Ohio State University Comprehensive Cancer Center
NCT04191187 COMPLETED
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
NCT02328014 COMPLETED
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
Acerta Pharma BV
NCT03567876 COMPLETED
Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL
Fondazione Italiana Linfomi - ETS
NCT05991973 COMPLETED
Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas
Zhejiang University
NCT04150913 COMPLETED
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
Marcela V. Maus, M.D.,Ph.D.
NCT01286272 COMPLETED
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
NCT01316523 TERMINATED
Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma
University of California, Davis
NCT02588651 COMPLETED
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Deepa Jagadeesh
NCT04214626 COMPLETED
R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
NCT07236151 COMPLETED
Sequential CD19/CD22 CAR-T Cell Therapy Following ASCT
The First Affiliated Hospital of Soochow University
NCT04880434 COMPLETED
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)
Kite, A Gilead Company
NCT03498612 TERMINATED
Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
University of Washington
NCT02875548 COMPLETED
A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
Epizyme, Inc.
NCT01760655 COMPLETED
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT04875195 COMPLETED
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
Merck Sharp & Dohme LLC
NCT04035434 TERMINATED
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
CRISPR Therapeutics AG
NCT04359784 COMPLETED
Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy
Fred Hutchinson Cancer Center
NCT01592370 COMPLETED
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Bristol-Myers Squibb
NCT04601831 COMPLETED
'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL
University of Texas Southwestern Medical Center
NCT05105841 COMPLETED
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
AbbVie
NCT01908777 COMPLETED
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
NCT03568461 COMPLETED
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma
Novartis Pharmaceuticals
NCT05564052 COMPLETED
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
Janssen Research & Development, LLC
NCT04607772 WITHDRAWN
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
NCT06439420 COMPLETED
CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial
Virginia Commonwealth University
NCT01258933 TERMINATED
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
M.D. Anderson Cancer Center
NCT04074746 COMPLETED
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
M.D. Anderson Cancer Center
NCT02356159 COMPLETED
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Cancer Institute (NCI)
NCT06018129 TERMINATED
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Genmab
NCT06670105 WITHDRAWN
A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma
M.D. Anderson Cancer Center
NCT05267054 COMPLETED
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
BeiGene
NCT02500407 COMPLETED
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Genentech, Inc.
NCT05626322 TERMINATED
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Pfizer
NCT06912529 TERMINATED
Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma
Universität Münster
NCT00911183 COMPLETED
Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial
Institut Bergonié
NCT02998476 COMPLETED
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
Incyte Corporation
NCT03677154 COMPLETED
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
NCT05883449 TERMINATED
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
Affimed GmbH
NCT06149247 COMPLETED
HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
Soligenix
NCT01660607 COMPLETED
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
Stanford University
NCT02327078 COMPLETED
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
NCT03834688 COMPLETED
Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age
PrECOG, LLC.
NCT05032183 TERMINATED
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
NCT04433182 TERMINATED
Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma
Fondazione Italiana Linfomi - ETS
NCT06005649 WITHDRAWN
Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Juventas Cell Therapy Ltd.
NCT02793544 COMPLETED
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
NCT02278796 COMPLETED
A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)
Insel Gruppe AG, University Hospital Bern
NCT03496779 COMPLETED
Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine
The Lymphoma Academic Research Organisation
NCT03862131 TERMINATED
PROactive Evaluation of Function to Avoid CardioToxicity
Washington University School of Medicine
NCT05011058 TERMINATED
An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas
Viracta Therapeutics, Inc.
NCT03409432 COMPLETED
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma
John Reneau
NCT02558816 COMPLETED
A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients
Nantes University Hospital
NCT00878254 COMPLETED
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
University of Miami
NCT03401853 TERMINATED
Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
University of Washington
NCT02956382 COMPLETED
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Georgetown University
NCT03287817 TERMINATED
Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma
Autolus Limited
NCT03144674 COMPLETED
A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
Incyte Corporation
NCT04477486 COMPLETED
Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma
AbbVie
NCT02329080 COMPLETED
New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement
International Extranodal Lymphoma Study Group (IELSG)
NCT03333486 TERMINATED
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
NCT06511869 COMPLETED
AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)
Dizal Pharmaceuticals
NCT02722668 COMPLETED
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
NCT04737265 COMPLETED
Pilot Study of an NTproBNP Guided Strategy of Cardioprotection
Abramson Cancer Center at Penn Medicine
NCT03133221 COMPLETED
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
University of Maryland, Baltimore
NCT01995669 COMPLETED
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
NCT02750670 COMPLETED
Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
University Health Network, Toronto
NCT03013491 TERMINATED
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
CytomX Therapeutics
NCT01359592 COMPLETED
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
SWOG Cancer Research Network
NCT05025423 TERMINATED
Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05265975 TERMINATED
A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL
Antengene Corporation
NCT02871219 COMPLETED
Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma
M.D. Anderson Cancer Center
NCT06839872 WITHDRAWN
A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
AstraZeneca
NCT02220985 COMPLETED
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Fred Hutchinson Cancer Center
NCT03246906 TERMINATED
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
NCT01350258 TERMINATED
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT04189952 TERMINATED
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
University of Miami
NCT00945724 COMPLETED
Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis
International Extranodal Lymphoma Study Group (IELSG)
NCT02953509 TERMINATED
Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Gilead Sciences
NCT05788289 TERMINATED
A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT03384654 COMPLETED
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Janssen Research & Development, LLC
NCT02811679 TERMINATED
A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma
Massachusetts General Hospital
NCT03113422 COMPLETED
Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy
PrECOG, LLC.
NCT04689659 COMPLETED
Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma
Beijing Boren Hospital
NCT01350245 COMPLETED
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT00626444 TERMINATED
Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL)
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT05972720 TERMINATED
A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma
CARGO Therapeutics
NCT03583424 COMPLETED
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
NCT02580539 COMPLETED
A Study of the Safety and Efficacy of EBV Specific T-cell Lines
Dr. Jean-Sebastien Delisle, MD, PhD
NCT04402138 COMPLETED
Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
SCRI Development Innovations, LLC
NCT04690192 COMPLETED
CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
NCT01532635 TERMINATED
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT04217317 TERMINATED
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma
Wake Forest University Health Sciences
NCT00994643 COMPLETED
Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT01458366 COMPLETED
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT04668365 SUSPENDED
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
NCT06941688 TERMINATED
Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma
Seoul National University Hospital
NCT02566304 COMPLETED
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT00848328 TERMINATED
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma
University of California, Davis
NCT03434730 COMPLETED
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Memorial Sloan Kettering Cancer Center
NCT04047797 TERMINATED
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
NCT03492125 TERMINATED
A Study Of The Selective PKC-β Inhibitor MS- 553
MingSight Pharmaceuticals, Inc
NCT04849351 COMPLETED
Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
Hutchison Medipharma Limited
NCT03615105 TERMINATED
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Memorial Sloan Kettering Cancer Center
NCT04105010 COMPLETED
Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)
Dizal Pharmaceuticals
NCT03187210 SUSPENDED
Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas
Insel Gruppe AG, University Hospital Bern
NCT04251065 TERMINATED
Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH
Fondazione Italiana Linfomi - ETS
NCT05296525 TERMINATED
Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL
Gamida Cell ltd
NCT03397706 COMPLETED
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies
Viracta Therapeutics, Inc.
NCT03235544 COMPLETED
A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor
Incyte Corporation
NCT04419389 TERMINATED
APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)
Aprea Therapeutics
NCT02631746 COMPLETED
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
National Cancer Institute (NCI)
NCT03126019 COMPLETED
A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma
Incyte Corporation
NCT03372057 COMPLETED
A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
SecuraBio
NCT02396134 COMPLETED
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT03484819 COMPLETED
Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma
National Cancer Institute (NCI)
NCT01437709 COMPLETED
Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
NCT04312841 COMPLETED
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
Ohio State University Comprehensive Cancer Center
NCT01701986 COMPLETED
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
M.D. Anderson Cancer Center
NCT03770416 COMPLETED
Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma
M.D. Anderson Cancer Center
NCT03804372 TERMINATED
The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide
Gruppo Italiano Malattie EMatologiche dell'Adulto
NCT03058289 COMPLETED
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
Intensity Therapeutics, Inc.
NCT03744676 COMPLETED
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Juno Therapeutics, a Subsidiary of Celgene
NCT04148742 WITHDRAWN
Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)
Dizal Pharmaceuticals
NCT03169790 WITHDRAWN
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
ImmunityBio, Inc.
NCT05844956 COMPLETED
A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)
Dizal Pharmaceuticals
NCT04718675 TERMINATED
A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)
Kronos Bio
NCT05348889 TERMINATED
First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies
Chimagen Biosciences, Ltd
NCT03088878 COMPLETED
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
Oncternal Therapeutics, Inc
NCT04102150 COMPLETED
Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma
Daiichi Sankyo Co., Ltd.
NCT03992339 COMPLETED
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Antengene Corporation
NCT04517435 TERMINATED
ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma
Deepa Jagadeesh
NCT03213691 COMPLETED
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT02413489 TERMINATED
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
Janssen Research & Development, LLC
NCT03495960 COMPLETED
Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System
International Extranodal Lymphoma Study Group (IELSG)
NCT05144009 TERMINATED
A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)
ADC Therapeutics S.A.
NCT03031483 COMPLETED
Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma
International Extranodal Lymphoma Study Group (IELSG)
NCT04432506 COMPLETED
Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma
M.D. Anderson Cancer Center
NCT03220035 COMPLETED
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT05467943 COMPLETED
Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma
Hutchmed
NCT05713110 COMPLETED
A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma
Hutchmed
NCT04716075 COMPLETED
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
Polish Lymphoma Research Group
NCT00670358 COMPLETED
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
Mayo Clinic
NCT04305444 TERMINATED
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
NCT02207062 COMPLETED
Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
NCT04841434 COMPLETED
A Phase I/II Study to Investigate the Use of VORAXAZE™ As Intended Intervention in Patients with CNSL
Charite University, Berlin, Germany
NCT04083170 TERMINATED
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Fred Hutchinson Cancer Center
NCT03768505 TERMINATED
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)
MEI Pharma, Inc.
NCT03484702 COMPLETED
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
Celgene
NCT03997968 COMPLETED
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
NCT05008055 COMPLETED
Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
AstraZeneca
NCT02910583 COMPLETED
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
Pharmacyclics LLC.
NCT03677141 COMPLETED
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
NCT03129828 COMPLETED
Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2
Prof. Dr. Clemens Schmitt
NCT03233204 COMPLETED
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT03761056 COMPLETED
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma
Kite, A Gilead Company
NCT01919619 COMPLETED
Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies
M.D. Anderson Cancer Center
NCT03307746 COMPLETED
A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma
University Hospital Southampton NHS Foundation Trust
NCT03890289 TERMINATED
Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma
Fondazione Italiana Linfomi - ETS
NCT03648372 TERMINATED
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
Takeda
NCT05269940 COMPLETED
A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies
Nanjing Zenshine Pharmaceuticals
NCT01755975 COMPLETED
Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
Memorial Sloan Kettering Cancer Center
NCT04101331 COMPLETED
Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides
Affimed GmbH
NCT03586999 COMPLETED
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
University of Colorado, Denver
NCT03493451 COMPLETED
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
BeiGene
NCT03206918 COMPLETED
Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
BeiGene
NCT03520920 COMPLETED
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
BeiGene
NCT03846427 COMPLETED
Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma
BeiGene
NCT03206970 COMPLETED
Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
BeiGene
NCT03145064 COMPLETED
Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
BeiGene
NCT03417765 WITHDRAWN
Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas
GlyPharma Therapeutics
NCT03311126 TERMINATED
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma
University of Wisconsin, Madison
NCT04358458 TERMINATED
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Genmab
NCT04434937 COMPLETED
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
Incyte Biosciences Japan GK
NCT02927964 COMPLETED
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
Robert Lowsky
NCT02692248 COMPLETED
Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
NCT03207867 TERMINATED
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Novartis Pharmaceuticals
NCT05315713 TERMINATED
An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
NCT06625359 TERMINATED
High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Central Nervous System Lymphoma
Seoul National University Hospital
NCT03788291 COMPLETED
Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
University of Rochester
NCT02532257 COMPLETED
Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma
M.D. Anderson Cancer Center
NCT04659044 TERMINATED
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Academic and Community Cancer Research United
NCT02529852 COMPLETED
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
M.D. Anderson Cancer Center
NCT02953652 COMPLETED
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
HUYABIO International, LLC.
NCT02955589 COMPLETED
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)
HUYABIO International, LLC.
NCT04038359 COMPLETED
A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma
SecuraBio
NCT02953301 COMPLETED
Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)
4SC AG
NCT02633137 COMPLETED
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT05140382 COMPLETED
AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL
AstraZeneca
NCT04847050 COMPLETED
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
National Cancer Institute (NCI)
NCT01998035 TERMINATED
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Columbia University
NCT04605666 COMPLETED
CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies
Nanfang Hospital, Southern Medical University
NCT03743246 TERMINATED
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
Celgene
NCT04676087 TERMINATED
Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides
Emory University
NCT02507336 COMPLETED
Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165
University of Miami
NCT06454266 COMPLETED
First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen)
Ningbo No. 1 Hospital
NCT04082936 TERMINATED
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
IGM Biosciences, Inc.
NCT05360238 TERMINATED
Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL
Mustang Bio
NCT05114837 WITHDRAWN
Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL
Masonic Cancer Center, University of Minnesota
NCT05720052 TERMINATED
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
MingSight Pharmaceuticals, Inc
NCT05272813 TERMINATED
A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
NCT01660451 COMPLETED
Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
Bayer
NCT01472562 COMPLETED
Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma
Weill Medical College of Cornell University
NCT03046953 COMPLETED
Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma
University of Birmingham
NCT05936229 WITHDRAWN
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Fred Hutchinson Cancer Center
NCT03088709 TERMINATED
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
Loyola University
NCT03346096 COMPLETED
TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in Lymphoma
Sheba Medical Center
NCT02295722 TERMINATED
GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma
AHS Cancer Control Alberta
NCT04111107 TERMINATED
Precision Medicine for Patients With Identified Actionable Mutations
Wake Forest University Health Sciences
NCT02384954 TERMINATED
QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
Altor BioScience
NCT02464228 COMPLETED
Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
Kura Oncology, Inc.
NCT05740449 WITHDRAWN
HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Princess Maxima Center for Pediatric Oncology
NCT01796171 COMPLETED
A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma
Nordic Nanovector
NCT03217643 COMPLETED
CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.
Imagine Institute
NCT03610724 COMPLETED
Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients
Novartis Pharmaceuticals
NCT03595657 COMPLETED
A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)
CStone Pharmaceuticals
NCT01611142 COMPLETED
Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
Kyowa Kirin Co., Ltd.
NCT04074330 TERMINATED
A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma
Takeda
NCT02564744 COMPLETED
Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL
Debiopharm International SA
NCT01716806 COMPLETED
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Seagen Inc.
NCT02199184 COMPLETED
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT05093322 COMPLETED
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
Hutchmed
NCT04298879 COMPLETED
IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma
Innovent Biologics (Suzhou) Co. Ltd.
NCT02348216 COMPLETED
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
Kite, A Gilead Company
NCT01492088 COMPLETED
Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Millennium Pharmaceuticals, Inc.
NCT02073097 COMPLETED
Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma
Case Comprehensive Cancer Center
NCT05966233 WITHDRAWN
R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Fondazione Italiana Linfomi - ETS
NCT06210750 WITHDRAWN
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
National Cancer Institute (NCI)
NCT04722601 TERMINATED
A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
University of Chicago
NCT04164368 COMPLETED
Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients
Fudan University
NCT05022797 TERMINATED
Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS
Fundacion CRIS de Investigación para Vencer el Cáncer
NCT04438005 COMPLETED
A Study of ICP-022 in Patients With R/R DLBCL
Beijing InnoCare Pharma Tech Co., Ltd.
NCT04942730 COMPLETED
Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)
St. Petersburg State Pavlov Medical University
NCT06400264 WITHDRAWN
Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)
National Cancer Institute (NCI)
NCT02624388 TERMINATED
Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)
University of Virginia
NCT01597219 COMPLETED
Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers
University College, London
NCT05328102 TERMINATED
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
Xencor, Inc.
NCT01979536 COMPLETED
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
National Cancer Institute (NCI)
NCT01626664 COMPLETED
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Kyowa Kirin, Inc.
NCT01226472 COMPLETED
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
Kyowa Kirin Co., Ltd.
NCT00888927 COMPLETED
Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma
Kyowa Kirin Co., Ltd.
NCT02445248 COMPLETED
Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients
Novartis Pharmaceuticals
NCT03246750 COMPLETED
B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma
The Thai Lymphoma Study Group
NCT02100423 COMPLETED
Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Paolo Caimi, MD
NCT00799513 COMPLETED
Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma
IRCCS San Raffaele
NCT02340884 COMPLETED
A Pilot RCT of the PRISM Intervention for AYAs With Cancer
Seattle Children's Hospital
NCT03310619 COMPLETED
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
Celgene
NCT01897571 COMPLETED
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL
Epizyme, Inc.
NCT04762160 TERMINATED
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Epizyme, Inc.
NCT03056339 COMPLETED
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
M.D. Anderson Cancer Center
NCT04668768 SUSPENDED
HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma
Fox Chase Cancer Center
NCT04508647 COMPLETED
Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma
University of Colorado, Denver
NCT02420912 COMPLETED
Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation
M.D. Anderson Cancer Center
NCT03098355 WITHDRAWN
Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
Zhujiang Hospital
NCT05613348 WITHDRAWN
CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma
Zhujiang Hospital
NCT02636322 COMPLETED
Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib
M.D. Anderson Cancer Center
NCT02451111 TERMINATED
Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma
Swiss Cancer Institute
NCT02282358 TERMINATED
Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
NCT04509466 TERMINATED
Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NCT02926833 COMPLETED
Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Kite, A Gilead Company
NCT06247540 WITHDRAWN
Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Northwestern University
NCT03012620 COMPLETED
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
UNICANCER
NCT02012088 COMPLETED
Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
NCT03357224 TERMINATED
PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)
European Organisation for Research and Treatment of Cancer - EORTC
NCT05611853 TERMINATED
Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
BioNova Pharmaceuticals (Shanghai) LTD.
NCT04002401 COMPLETED
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma
Kite, A Gilead Company
NCT04478123 COMPLETED
Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer
Memorial Sloan Kettering Cancer Center
NCT01527149 COMPLETED
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Roswell Park Cancer Institute
NCT03684694 TERMINATED
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
ADC Therapeutics S.A.
NCT02653976 COMPLETED
A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Solasia Pharma K.K.
NCT04465760 TERMINATED
Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy
OHSU Knight Cancer Institute
NCT03543813 COMPLETED
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL
CytomX Therapeutics
NCT03323151 COMPLETED
A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
PrECOG, LLC.
NCT03422679 TERMINATED
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Cellestia Biotech AG
NCT04220008 WITHDRAWN
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
NCT01991457 COMPLETED
Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia
University of Alabama at Birmingham
NCT03128359 COMPLETED
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
City of Hope Medical Center
NCT03399513 COMPLETED
Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma
University Hospital Muenster
NCT02332980 COMPLETED
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Mayo Clinic
NCT02600897 COMPLETED
A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
NCT03483103 COMPLETED
Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)
Juno Therapeutics, a Subsidiary of Celgene
NCT02561273 COMPLETED
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
University of Nebraska
NCT03552692 TERMINATED
Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma
Fondazione Italiana Linfomi - ETS
NCT03734601 COMPLETED
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Stanford University
NCT01524926 COMPLETED
CREATE: Cross-tumoral Phase 2 With Crizotinib
European Organisation for Research and Treatment of Cancer - EORTC
NCT01393756 COMPLETED
Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma
The Lymphoma Academic Research Organisation
NCT01145209 COMPLETED
Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL
National Heart, Lung, and Blood Institute (NHLBI)
NCT03255018 COMPLETED
Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas
National Cancer Institute (NCI)
NCT03900377 COMPLETED
Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma
SymBio Pharmaceuticals
NCT01193842 COMPLETED
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
National Cancer Institute (NCI)
NCT02733042 COMPLETED
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
Celgene
NCT05929716 WITHDRAWN
An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
M.D. Anderson Cancer Center
NCT05138458 SUSPENDED
A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL
Myeloid Therapeutics
NCT03572634 TERMINATED
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
Sumitomo Pharma America, Inc.
NCT04218825 TERMINATED
REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)
European Organisation for Research and Treatment of Cancer - EORTC
NCT02639559 COMPLETED
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Washington University School of Medicine
NCT01685008 COMPLETED
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)
MorphoSys AG
NCT04684979 WITHDRAWN
Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies
Baptist Health South Florida
NCT05222438 WITHDRAWN
Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant
Barbara Ann Karmanos Cancer Institute
NCT02763384 TERMINATED
BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Washington University School of Medicine
NCT04699461 TERMINATED
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma
ADC Therapeutics S.A.
NCT02869633 COMPLETED
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
NCT02399085 COMPLETED
Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL
MorphoSys AG
NCT03534180 COMPLETED
Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma
City of Hope Medical Center
NCT02304458 COMPLETED
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
National Cancer Institute (NCI)
NCT03947255 TERMINATED
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
Seagen Inc.
NCT04660799 COMPLETED
A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
NCT03096782 COMPLETED
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
M.D. Anderson Cancer Center
NCT03093831 TERMINATED
Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma
National Cancer Centre, Singapore
NCT02957019 TERMINATED
A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Philogen S.p.A.
NCT04795869 WITHDRAWN
Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma
Northwestern University
NCT02611323 COMPLETED
A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
NCT01035463 COMPLETED
Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma
University of Nebraska
NCT01431209 COMPLETED
Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant
University of Nebraska
NCT02874404 COMPLETED
TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
University of Nebraska
NCT01060384 COMPLETED
Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
University of Nebraska
NCT02065869 TERMINATED
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
NCT04692155 TERMINATED
Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)
University of Alabama at Birmingham
NCT02391545 TERMINATED
A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
SecuraBio
NCT03571308 COMPLETED
A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)
University Hospital Southampton NHS Foundation Trust
NCT03733249 TERMINATED
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Bellicum Pharmaceuticals
NCT01336933 COMPLETED
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
University of Nebraska
NCT03309878 COMPLETED
Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI)
NCT02661035 COMPLETED
Allo HSCT Using RIC for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT01696461 COMPLETED
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
Center for International Blood and Marrow Transplant Research
NCT04022005 COMPLETED
Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL
Sun Yat-sen University
NCT01882803 COMPLETED
A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma
SecuraBio
NCT01044745 TERMINATED
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
University of Nebraska
NCT03589469 COMPLETED
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics S.A.
NCT03542266 COMPLETED
CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Weill Medical College of Cornell University
NCT04029038 WITHDRAWN
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
M.D. Anderson Cancer Center
NCT01484093 COMPLETED
Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT03229382 TERMINATED
Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse
Polish Lymphoma Research Group
NCT00816413 WITHDRAWN
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
University of Nebraska
NCT03010358 COMPLETED
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
Alexey Danilov, MD
NCT04644315 TERMINATED
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
Hoffmann-La Roche
NCT03702231 COMPLETED
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)
National Heart, Lung, and Blood Institute (NHLBI)
NCT01652144 COMPLETED
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma
NCIC Clinical Trials Group
NCT01267812 COMPLETED
Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
City of Hope Medical Center
NCT02576990 COMPLETED
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
Merck Sharp & Dohme LLC
NCT03828448 TERMINATED
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma
TG Therapeutics, Inc.
NCT01399372 COMPLETED
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Radiation Therapy Oncology Group
NCT00788125 TERMINATED
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
City of Hope Medical Center
NCT01203020 COMPLETED
Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation
West Virginia University
NCT02226965 COMPLETED
PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)
Sierra Oncology LLC - a GSK company
NCT01216683 COMPLETED
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
ECOG-ACRIN Cancer Research Group
NCT01572662 COMPLETED
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
M.D. Anderson Cancer Center
NCT01390584 TERMINATED
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
ECOG-ACRIN Cancer Research Group
NCT01307605 TERMINATED
Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma
Swiss Cancer Institute
NCT01754857 COMPLETED
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
University of Wisconsin, Madison
NCT01145495 COMPLETED
Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
NCT03364231 COMPLETED
Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma
TG Therapeutics, Inc.
NCT02030834 COMPLETED
Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
University of Pennsylvania
NCT01733238 COMPLETED
Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Sierra Oncology LLC - a GSK company
NCT02760485 COMPLETED
A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Incyte Corporation
NCT01378871 TERMINATED
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Amit Verma
NCT05380635 COMPLETED
PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma
Soligenix
NCT02440685 TERMINATED
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Asana BioSciences
NCT05152459 WITHDRAWN
Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma
City of Hope Medical Center
NCT04121507 COMPLETED
ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy
GWT-TUD GmbH
NCT04190433 WITHDRAWN
Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial
Mayo Clinic
NCT03003520 COMPLETED
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
Celgene
NCT00896493 COMPLETED
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
Stanford University
NCT04161118 TERMINATED
TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma
University of Cologne
NCT01027000 COMPLETED
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Alliance for Clinical Trials in Oncology
NCT03999658 WITHDRAWN
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
Sorrento Therapeutics, Inc.
NCT02581007 COMPLETED
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Northside Hospital, Inc.
NCT01092182 COMPLETED
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
NCT05393999 WITHDRAWN
SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations
Imperial College Healthcare NHS Trust
NCT04775680 TERMINATED
Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma
Adagene (Suzhou) Limited
NCT04094142 COMPLETED
Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Seoul National University Hospital
NCT03994913 COMPLETED
Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma
CARsgen Therapeutics Co., Ltd.
NCT01182415 COMPLETED
High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma
Massachusetts General Hospital
NCT05319028 TERMINATED
Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Calithera Biosciences, Inc
NCT03238599 COMPLETED
Pedometer Activity Monitoring After ASCT
Insel Gruppe AG, University Hospital Bern
NCT02546440 COMPLETED
Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)
Universitätsmedizin Mannheim
NCT03492775 COMPLETED
First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years
Prof. Dr. Wolfgang Hiddemann
NCT02836925 COMPLETED
Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection
Fondazione Italiana Linfomi - ETS
NCT00783367 COMPLETED
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Abramson Cancer Center at Penn Medicine
NCT05365100 WITHDRAWN
A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL
BioNova Pharmaceuticals (Shanghai) LTD.
NCT04730349 TERMINATED
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
Bristol-Myers Squibb
NCT01238692 COMPLETED
A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)
Sarit Assouline
NCT02840539 COMPLETED
Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma
Seoul National University Hospital
NCT01582776 COMPLETED
Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma
The Lymphoma Academic Research Organisation
NCT04323657 COMPLETED
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
TCR2 Therapeutics
NCT00644189 COMPLETED
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Massachusetts General Hospital
NCT04602065 TERMINATED
Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial
Innovent Biologics (Suzhou) Co. Ltd.
NCT01992653 COMPLETED
A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma
Genentech, Inc.
NCT02419287 COMPLETED
Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas
University of Milano Bicocca
NCT05338047 COMPLETED
Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant
Hospital Universitario Dr. Jose E. Gonzalez
NCT03370185 WITHDRAWN
Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
SecuraBio
NCT03019640 COMPLETED
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
NCT03123393 TERMINATED
TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Calithera Biosciences, Inc
NCT04334174 WITHDRAWN
Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas
University of Kansas Medical Center
NCT02853370 COMPLETED
Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma
International Extranodal Lymphoma Study Group (IELSG)
NCT04030195 COMPLETED
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
Precision BioSciences, Inc.
NCT01746173 TERMINATED
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
Dana-Farber Cancer Institute
NCT02314247 TERMINATED
Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma
Karyopharm Therapeutics Inc
NCT01028716 TERMINATED
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
NCT02593123 COMPLETED
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Virginia Commonwealth University
NCT03109353 COMPLETED
Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease
St. Olavs Hospital
NCT03276468 COMPLETED
Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas
The Lymphoma Academic Research Organisation
NCT00849147 COMPLETED
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
Medical College of Wisconsin
NCT01141712 COMPLETED
Autologous Transplant in HIV Patients (BMT CTN 0803)
Medical College of Wisconsin
NCT02955823 COMPLETED
A Phase II Study of the FIL on Elderly Frail Patients With DLBCL
Fondazione Italiana Linfomi - ETS
NCT03456726 COMPLETED
Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
Eisai Co., Ltd.
NCT00864227 COMPLETED
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
Medical College of Wisconsin
NCT03877055 COMPLETED
A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT01177397 COMPLETED
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Celgene
NCT00912223 COMPLETED
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)
Medical College of Wisconsin
NCT01410344 COMPLETED
Allogeneic Transplant in HIV Patients (BMT CTN 0903)
Medical College of Wisconsin
NCT00739141 COMPLETED
Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.
Memorial Sloan Kettering Cancer Center
NCT02643303 COMPLETED
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
NCT05570188 WITHDRAWN
Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies
Kunming Hope of Health Hospital
NCT04934579 COMPLETED
Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT01947140 COMPLETED
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
Jennifer Amengual
NCT01647971 COMPLETED
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
TG Therapeutics, Inc.
NCT02257567 COMPLETED
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
NCT03200015 COMPLETED
Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell Lymphoma
Hospital Universitario Dr. Jose E. Gonzalez
NCT02556931 COMPLETED
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01807611 COMPLETED
Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
St. Jude Children's Research Hospital
NCT03770000 COMPLETED
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
Rhizen Pharmaceuticals SA
NCT02660710 COMPLETED
Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
NCT03578198 TERMINATED
Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)
Seoul National University Hospital
NCT01842672 COMPLETED
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
New York Medical College
NCT04504708 TERMINATED
Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies
Hangzhou Zenshine Pharmaceuticals Co., Ltd.
NCT01498484 COMPLETED
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
Atara Biotherapeutics
NCT04444141 TERMINATED
A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma
Akeso
NCT05239910 WITHDRAWN
Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL
Rhizen Pharmaceuticals SA
NCT01775475 COMPLETED
Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma
AIDS Malignancy Consortium
NCT01030900 COMPLETED
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
National Cancer Institute (NCI)
NCT02065154 COMPLETED
Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis
University of Alabama at Birmingham
NCT02225275 TERMINATED
Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
NCT01700946 COMPLETED
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
NCT02531308 TERMINATED
Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)
Rush University Medical Center
NCT02898259 TERMINATED
Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Brian Hill
NCT01976585 COMPLETED
In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
Joshua Brody
NCT02572453 TERMINATED
Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL
National Cancer Institute (NCI)
NCT00858793 TERMINATED
High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT
Universitätsklinikum Hamburg-Eppendorf
NCT03422523 TERMINATED
Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy
University Hospital Southampton NHS Foundation Trust
NCT03379051 TERMINATED
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
TG Therapeutics, Inc.
NCT02361346 TERMINATED
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
Molecular Templates, Inc.
NCT00822120 COMPLETED
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
SWOG Cancer Research Network
NCT03645395 TERMINATED
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)
Molecular Templates, Inc.
NCT03488251 TERMINATED
PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma
Molecular Templates, Inc.
NCT03704714 SUSPENDED
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
Northwestern University
NCT01516606 COMPLETED
Salvage Therapy With High Dose Oral Clarithromycin in Relapsed or Refractory Extranodal Marginal Zone Lymphoma
Andres J. M. Ferreri
NCT01516619 COMPLETED
Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia
Andres J. M. Ferreri
NCT01662050 COMPLETED
Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL
Fondazione Italiana Linfomi - ETS
NCT01682226 COMPLETED
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
Memorial Sloan Kettering Cancer Center
NCT01514344 COMPLETED
Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma
Andres J. M. Ferreri
NCT01516593 COMPLETED
Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma
Andres J. M. Ferreri
NCT03536039 COMPLETED
RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor
Andres J. M. Ferreri
NCT04665115 WITHDRAWN
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
Academic and Community Cancer Research United
NCT03207256 TERMINATED
Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
TG Therapeutics, Inc.
NCT01241786 TERMINATED
Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL
Hackensack Meridian Health
NCT03023046 COMPLETED
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
University of Washington
NCT02535247 TERMINATED
Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma
Fox Chase Cancer Center
NCT01555541 COMPLETED
Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
C. Babis Andreadis
NCT01451515 COMPLETED
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
St. Jude Children's Research Hospital
NCT00712582 COMPLETED
Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT02710643 COMPLETED
"MIRO" Molecularly Oriented Immuno-radio-therapy
Fondazione Italiana Linfomi - ETS
NCT03936452 COMPLETED
Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma
Sun Yat-sen University
NCT02374424 TERMINATED
Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients
Fondazione Italiana Linfomi - ETS
NCT03365791 COMPLETED
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Novartis Pharmaceuticals
NCT01865617 COMPLETED
Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
Fred Hutchinson Cancer Center
NCT01261247 COMPLETED
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Mayo Clinic
NCT03141203 COMPLETED
Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients
University of Birmingham
NCT02584920 COMPLETED
A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma
Shanghai Henlius Biotech
NCT01658241 COMPLETED
Panobinostat Biological Correlates Study
Peter MacCallum Cancer Centre, Australia
NCT02043587 TERMINATED
Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
University of California, San Diego
NCT02674750 COMPLETED
Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations
Curis, Inc.
NCT03964688 COMPLETED
Effect of Vitamin C in Autologous Stem Cell Transplantations
Maastricht University Medical Center
NCT02542514 COMPLETED
Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma
The Lymphoma Academic Research Organisation
NCT02631577 COMPLETED
A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Hoffmann-La Roche
NCT04155840 TERMINATED
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
University of Washington
NCT03713320 TERMINATED
SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides
miRagen Therapeutics, Inc.
NCT01994382 COMPLETED
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
Alexion Pharmaceuticals, Inc.
NCT02420795 TERMINATED
Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
NCT03465527 COMPLETED
Pre-phase Treatment Before R-CHOP Chemotherapy in Elderly Patients With Newly Diagnosed DLBCL
Kosin University Gospel Hospital
NCT02499003 COMPLETED
GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma
Johannes Gutenberg University Mainz
NCT02356458 TERMINATED
Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
Swiss Cancer Institute
NCT04990778 WITHDRAWN
Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
NCT03974243 COMPLETED
Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma
Chipscreen Biosciences, Ltd.
NCT04961801 WITHDRAWN
Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
Shin Mineishi
NCT01685606 TERMINATED
Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma
Brown University
NCT02462538 TERMINATED
Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL
Arbeitsgemeinschaft medikamentoese Tumortherapie
NCT03364439 COMPLETED
R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients
Fondazione Italiana Linfomi - ETS
NCT04456023 WITHDRAWN
Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)
Novartis Pharmaceuticals
NCT03880279 WITHDRAWN
Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma
Triumvira Immunologics, Inc.
NCT02987400 COMPLETED
Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL
Arbeitsgemeinschaft medikamentoese Tumortherapie
NCT02178722 COMPLETED
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation
NCT03137537 TERMINATED
Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.
Dana-Farber Cancer Institute
NCT02077166 COMPLETED
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Pharmacyclics LLC.
NCT03322384 COMPLETED
UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma
University of California, Davis
NCT00924326 COMPLETED
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
National Cancer Institute (NCI)
NCT00637832 TERMINATED
Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma
University of Southampton
NCT02736617 COMPLETED
Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
OHSU Knight Cancer Institute
NCT01988571 COMPLETED
Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)
Wake Forest University Health Sciences
NCT02038946 COMPLETED
Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)
Bristol-Myers Squibb
NCT01481272 COMPLETED
Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients
Polish Lymphoma Research Group
NCT02857426 COMPLETED
A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)
Bristol-Myers Squibb
NCT03161054 COMPLETED
Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas
Fondazione Italiana Linfomi - ETS
NCT02639910 COMPLETED
Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi
MorphoSys AG
NCT03954106 TERMINATED
A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity
Jazz Pharmaceuticals
NCT03135262 TERMINATED
A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
NCT01118026 COMPLETED
Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
NCT03380026 COMPLETED
Mechlorethamine Induced Contact Dermatitis Avoidance Study
Rochester Skin Lymphoma Medical Group, PLLC
NCT00599170 COMPLETED
Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
University of Southern California
NCT00998946 COMPLETED
Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Spectrum Pharmaceuticals, Inc
NCT00865969 COMPLETED
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
Spectrum Pharmaceuticals, Inc
NCT01412879 COMPLETED
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
SWOG Cancer Research Network
NCT01665768 COMPLETED
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00695786 COMPLETED
Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
NCT03068416 COMPLETED
CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy
Uppsala University
NCT02038933 COMPLETED
Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)
Bristol-Myers Squibb
NCT03576443 COMPLETED
Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma
Nordic Lymphoma Group
NCT04882163 WITHDRAWN
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
Celgene
NCT01549886 TERMINATED
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Spectrum Pharmaceuticals, Inc
NCT01381692 COMPLETED
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
National Cancer Institute (NCI)
NCT03045328 COMPLETED
Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL
Steven E. Coutre
NCT03618238 COMPLETED
Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
NCT03563040 WITHDRAWN
Study of Photopheresis in the Treatment of Erythrodermic MF and SS
European Organisation for Research and Treatment of Cancer - EORTC
NCT01805037 TERMINATED
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Northwestern University
NCT01101581 WITHDRAWN
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
Gilead Sciences
NCT01190449 COMPLETED
Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
NCT01449461 COMPLETED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)
Ariad Pharmaceuticals
NCT03873025 WITHDRAWN
A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
University College, London
NCT00603668 COMPLETED
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
Gilead Sciences
NCT00546793 COMPLETED
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
Gilead Sciences
NCT03711578 COMPLETED
Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)
Rhizen Pharmaceuticals SA
NCT02489123 TERMINATED
Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
University of Washington
NCT01221857 COMPLETED
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
Gamida Cell ltd
NCT02265731 COMPLETED
Study Evaluating Venetoclax in Subjects With Hematological Malignancies
AbbVie
NCT01553786 COMPLETED
Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)
The Lymphoma Academic Research Organisation
NCT01434472 TERMINATED
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
Fred Hutchinson Cancer Center
NCT02676778 COMPLETED
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
Eisai Co., Ltd.
NCT02933320 COMPLETED
BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
Cancer Research UK
NCT03602898 WITHDRAWN
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
Fred Hutchinson Cancer Center
NCT04439240 COMPLETED
Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)
National Cancer Institute (NCI)
NCT02424968 COMPLETED
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
Robert Lowsky
NCT01643408 COMPLETED
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Jazz Pharmaceuticals
NCT02323230 TERMINATED
A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL
ImmunoVaccine Technologies, Inc. (IMV Inc.)
NCT01132807 COMPLETED
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
NCT03259529 COMPLETED
Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL
St. Petersburg State Pavlov Medical University
NCT00702052 COMPLETED
Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy
Novartis Pharmaceuticals
NCT02596971 COMPLETED
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
NCT03892421 COMPLETED
Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma
La Raza Medical Center
NCT01234766 COMPLETED
Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
Dartmouth-Hitchcock Medical Center
NCT01018979 COMPLETED
Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
GPCR Therapeutics, Inc.
NCT03586024 WITHDRAWN
Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas
Abramson Cancer Center at Penn Medicine
NCT01427114 COMPLETED
R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)
Konkuk University Medical Center
NCT01363128 COMPLETED
Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
NCT01497496 COMPLETED
Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
H. Lee Moffitt Cancer Center and Research Institute
NCT02341209 TERMINATED
Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma
Rochester General Hospital
NCT02104427 COMPLETED
PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
GPCR Therapeutics, Inc.
NCT01458288 COMPLETED
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
GPCR Therapeutics, Inc.
NCT03292406 COMPLETED
A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
Galderma R&D
NCT04439214 COMPLETED
Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)
National Cancer Institute (NCI)
NCT03076437 COMPLETED
Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Shenzhen Institute for Innovation and Translational Medicine
NCT02605694 WITHDRAWN
Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)
SecuraBio
NCT00775268 TERMINATED
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
National Cancer Institute (NCI)
NCT02677155 COMPLETED
Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma
Oslo University Hospital
NCT02939014 COMPLETED
Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
Takeda
NCT02273739 COMPLETED
Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Celgene
NCT02078102 COMPLETED
A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
Sherif S. Farag
NCT02059239 COMPLETED
Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma
Weill Medical College of Cornell University
NCT04002622 TERMINATED
Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT02309515 TERMINATED
Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis
Mayo Clinic
NCT02927925 COMPLETED
A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type
Janssen Research & Development, LLC
NCT03465891 TERMINATED
Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
NCT03205046 TERMINATED
A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
Acerta Pharma BV
NCT01930162 COMPLETED
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant
Novartis Pharmaceuticals
NCT01994850 COMPLETED
Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients
Abramson Cancer Center at Penn Medicine
NCT03719898 WITHDRAWN
Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
Fox Chase Cancer Center
NCT01474681 COMPLETED
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Novartis Pharmaceuticals
NCT02729896 COMPLETED
A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
NCT00670592 COMPLETED
Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies
Novartis Pharmaceuticals
NCT01956695 COMPLETED
Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma
Institut Curie
NCT01121120 TERMINATED
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Tarix Pharmaceuticals
NCT02151903 TERMINATED
Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL
Alopexx Oncology, LLC
NCT01874288 TERMINATED
A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL
Alopexx Oncology, LLC
NCT01799889 TERMINATED
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies
Gilead Sciences
NCT03837457 TERMINATED
PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study
miRagen Therapeutics, Inc.
NCT02495454 TERMINATED
GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma
Fondazione Italiana Linfomi - ETS
NCT02752204 COMPLETED
An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma
University of Birmingham
NCT01258998 COMPLETED
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
National Cancer Institute (NCI)
NCT02937675 TERMINATED
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
Effector Therapeutics
NCT03487133 COMPLETED
Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma
Samsung Medical Center
NCT02670616 COMPLETED
Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
Samsung Medical Center
NCT01075321 COMPLETED
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Mayo Clinic
NCT00744991 COMPLETED
A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
Eli Lilly and Company
NCT03037645 TERMINATED
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
Sunesis Pharmaceuticals
NCT03070964 TERMINATED
A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
PharmaMar
NCT02253992 TERMINATED
An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma
Bristol-Myers Squibb
NCT00981799 TERMINATED
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Therapeutic Advances in Childhood Leukemia Consortium
NCT02991898 TERMINATED
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT03023878 COMPLETED
Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma
Amgen
NCT03298412 TERMINATED
Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
Amgen
NCT02501473 TERMINATED
Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT02266147 TERMINATED
Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
Dynavax Technologies Corporation
NCT03097770 COMPLETED
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
Chinese PLA General Hospital
NCT03225924 TERMINATED
Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy
The Lymphoma Academic Research Organisation
NCT01460602 WITHDRAWN
Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma
Louisiana State University Health Sciences Center Shreveport
NCT02875067 TERMINATED
Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma
NYU Langone Health
NCT01885897 COMPLETED
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
Masonic Cancer Center, University of Minnesota
NCT01921387 COMPLETED
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies
Fred Hutchinson Cancer Center
NCT01973062 TERMINATED
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma
Case Comprehensive Cancer Center
NCT01866839 COMPLETED
Preventing Stem Cell Transplant Complications With a Blood Separator Machine
National Heart, Lung, and Blood Institute (NHLBI)
NCT04439305 WITHDRAWN
Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)
National Cancer Institute (NCI)
NCT01657331 COMPLETED
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)
Columbia University
NCT02547948 WITHDRAWN
CD19-targeting CAR T Cells for B Cell Lymphoma
Fuda Cancer Hospital, Guangzhou
NCT01329900 COMPLETED
Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas
M.D. Anderson Cancer Center
NCT01317940 COMPLETED
Nutrition and Body Composition in Acute Lymphoblastic Leukemia
Children's Hospital Los Angeles
NCT03617484 WITHDRAWN
Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
University of Michigan Rogel Cancer Center
NCT02055820 COMPLETED
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL
Hoffmann-La Roche
NCT00939770 COMPLETED
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Children's Oncology Group
NCT01796470 TERMINATED
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
Gilead Sciences
NCT01109069 COMPLETED
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Pharmacyclics LLC.
NCT02624986 TERMINATED
A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hoffmann-La Roche
NCT01939327 COMPLETED
Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma
Institut Paoli-Calmettes
NCT01490723 COMPLETED
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
NCT00662948 COMPLETED
ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)
PETHEMA Foundation
NCT00632827 TERMINATED
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
University of California, San Francisco
NCT02460276 COMPLETED
A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Lund University Hospital
NCT03075553 TERMINATED
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Mayo Clinic
NCT03719560 WITHDRAWN
Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma
Brown University
NCT00857389 COMPLETED
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
M.D. Anderson Cancer Center
NCT00901927 TERMINATED
Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma
M.D. Anderson Cancer Center
NCT01626495 COMPLETED
Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma
University of Pennsylvania
NCT00992446 COMPLETED
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
NCT02210065 COMPLETED
Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation
M.D. Anderson Cancer Center
NCT00918333 COMPLETED
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Mayo Clinic
NCT04260009 WITHDRAWN
Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
Takeda
NCT01788189 COMPLETED
Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas
University Hospital, Essen
NCT00918723 COMPLETED
Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Fred Hutchinson Cancer Center
NCT01691898 COMPLETED
A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Genentech, Inc.
NCT02890602 COMPLETED
Erythropoietin for Management of Anemia Caused by Chemotherapy
Kosin University Gospel Hospital
NCT02141451 COMPLETED
ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL
Masonic Cancer Center, University of Minnesota
NCT00789776 COMPLETED
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT01200485 COMPLETED
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
M.D. Anderson Cancer Center
NCT03579927 WITHDRAWN
CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma
M.D. Anderson Cancer Center
NCT00602836 COMPLETED
Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
NCT00558675 COMPLETED
A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy
Mirror Biologics, Inc.
NCT03269552 TERMINATED
Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
University of Washington
NCT00490529 COMPLETED
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
Ronald Levy
NCT02370160 COMPLETED
HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma
Masonic Cancer Center, University of Minnesota
NCT02340936 COMPLETED
Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
NCT00509184 COMPLETED
Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma
Klaus Herfarth, MD
NCT01527045 COMPLETED
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
NCT00980395 COMPLETED
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma
University of Arizona
NCT02633020 COMPLETED
Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease
Amgen
NCT00723099 COMPLETED
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT01415765 WITHDRAWN
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
National Cancer Institute (NCI)
NCT01200329 COMPLETED
High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease
M.D. Anderson Cancer Center
NCT01326702 COMPLETED
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
National Cancer Institute (NCI)
NCT02589145 TERMINATED
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
M.D. Anderson Cancer Center
NCT01281917 COMPLETED
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
University of Wisconsin, Madison
NCT02682953 WITHDRAWN
Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers
University of Maryland, Baltimore
NCT01251575 COMPLETED
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT00974233 COMPLETED
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
University of Wisconsin, Madison
NCT02169505 TERMINATED
Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
M.D. Anderson Cancer Center
NCT00691652 TERMINATED
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
OHSU Knight Cancer Institute
NCT01353664 COMPLETED
A Rollover Study for Patients Who Participated in Other Romidepsin Protocols
Celgene
NCT00655668 TERMINATED
A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma
Celgene
NCT01523834 COMPLETED
Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT
Fondazione Italiana Linfomi - ETS
NCT02106650 COMPLETED
Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies
Acrotech Biopharma Inc.
NCT01754870 WITHDRAWN
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
University of Wisconsin, Madison
NCT01939899 COMPLETED
Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma
Millennium Pharmaceuticals, Inc.
NCT03195010 TERMINATED
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Fred Hutchinson Cancer Center
NCT01076543 COMPLETED
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
NCT01980628 COMPLETED
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Pharmacyclics LLC.
NCT01747499 TERMINATED
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Washington University School of Medicine
NCT01822886 COMPLETED
Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients
Fondazione Italiana Linfomi - ETS
NCT02729961 WITHDRAWN
Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
University of Washington
NCT02776891 WITHDRAWN
A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell Lymphoma
University of California, San Francisco
NCT02062632 TERMINATED
Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
Mayo Clinic
NCT01289210 TERMINATED
VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas
Celgene
NCT01529827 COMPLETED
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Roswell Park Cancer Institute
NCT01964755 TERMINATED
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
University of Miami
NCT00875667 COMPLETED
A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Celgene
NCT02843061 COMPLETED
Combination of Rituximab and NK Immunotherapy for B Lymphoma
Fuda Cancer Hospital, Guangzhou
NCT02518113 COMPLETED
A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
Eli Lilly and Company
NCT02249429 COMPLETED
Open-Label, Non Randomized Phase 2 Study With Safety Run-In
PIQUR Therapeutics AG
NCT02053545 WITHDRAWN
Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
Ann & Robert H Lurie Children's Hospital of Chicago
NCT00770224 COMPLETED
S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
SWOG Cancer Research Network
NCT01090414 TERMINATED
An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study
Gilead Sciences
NCT03232307 WITHDRAWN
Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
NCT01065805 TERMINATED
A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma
AHS Cancer Control Alberta
NCT01676831 COMPLETED
Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)
Abramson Cancer Center at Penn Medicine
NCT02535806 TERMINATED
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Children's Mercy Hospital Kansas City
NCT01839916 COMPLETED
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
University of Chicago
NCT01448096 COMPLETED
Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma
Chonbuk National University Hospital
NCT01162551 COMPLETED
Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma
Children's Hospital of Philadelphia
NCT01282424 COMPLETED
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas
Gilead Sciences
NCT02669511 COMPLETED
PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
PIQUR Therapeutics AG
NCT03127020 COMPLETED
Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients
PIQUR Therapeutics AG
NCT02401048 COMPLETED
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
Pharmacyclics LLC.
NCT01159067 TERMINATED
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
City of Hope Medical Center
NCT02624492 COMPLETED
To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL
Boehringer Ingelheim
NCT01008462 COMPLETED
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Fred Hutchinson Cancer Center
NCT02187861 COMPLETED
A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)
Hoffmann-La Roche
NCT02592876 TERMINATED
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
Seagen Inc.
NCT00987493 COMPLETED
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma
Swiss Cancer Institute
NCT02258529 TERMINATED
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
Gilead Sciences
NCT01002755 COMPLETED
Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
NCT02042950 TERMINATED
A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
NCT02568683 TERMINATED
Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
Gilead Sciences
NCT00711828 COMPLETED
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
Mayo Clinic
NCT01980654 COMPLETED
Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
Pharmacyclics LLC.
NCT02518750 TERMINATED
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
St. Jude Children's Research Hospital
NCT01116232 TERMINATED
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Barbara Ann Karmanos Cancer Institute
NCT02763254 TERMINATED
Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas
Cell Medica Ltd
NCT01948180 TERMINATED
Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
Cell Medica Ltd
NCT02855359 TERMINATED
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Seagen Inc.
NCT01456039 COMPLETED
A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)
Celgene
NCT01007526 COMPLETED
Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy in NK/T-cell Lymphoma
Samsung Medical Center
NCT02142049 COMPLETED
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Pharmacyclics LLC.
NCT00943319 COMPLETED
Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies
University of Chicago
NCT01408563 COMPLETED
Reduced Intensity Double Umbilical Cord Blood Transplantation
Massachusetts General Hospital
NCT02208037 COMPLETED
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
National Heart, Lung, and Blood Institute (NHLBI)
NCT01720264 COMPLETED
Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant
Sherif S. Farag
NCT02008006 TERMINATED
BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT)
Centre Leon Berard
NCT03794167 COMPLETED
BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma
Soonchunhyang University Hospital
NCT02391116 COMPLETED
Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Bayer
NCT03792815 COMPLETED
Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL)
Soonchunhyang University Hospital
NCT01686321 COMPLETED
Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma
University of Göttingen
NCT01479582 WITHDRAWN
Providing Access to Cord Blood Units for Transplants
National Cancer Institute (NCI)
NCT00667017 TERMINATED
RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
University of Texas Southwestern Medical Center
NCT00737529 COMPLETED
A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial
Celgene
NCT02272686 TERMINATED
Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma
M.D. Anderson Cancer Center
NCT01165112 COMPLETED
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma
University of Washington
NCT03438344 WITHDRAWN
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT01235793 TERMINATED
The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma
Cedars-Sinai Medical Center
NCT01306643 COMPLETED
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
Gilead Sciences
NCT01203930 TERMINATED
A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
Gilead Sciences
NCT03120000 WITHDRAWN
PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
PIQUR Therapeutics AG
NCT02538926 WITHDRAWN
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
University of Washington
NCT00709592 COMPLETED
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
Virginia Commonwealth University
NCT01133158 COMPLETED
R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
NCT01965119 COMPLETED
Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma
Samsung Medical Center
NCT00958074 TERMINATED
Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma
University of Washington
NCT00896454 COMPLETED
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Amgen
NCT02594163 TERMINATED
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma
Seagen Inc.
NCT01693614 COMPLETED
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
Novartis Pharmaceuticals
NCT00809341 TERMINATED
R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01848132 COMPLETED
Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
NCT01910025 COMPLETED
PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy
Polaris Group
NCT01024010 COMPLETED
Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
NCT03212807 WITHDRAWN
Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL
Singapore General Hospital
NCT01273766 COMPLETED
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
Wake Forest University Health Sciences
NCT02280785 COMPLETED
Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas
Samsung Medical Center
NCT02424045 COMPLETED
Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma
Samsung Medical Center
NCT00918463 TERMINATED
A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Weill Medical College of Cornell University
NCT02228512 WITHDRAWN
Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
National Cancer Institute (NCI)
NCT01686165 COMPLETED
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
University of Arizona
NCT00946023 TERMINATED
Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01049854 COMPLETED
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
New York Medical College
NCT02545361 WITHDRAWN
Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients
Kahr Medical
NCT01294579 COMPLETED
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Novartis Pharmaceuticals
NCT00703664 COMPLETED
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
NCT00990249 COMPLETED
Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation
M.D. Anderson Cancer Center
NCT00720876 COMPLETED
Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT01789255 COMPLETED
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
National Cancer Institute (NCI)
NCT01610180 COMPLETED
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
Fondazione Progetto Ematologia
NCT01745913 TERMINATED
Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies
Weill Medical College of Cornell University
NCT00695409 COMPLETED
Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT01135329 TERMINATED
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01050764 TERMINATED
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
Everett Meyer
NCT03407430 TERMINATED
Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain
UNC Lineberger Comprehensive Cancer Center
NCT01563302 COMPLETED
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
Ionis Pharmaceuticals, Inc.
NCT01925612 TERMINATED
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Seagen Inc.
NCT02419469 TERMINATED
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
NCT02420210 TERMINATED
Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma
University of Chicago
NCT01812005 TERMINATED
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
NCT01724177 COMPLETED
A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma
Celgene
NCT00961220 COMPLETED
O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma
National Cancer Institute (NCI)
NCT02533323 TERMINATED
P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens
Sun Yat-sen University
NCT00984165 TERMINATED
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
National Cancer Institute (NCI)
NCT02877082 TERMINATED
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Emory University
NCT01414855 COMPLETED
A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
Genentech, Inc.
NCT03241017 WITHDRAWN
Durvalumab in DLBCL After Autologous Transplant
Insel Gruppe AG, University Hospital Bern
NCT01030536 COMPLETED
Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)
MedImmune LLC
NCT03485118 COMPLETED
RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Zhejiang Hisun Pharmaceutical Co. Ltd.
NCT00807495 COMPLETED
Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma
Millennium Pharmaceuticals, Inc.
NCT01397825 COMPLETED
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine
Millennium Pharmaceuticals, Inc.
NCT02488512 TERMINATED
Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT02530125 TERMINATED
Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission
Northwestern University
NCT01515176 COMPLETED
Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
National Cancer Institute (NCI)
NCT01622439 COMPLETED
Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma
Lund University Hospital
NCT00963534 COMPLETED
Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.
Lund University Hospital
NCT01453205 COMPLETED
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
MedImmune LLC
NCT01737177 COMPLETED
Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL
Fondazione Italiana Linfomi - ETS
NCT01313611 TERMINATED
BRIEF Bendamustine and Rituximab In Elderly Follicular
The Lymphoma Academic Research Organisation
NCT01195714 COMPLETED
Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 Years
The Lymphoma Academic Research Organisation
NCT01147393 TERMINATED
Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma
Weill Medical College of Cornell University
NCT01969435 COMPLETED
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma
Washington University School of Medicine
NCT01181258 COMPLETED
Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies
Masonic Cancer Center, University of Minnesota
NCT01446900 TERMINATED
R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
European Institute of Oncology
NCT01472887 COMPLETED
SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients
Sanofi
NCT01097057 COMPLETED
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells
Fred Hutchinson Cancer Center
NCT02983097 TERMINATED
Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
NCT02294552 COMPLETED
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
Ivan S Moiseev
NCT01564277 TERMINATED
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
Roswell Park Cancer Institute
NCT00667615 COMPLETED
Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
Memorial Sloan Kettering Cancer Center
NCT00867529 COMPLETED
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
Fred Hutchinson Cancer Center
NCT00963872 TERMINATED
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
Masonic Cancer Center, University of Minnesota
NCT00882206 TERMINATED
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
Masonic Cancer Center, University of Minnesota
NCT00625729 TERMINATED
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Masonic Cancer Center, University of Minnesota
NCT01636388 TERMINATED
Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma
New York Medical College
NCT02252146 COMPLETED
Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation
Idera Pharmaceuticals, Inc.
NCT00764517 COMPLETED
Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma
OHSU Knight Cancer Institute
NCT02229981 WITHDRAWN
Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma
RedHill Biopharma Limited
NCT00867087 COMPLETED
Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Pfizer
NCT01343368 TERMINATED
Preservation of Ovarian Function After Hematopoietic Cell Transplant
Masonic Cancer Center, University of Minnesota
NCT01163201 WITHDRAWN
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
Masonic Cancer Center, University of Minnesota
NCT00983944 WITHDRAWN
Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
NCT01626352 COMPLETED
Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy
SCRI Development Innovations, LLC
NCT01187446 TERMINATED
Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
Stanford University
NCT02815397 TERMINATED
DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma
Rush University Medical Center
NCT02825147 COMPLETED
Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma
Ruijin Hospital
NCT02158975 COMPLETED
Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
University of Michigan Rogel Cancer Center
NCT02013362 COMPLETED
Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Mundipharma K.K.
NCT01611259 COMPLETED
Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue
Arbeitsgemeinschaft medikamentoese Tumortherapie
NCT00868608 COMPLETED
Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma
Pfizer
NCT02132624 COMPLETED
CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.
Uppsala University
NCT01562977 COMPLETED
Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
NCT02301364 COMPLETED
Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Memorial Sloan Kettering Cancer Center
NCT01239394 COMPLETED
Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
Massachusetts General Hospital
NCT01929265 COMPLETED
A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma
Fondazione Italiana Linfomi - ETS
NCT02455297 TERMINATED
Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Bayer
NCT01481129 COMPLETED
Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
NCT02662296 WITHDRAWN
Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT00837174 WITHDRAWN
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study
The Methodist Hospital Research Institute
NCT01369849 COMPLETED
Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
NCT01116193 COMPLETED
Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia
Institut de Cancérologie de la Loire
NCT01078142 COMPLETED
Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma
Georg Hess, MD
NCT02677948 WITHDRAWN
Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
University of Michigan Rogel Cancer Center
NCT02276248 COMPLETED
Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma
Chinese Academy of Medical Sciences
NCT01403896 COMPLETED
Healthy Donor Study II - Comparing Plerixafor With G-CSF and Plerixafor
Stephen Couban
NCT01339572 COMPLETED
Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation
University of Florida
NCT01419795 TERMINATED
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT00837200 TERMINATED
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
Milton S. Hershey Medical Center
NCT01779791 COMPLETED
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
Janssen Research & Development, LLC
NCT02098109 COMPLETED
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Washington University School of Medicine
NCT00691015 COMPLETED
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
NCT02408042 WITHDRAWN
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
Western Regional Medical Center
NCT02423291 COMPLETED
A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL
Fondazione Italiana Linfomi - ETS
NCT00816595 COMPLETED
Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
NCT00637117 WITHDRAWN
Intratumoral Dendritic Cell Vaccination Combined With Local Radiotherapy in Patients With Recurrent Lymphoma.
Baylor Research Institute
NCT00895661 COMPLETED
High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas
Massachusetts General Hospital
NCT00517049 COMPLETED
A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)
Genentech, Inc.
NCT01158118 COMPLETED
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
Washington University School of Medicine
NCT01323920 COMPLETED
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
Dana-Farber Cancer Institute
NCT00448201 COMPLETED
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
UNC Lineberger Comprehensive Cancer Center
NCT00856245 COMPLETED
Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma
University of Kansas Medical Center
NCT02259348 TERMINATED
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
St. Jude Children's Research Hospital
NCT01110135 COMPLETED
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
University of Washington
NCT01234467 COMPLETED
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
NCT00795769 COMPLETED
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT02623920 WITHDRAWN
Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
University of Arizona
NCT01427881 COMPLETED
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
NCT02766842 WITHDRAWN
Evaluation of a New EUS Guided Biopsy Needle (SharkCore) Comparing to Standard EUS Needle (ProCore)
Johns Hopkins University
NCT02260414 COMPLETED
Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer
Centre Hospitalier Universitaire de Saint Etienne
NCT01282476 TERMINATED
Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Massachusetts General Hospital
NCT01889797 TERMINATED
Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
PrECOG, LLC.
NCT02961816 WITHDRAWN
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
M.D. Anderson Cancer Center
NCT00460109 COMPLETED
Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
NCT01173679 TERMINATED
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL
Massachusetts General Hospital
NCT00923910 COMPLETED
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
National Cancer Institute (NCI)
NCT01004991 COMPLETED
Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma
Weill Medical College of Cornell University
NCT02973191 WITHDRAWN
A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia
Celgene
NCT01120834 COMPLETED
Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)
Weill Medical College of Cornell University
NCT02200380 TERMINATED
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
Celldex Therapeutics
NCT01396070 COMPLETED
Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level
Youn Kim
NCT02285244 WITHDRAWN
Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation
James Blachly
NCT02257684 TERMINATED
A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)
Jazz Pharmaceuticals
NCT01325701 COMPLETED
Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Pharmacyclics LLC.
NCT01173887 COMPLETED
Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15
Kyowa Kirin Co., Ltd.
NCT00920790 COMPLETED
Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma
Kyowa Kirin Co., Ltd.
NCT01000285 COMPLETED
EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma
Washington University School of Medicine
NCT01118013 TERMINATED
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Alliance for Clinical Trials in Oncology
NCT00866047 COMPLETED
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
Seagen Inc.
NCT02724904 WITHDRAWN
Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma
Massachusetts General Hospital
NCT02670317 TERMINATED
Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.
Fondazione Italiana Linfomi - ETS
NCT00880581 COMPLETED
A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas
Ronald Levy
NCT01944943 TERMINATED
Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia
The Lymphoma Academic Research Organisation
NCT00733824 COMPLETED
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma
Washington University School of Medicine
NCT01389427 COMPLETED
Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).
The Lymphoma Academic Research Organisation
NCT01192984 COMPLETED
Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell Lymphoma
Kyowa Kirin Co., Ltd.
NCT00705250 COMPLETED
Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
NCT01744691 COMPLETED
A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
Pharmacyclics LLC.
NCT01621477 TERMINATED
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
St. Jude Children's Research Hospital
NCT01475058 COMPLETED
CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant
Fred Hutchinson Cancer Center
NCT02113007 TERMINATED
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
SCRI Development Innovations, LLC
NCT00989586 COMPLETED
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Beth Christian
NCT00947856 COMPLETED
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Seagen Inc.
NCT00633594 COMPLETED
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
SCRI Development Innovations, LLC
NCT01389076 TERMINATED
Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma
University of Michigan Rogel Cancer Center
NCT00873093 COMPLETED
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
National Cancer Institute (NCI)
NCT02169180 COMPLETED
Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Janssen Pharmaceutical K.K.
NCT01810120 COMPLETED
Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT
Mariella Enoc
NCT00931918 COMPLETED
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Millennium Pharmaceuticals, Inc.
NCT01741792 COMPLETED
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Amgen Research (Munich) GmbH
NCT00684411 COMPLETED
Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma
Dana-Farber Cancer Institute
NCT01944982 TERMINATED
Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
NCT00881387 WITHDRAWN
Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment
University of Miami
NCT01733953 COMPLETED
Statin Therapy in Young Adult Survivors of Childhood Cancer
University of Minnesota
NCT00611208 COMPLETED
A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)
Virogen Biotechnology Inc.
NCT01421667 COMPLETED
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
Seagen Inc.
NCT02653989 WITHDRAWN
Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Medivation, Inc.
NCT00978432 TERMINATED
Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Anne Beaven, MD
NCT01244009 WITHDRAWN
A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)
Tesaro, Inc.
NCT01486277 COMPLETED
A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
Janssen Research & Development, LLC
NCT01423539 WITHDRAWN
A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)
Genentech, Inc.
NCT02115126 WITHDRAWN
Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant
David Rizzieri, MD
NCT00891618 COMPLETED
Acupuncture for Chemo-Induced Peripheral Neuropathy
M.D. Anderson Cancer Center
NCT01186458 TERMINATED
Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Hoosier Cancer Research Network
NCT01144403 TERMINATED
A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.
Hoffmann-La Roche
NCT01699581 TERMINATED
Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant
Greg Monohan
NCT00788606 TERMINATED
R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma
Royal Marsden NHS Foundation Trust
NCT02141100 WITHDRAWN
Study of 6-Thioguanine in Combination With 6-Mercaptopurine During Maintenance Therapy of Childhood Lymphoma
Kjeld Schmiegelow
NCT00784927 COMPLETED
Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma
Mayo Clinic
NCT00607854 COMPLETED
Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)
University Hospital, Bordeaux
NCT01556035 COMPLETED
Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma
University Hospital, Bordeaux
NCT01113632 COMPLETED
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
SCRI Development Innovations, LLC
NCT00798096 COMPLETED
Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
Rigel Pharmaceuticals
NCT00800839 COMPLETED
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
M.D. Anderson Cancer Center
NCT01121757 TERMINATED
Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
Duke University
NCT01015248 COMPLETED
Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
NCT02808091 TERMINATED
Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma
National Cancer Centre, Singapore
NCT01029730 COMPLETED
Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma
SCRI Development Innovations, LLC
NCT00786851 COMPLETED
Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Fondazione Italiana Linfomi - ETS
NCT02281279 WITHDRAWN
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Mayo Clinic
NCT01652014 WITHDRAWN
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
University of Medicine and Dentistry of New Jersey
NCT02046928 TERMINATED
Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)
Ångstrom Pharmaceuticals
NCT00516217 COMPLETED
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
NCT00553501 COMPLETED
Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
NCT00904722 COMPLETED
Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma
M.D. Anderson Cancer Center
NCT01599949 COMPLETED
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Janssen Research & Development, LLC
NCT01562990 COMPLETED
Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse
The Lymphoma Academic Research Organisation
NCT02701673 WITHDRAWN
Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma
M.D. Anderson Cancer Center
NCT01718691 COMPLETED
Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
SymBio Pharmaceuticals
NCT02337595 COMPLETED
Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
NCT00831597 COMPLETED
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Pharmatech
NCT01578343 TERMINATED
Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma
Samsung Medical Center
NCT00765245 COMPLETED
Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
Vanderbilt-Ingram Cancer Center
NCT01213095 COMPLETED
Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)
Dong-A University Hospital
NCT02221492 COMPLETED
Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma
Genzyme, a Sanofi Company
NCT02412267 COMPLETED
Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
National Cancer Centre, Singapore
NCT01403636 COMPLETED
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Sanofi
NCT01518153 TERMINATED
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
NCT00836173 WITHDRAWN
Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Loyola University
NCT01457144 COMPLETED
Study of Mantle Cell Lymphoma Treatment by RiBVD
French Innovative Leukemia Organisation
NCT01528865 WITHDRAWN
Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma
University of Michigan Rogel Cancer Center
NCT01466881 COMPLETED
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
NCT01523860 COMPLETED
Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma
Fondazione Italiana Linfomi - ETS
NCT00975975 COMPLETED
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
Indiana University
NCT01413568 COMPLETED
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
Polyphor Ltd.
NCT01205503 COMPLETED
Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
Mara Chambers
NCT00761384 COMPLETED
High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma
Lund University Hospital
NCT01296256 COMPLETED
Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL).
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
NCT00646750 COMPLETED
Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
NCT01500538 TERMINATED
A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)
Peter MacCallum Cancer Centre, Australia
NCT01278615 TERMINATED
Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
National Cancer Institute (NCI)
NCT01419691 COMPLETED
Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)
University of Kansas Medical Center
NCT01336712 COMPLETED
Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases
Northside Hospital, Inc.
NCT01314014 COMPLETED
Imexon for Relapsed Follicular and Aggressive Lymphomas
University of Rochester
NCT01073267 COMPLETED
Study of Total Skin Electron Beam Therapy (TSEBT) in Stage IB-IIIA Mycosis Fungoides
M.D. Anderson Cancer Center
NCT00849524 TERMINATED
Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Januario Castro, M.D.
NCT01010568 TERMINATED
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Georgetown University
NCT01624701 TERMINATED
Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells
Singapore General Hospital
NCT01050946 TERMINATED
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit
Medical College of Wisconsin
NCT01007292 COMPLETED
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
Astellas Pharma Inc
NCT01263418 WITHDRAWN
Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas
UNC Lineberger Comprehensive Cancer Center
NCT01180569 WITHDRAWN
Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
NCT01236391 COMPLETED
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Pharmacyclics LLC.
NCT00759603 COMPLETED
Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT01119794 TERMINATED
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
Brown University
NCT00871546 TERMINATED
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
Merck Sharp & Dohme LLC
NCT01497275 TERMINATED
Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
Duke University
NCT01848652 TERMINATED
Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.
University Hospital, Brest
NCT00905398 TERMINATED
Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Rony Schaffel
NCT01217749 COMPLETED
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL
Pharmacyclics LLC.
NCT01843998 WITHDRAWN
Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)
Stefan Schieke MD
NCT02310997 TERMINATED
Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)
University College, London
NCT00958256 COMPLETED
Study of Bortezomib in Combination With Cyclophosphamide and Rituximab
M.D. Anderson Cancer Center
NCT00833534 WITHDRAWN
Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT00723658 WITHDRAWN
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
SWOG Cancer Research Network
NCT01198665 COMPLETED
RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas
Samsung Medical Center
NCT01238159 COMPLETED
Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma
Samsung Medical Center
NCT00967044 COMPLETED
Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma
M.D. Anderson Cancer Center
NCT00809276 COMPLETED
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00916045 TERMINATED
Pilot Study of Unrelated Cord Blood Transplantation
King's College Hospital NHS Trust
NCT00666484 COMPLETED
Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma
University College, London
NCT00660231 COMPLETED
Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma
University College, London
NCT01470456 COMPLETED
Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Sanofi
NCT00891839 COMPLETED
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
Cephalon
NCT00869999 COMPLETED
Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Massachusetts General Hospital
NCT01926639 COMPLETED
Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma
Oslo University Hospital
NCT01095757 COMPLETED
Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection
Emory University
NCT00787527 COMPLETED
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
NCT01499303 COMPLETED
Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
AstraZeneca
NCT00576758 COMPLETED
GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma
Hoffmann-La Roche
NCT00948090 COMPLETED
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
Otsuka Pharmaceutical Development & Commercialization, Inc.
NCT01397591 TERMINATED
Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma
OHSU Knight Cancer Institute
NCT00851552 TERMINATED
Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
Roswell Park Cancer Institute
NCT01466868 TERMINATED
Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Centre Leon Berard
NCT01354392 COMPLETED
AZD1152 in Diffuse Large B-cell Lymphoma
Oxford University Hospitals NHS Trust
NCT00669318 COMPLETED
Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
NCT00901147 COMPLETED
Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
Singapore General Hospital
NCT01283776 COMPLETED
Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation
University of Cologne
NCT00597714 COMPLETED
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
David Rizzieri, MD
NCT01280526 COMPLETED
A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas
The Lymphoma Academic Research Organisation
NCT00901225 COMPLETED
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
Duke University
NCT00724984 COMPLETED
Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma
Pharmacyclics LLC.
NCT00949117 TERMINATED
Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer
University of South Florida
NCT00727831 COMPLETED
Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
University College, London
NCT01040871 COMPLETED
Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Millennium Pharmaceuticals, Inc.
NCT00656812 COMPLETED
Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma
Arbeitsgemeinschaft medikamentoese Tumortherapie
NCT00972842 TERMINATED
Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)
Arbeitsgemeinschaft medikamentoese Tumortherapie
NCT00040690 COMPLETED
Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Medical Research Council
NCT01090973 TERMINATED
Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
H. Lee Moffitt Cancer Center and Research Institute
NCT01854372 WITHDRAWN
Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement.
The University of Texas Health Science Center at San Antonio
NCT01164267 COMPLETED
Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)
International Extranodal Lymphoma Study Group (IELSG)
NCT01500161 TERMINATED
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Texas Oncology Cancer Center
NCT00782379 COMPLETED
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer
Northside Hospital, Inc.
NCT01037517 COMPLETED
Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization
CancerCare Manitoba
NCT00799136 COMPLETED
A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL
Ontario Clinical Oncology Group (OCOG)
NCT00829205 WITHDRAWN
Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
Cancer Research UK
NCT01118845 COMPLETED
Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
SymBio Pharmaceuticals
NCT00776802 WITHDRAWN
GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
La Jolla Pharmaceutical Company
NCT01238146 WITHDRAWN
Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
NCT00873457 COMPLETED
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Daphne Friedman
NCT00715208 COMPLETED
Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma
Millennium Pharmaceuticals, Inc.
NCT01148108 COMPLETED
Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma
Telik
NCT00823719 COMPLETED
Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)
GlaxoSmithKline
NCT01667289 TERMINATED
Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell Lymphoma
Fudan University
NCT00823524 COMPLETED
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
Asan Medical Center
NCT00959686 COMPLETED
Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma
French Innovative Leukemia Organisation
NCT00902525 TERMINATED
Zevalin Twice in Aggressive Non-Hodgkin Lymphoma
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
NCT00727207 TERMINATED
Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy
Technical University of Munich
NCT00850499 TERMINATED
Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab
Millennium Pharmaceuticals, Inc.
NCT00636155 TERMINATED
EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
David Rizzieri
NCT00699296 TERMINATED
Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
Novartis Pharmaceuticals
NCT01649622 WITHDRAWN
Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)
M.D. Anderson Cancer Center
NCT00742495 TERMINATED
Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.
Mundipharma Research Limited
NCT01054781 COMPLETED
Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)
Samsung Medical Center
NCT00992134 COMPLETED
Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma
St. Bortolo Hospital
NCT00969085 WITHDRAWN
Trial of Curcumin in Cutaneous T-cell Lymphoma Patients
M.D. Anderson Cancer Center
NCT01108341 COMPLETED
Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)
Cephalon
NCT01036399 TERMINATED
Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients
University of Bologna
NCT00968331 TERMINATED
Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
University of Bologna
NCT00810576 TERMINATED
Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
NCT00843050 TERMINATED
A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma
Piramal Enterprises Limited
NCT01083342 COMPLETED
High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study
Samsung Medical Center
NCT00570999 WITHDRAWN
Palifermin After Haploidentical PBSCT
European Society for Blood and Marrow Transplantation
NCT01263899 COMPLETED
A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
S*BIO
NCT00854425 COMPLETED
L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell Lymphoma
Fudan University
NCT00636792 COMPLETED
A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma
Millennium Pharmaceuticals, Inc.
NCT00712062 WITHDRAWN
Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System Lymphoma
University of Florida
NCT00768339 TERMINATED
A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
Aegera Therapeutics
NCT01170052 WITHDRAWN
Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)
Charite University, Berlin, Germany
NCT00794261 COMPLETED
Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma
Centre Leon Berard
NCT07583771 NOT YET RECRUITING
A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
Chipscreen Biosciences, Ltd.
NCT07052305 RECRUITING
NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
Washington University School of Medicine
NCT03502733 ACTIVE NOT RECRUITING
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
National Cancer Institute (NCI)
NCT06223542 RECRUITING
Studying TAK-243 in Patients With Advanced Cancer
National Cancer Institute (NCI)
NCT02160015 ACTIVE NOT RECRUITING
Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT07101328 NOT YET RECRUITING
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Eli Lilly and Company
NCT03321643 ACTIVE NOT RECRUITING
Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
NCT05272384 RECRUITING
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
National Cancer Institute (NCI)
NCT07444710 NOT YET RECRUITING
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
NCT06015880 RECRUITING
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
NCT05627245 ACTIVE NOT RECRUITING
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
National Cancer Institute (NCI)
NCT07332507 NOT YET RECRUITING
Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma
National Cancer Institute (NCI)
NCT01955499 ACTIVE NOT RECRUITING
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
NCT07226843 RECRUITING
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Eli Lilly and Company
NCT06470438 ACTIVE NOT RECRUITING
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Janssen Research & Development, LLC
NCT05424822 ACTIVE NOT RECRUITING
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Janssen Research & Development, LLC
NCT06788509 ENROLLING BY INVITATION
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
NCT06139406 ACTIVE NOT RECRUITING
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
Janssen Research & Development, LLC
NCT07443137 NOT YET RECRUITING
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)
Stanford University
NCT05784441 ACTIVE NOT RECRUITING
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
Janssen Research & Development, LLC
NCT06660563 ACTIVE NOT RECRUITING
A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)
Janssen Research & Development, LLC
NCT07308132 RECRUITING
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
Janssen Research & Development, LLC
NCT05397496 ACTIVE NOT RECRUITING
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
Novartis Pharmaceuticals
NCT05887167 RECRUITING
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Joshua Sasine, MD, PhD
NCT04609046 RECRUITING
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
National Cancer Institute (NCI)
NCT06014762 ACTIVE NOT RECRUITING
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Poseida Therapeutics, Inc.
NCT05377827 ACTIVE NOT RECRUITING
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Washington University School of Medicine
NCT07570017 NOT YET RECRUITING
A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
NCT07093073 RECRUITING
Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
NCT07082868 RECRUITING
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
Memorial Sloan Kettering Cancer Center
NCT05400109 ACTIVE NOT RECRUITING
Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas
David Wald
NCT03460977 RECRUITING
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
NCT06970496 NOT YET RECRUITING
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
NCT04771572 RECRUITING
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical Inc
NCT07555561 RECRUITING
Autologous CD19-CD20-NKG2D-nsBicephali CAR-T for Relapsed/Refractory Central Nervous System Lymphoma
Beijing Boren Hospital
NCT06624085 RECRUITING
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
NCT05618028 ACTIVE NOT RECRUITING
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
AbbVie
NCT05685173 RECRUITING
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Regeneron Pharmaceuticals
NCT05797233 ACTIVE NOT RECRUITING
Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies
National Cancer Institute (NCI)
NCT06334991 RECRUITING
Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
ImmunityBio, Inc.
NCT07140016 RECRUITING
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Astellas Pharma Global Development, Inc.
NCT07361224 RECRUITING
Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.
Tel-Aviv Sourasky Medical Center
NCT06441331 RECRUITING
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
ITM Solucin GmbH
NCT03913949 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies
Ascentage Pharma Group Inc.
NCT06696846 RECRUITING
CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT04739813 RECRUITING
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
National Cancer Institute (NCI)
NCT05389423 RECRUITING
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
National Cancer Institute (NCI)
NCT03479268 ACTIVE NOT RECRUITING
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT02203526 ACTIVE NOT RECRUITING
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
National Cancer Institute (NCI)
NCT05995028 RECRUITING
Universal 4SCAR7U Targeting CD7-positive Malignancies
Shenzhen Geno-Immune Medical Institute
NCT06539338 ACTIVE NOT RECRUITING
A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment
Kite, A Gilead Company
NCT02390752 RECRUITING
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
National Cancer Institute (NCI)
NCT07548255 NOT YET RECRUITING
The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL
Ruijin Hospital
NCT05412290 RECRUITING
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
Washington University School of Medicine
NCT05757700 ACTIVE NOT RECRUITING
Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT07137494 RECRUITING
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Memorial Sloan Kettering Cancer Center
NCT07513129 NOT YET RECRUITING
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
NCT05169515 RECRUITING
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
NCT06859008 RECRUITING
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT05020678 ACTIVE NOT RECRUITING
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
Nkarta, Inc.
NCT07539688 NOT YET RECRUITING
Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
NCT02717624 ACTIVE NOT RECRUITING
A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL
Acerta Pharma BV
NCT07192471 NOT YET RECRUITING
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Kyowa Kirin, Inc.
NCT07528352 NOT YET RECRUITING
External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
University of Utah
NCT04884035 RECRUITING
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Celgene
NCT07532525 NOT YET RECRUITING
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
University of Michigan Rogel Cancer Center
NCT07198087 ACTIVE NOT RECRUITING
A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants
Ono Pharmaceutical Co., Ltd.
NCT03853616 ACTIVE NOT RECRUITING
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)
Miltenyi Biomedicine GmbH
NCT04972942 RECRUITING
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
New York Medical College
NCT07166419 RECRUITING
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
NCT05077527 RECRUITING
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
AIDS Malignancy Consortium
NCT05131022 RECRUITING
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
NCT07260812 RECRUITING
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
TCRx Therapeutics Co.Ltd
NCT01829568 ACTIVE NOT RECRUITING
Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma
National Cancer Institute (NCI)
NCT03017820 RECRUITING
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
NCT06508463 RECRUITING
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Mayo Clinic
NCT00740805 ACTIVE NOT RECRUITING
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
NCT02159755 ACTIVE NOT RECRUITING
Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma
National Cancer Institute (NCI)
NCT01695941 ACTIVE NOT RECRUITING
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
NCT02520791 ACTIVE NOT RECRUITING
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
National Cancer Institute (NCI)
NCT06176690 RECRUITING
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Baylor College of Medicine
NCT03220022 ACTIVE NOT RECRUITING
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
National Cancer Institute (NCI)
NCT05414500 RECRUITING
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
University of Alabama at Birmingham
NCT07001384 RECRUITING
A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
Memorial Sloan Kettering Cancer Center
NCT07518329 NOT YET RECRUITING
Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.
Arovella Therapeutics Ltd
NCT06675123 RECRUITING
Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
City of Hope Medical Center
NCT07254793 NOT YET RECRUITING
Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
University of Arizona
NCT07511426 RECRUITING
U96-CAR-T-Cells For R/R B-ALL
The First Affiliated Hospital of Soochow University
NCT06208735 RECRUITING
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
British Columbia Cancer Agency
NCT05544968 RECRUITING
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Medical College of Wisconsin
NCT06451497 RECRUITING
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
NCT05618925 RECRUITING
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
ImmunityBio, Inc.
NCT07047885 RECRUITING
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
H. Lee Moffitt Cancer Center and Research Institute
NCT02051257 ACTIVE NOT RECRUITING
Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT04328844 ACTIVE NOT RECRUITING
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
NCT07020533 RECRUITING
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
City of Hope Medical Center
NCT06192888 ACTIVE NOT RECRUITING
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT07082803 RECRUITING
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Treeline Biosciences, Inc.
NCT04756726 ACTIVE NOT RECRUITING
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
C4 Therapeutics, Inc.
NCT03361852 ACTIVE NOT RECRUITING
Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma
Dana-Farber Cancer Institute
NCT02446236 ACTIVE NOT RECRUITING
Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
Hackensack Meridian Health
NCT01479842 ACTIVE NOT RECRUITING
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Kami Maddocks, MD
NCT02287311 ACTIVE NOT RECRUITING
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
Baylor College of Medicine
NCT04830137 RECRUITING
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
NCT05359211 ACTIVE NOT RECRUITING
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Fred Hutchinson Cancer Center
NCT07350863 RECRUITING
U69-CART-Cells For R/R T-ALL
The First Affiliated Hospital of Soochow University
NCT06189391 RECRUITING
A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
MSD R&D (China) Co., Ltd.
NCT07478848 NOT YET RECRUITING
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
Abramson Cancer Center at Penn Medicine
NCT03478462 ACTIVE NOT RECRUITING
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
Cellectar Biosciences, Inc.
NCT07164560 RECRUITING
Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT04970901 RECRUITING
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
ADC Therapeutics S.A.
NCT06875063 RECRUITING
GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
The First Affiliated Hospital of Xiamen University
NCT04462328 ACTIVE NOT RECRUITING
Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma
Washington University School of Medicine
NCT05292664 RECRUITING
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Andrew E. Place, MD
NCT05828589 ACTIVE NOT RECRUITING
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
BeOne Medicines
NCT05679895 RECRUITING
Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL
OneChain Immunotherapeutics
NCT05540340 ACTIVE NOT RECRUITING
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
Memorial Sloan Kettering Cancer Center
NCT07456371 RECRUITING
PIC1 Injection Therapy for Relapsed/Refractory B-NHL
Chongqing Precision Biotech Co., Ltd
NCT05801913 RECRUITING
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT07220993 RECRUITING
Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells
Baylor College of Medicine
NCT07297160 NOT YET RECRUITING
CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors
Baylor College of Medicine
NCT04231877 RECRUITING
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
University of Washington
NCT05024045 ACTIVE NOT RECRUITING
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
NCT01555892 RECRUITING
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
Baylor College of Medicine
NCT06173518 RECRUITING
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Autolus Limited
NCT06209619 RECRUITING
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
Nathan Denlinger
NCT03434769 ACTIVE NOT RECRUITING
AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma
Benjamin Tomlinson
NCT07369492 RECRUITING
Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
NCT05755087 RECRUITING
Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
Lapo Alinari
NCT05403450 ACTIVE NOT RECRUITING
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Taiho Oncology, Inc.
NCT05432635 RECRUITING
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT05990465 RECRUITING
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Medical College of Wisconsin
NCT06475235 RECRUITING
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
Dana-Farber Cancer Institute
NCT07055477 RECRUITING
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
National Cancer Institute (NCI)
NCT07424833 NOT YET RECRUITING
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ascentage Pharma Group Inc.
NCT06227026 RECRUITING
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
University of Utah
NCT04775745 RECRUITING
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Newave Pharmaceutical Inc
NCT05079282 RECRUITING
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Ono Pharmaceutical Co., Ltd.
NCT06191887 RECRUITING
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Mayo Clinic
NCT05053659 ACTIVE NOT RECRUITING
Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma
Paolo Caimi, MD
NCT04848064 RECRUITING
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
John Reneau
NCT07398963 RECRUITING
Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT07121946 RECRUITING
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
LTZ Therapeutics, Inc.
NCT01192464 ACTIVE NOT RECRUITING
EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma
Baylor College of Medicine
NCT00586391 ACTIVE NOT RECRUITING
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL
Baylor College of Medicine
NCT06565689 RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
Excyte Biopharma Ltd
NCT05892718 RECRUITING
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
FBD Biologics Limited
NCT05296304 RECRUITING
A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
Memorial Sloan Kettering Cancer Center
NCT07383233 NOT YET RECRUITING
CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma
Qi deng
NCT02651662 ACTIVE NOT RECRUITING
A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies
Regeneron Pharmaceuticals
NCT04323956 ACTIVE NOT RECRUITING
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
Mayo Clinic
NCT05044039 ACTIVE NOT RECRUITING
Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
Washington University School of Medicine
NCT03666000 RECRUITING
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Imugene Limited
NCT07368270 RECRUITING
Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
NCT05371132 RECRUITING
Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)
City of Hope Medical Center
NCT01959698 ACTIVE NOT RECRUITING
Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma
Roswell Park Cancer Institute
NCT06484985 RECRUITING
Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
Axter Therapeutics (Beijing) Co., Ltd
NCT07367685 NOT YET RECRUITING
Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma
The Second Affiliated Hospital of Fujian Medical University
NCT06667687 RECRUITING
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
AbbVie
NCT06326463 RECRUITING
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
St. Jude Children's Research Hospital
NCT04223765 RECRUITING
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
UNC Lineberger Comprehensive Cancer Center
NCT05737628 ACTIVE NOT RECRUITING
First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228
Byondis B.V.
NCT05512390 RECRUITING
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
AbbVie
NCT07343934 NOT YET RECRUITING
huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma
University of Pennsylvania
NCT04545762 RECRUITING
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
C. Babis Andreadis
NCT07335328 NOT YET RECRUITING
Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies
Medical College of Wisconsin
NCT06528301 RECRUITING
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Umoja Biopharma
NCT05211336 ACTIVE NOT RECRUITING
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
National Cancer Institute (NCI)
NCT06079164 ACTIVE NOT RECRUITING
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
Kite, A Gilead Company
NCT05464329 ACTIVE NOT RECRUITING
Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma
Washington University School of Medicine
NCT06291220 ACTIVE NOT RECRUITING
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
AbbVie
NCT04843904 ACTIVE NOT RECRUITING
Safe Accelerated Venetoclax Escalation in CLL
Dana-Farber Cancer Institute
NCT03602157 ACTIVE NOT RECRUITING
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
UNC Lineberger Comprehensive Cancer Center
NCT07316920 NOT YET RECRUITING
A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
YANRU WANG
NCT04640779 ACTIVE NOT RECRUITING
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
Mayo Clinic
NCT01853631 RECRUITING
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Baylor College of Medicine
NCT07316907 NOT YET RECRUITING
A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies
YANRU WANG
NCT03884998 ACTIVE NOT RECRUITING
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT06522932 RECRUITING
PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy
Michael Randall
NCT07300683 RECRUITING
Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma
University College, London
NCT06022029 RECRUITING
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
OncoNano Medicine, Inc.
NCT07166549 NOT YET RECRUITING
Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)
University Hospital, Basel, Switzerland
NCT05098613 RECRUITING
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
University of Colorado, Denver
NCT06392477 RECRUITING
A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma
Sanofi
NCT06703892 RECRUITING
A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
GenomeFrontier Therapeutics TW Co., Ltd.
NCT07283796 RECRUITING
A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
Haisco Pharmaceutical Group Co., Ltd.
NCT07284927 RECRUITING
Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
NCT03330691 ACTIVE NOT RECRUITING
A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia
Seattle Children's Hospital
NCT07278856 NOT YET RECRUITING
Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
City of Hope Medical Center
NCT04664179 RECRUITING
EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
Baylor College of Medicine
NCT05602363 RECRUITING
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Carna Biosciences, Inc.
NCT03560752 ACTIVE NOT RECRUITING
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
City of Hope Medical Center
NCT05950802 RECRUITING
Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta
University Health Network, Toronto
NCT03696784 ACTIVE NOT RECRUITING
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
NCT06708897 RECRUITING
A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas
Lomond Therapeutics Holdings, Inc.
NCT03352765 ACTIVE NOT RECRUITING
A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients
Memorial Sloan Kettering Cancer Center
NCT01840566 ACTIVE NOT RECRUITING
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
NCT06607549 RECRUITING
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
University of Utah
NCT05618327 ACTIVE NOT RECRUITING
Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Shanghai Junshi Bioscience Co., Ltd.
NCT06285422 ACTIVE NOT RECRUITING
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
Sana Biotechnology
NCT01961063 ACTIVE NOT RECRUITING
Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT05741359 RECRUITING
The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma
Bioray Laboratories
NCT06707259 RECRUITING
Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT07239323 RECRUITING
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Chongqing Precision Biotech Co., Ltd
NCT05370430 RECRUITING
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
PeproMene Bio, Inc.
NCT07234045 NOT YET RECRUITING
A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
Institute of Hematology & Blood Diseases Hospital, China
NCT04999384 RECRUITING
First in Human, Dose Escalation Study of AN4005
Adlai Nortye Biopharma Co., Ltd.
NCT07053670 RECRUITING
A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )
Tongji Hospital
NCT02050347 ACTIVE NOT RECRUITING
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
Baylor College of Medicine
NCT01209871 ACTIVE NOT RECRUITING
Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma
M.D. Anderson Cancer Center
NCT02337985 ACTIVE NOT RECRUITING
Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT06420089 RECRUITING
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
Vittoria Biotherapeutics
NCT06916767 RECRUITING
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Paolo Caimi, MD
NCT06922604 RECRUITING
Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma
City of Hope Medical Center
NCT07225439 NOT YET RECRUITING
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Paolo Caimi, MD
NCT05081479 ACTIVE NOT RECRUITING
A Study of N-Acetylcysteine (N-AC) in People Receiving CAR T-cell Therapy for Lymphoma
Memorial Sloan Kettering Cancer Center
NCT05574114 ACTIVE NOT RECRUITING
A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT03690011 RECRUITING
Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
Baylor College of Medicine
NCT00881920 ACTIVE NOT RECRUITING
Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
Baylor College of Medicine
NCT06789159 RECRUITING
A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)
Thomas Jefferson University
NCT02508038 RECRUITING
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
University of Wisconsin, Madison
NCT01697930 ACTIVE NOT RECRUITING
A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)
Memorial Sloan Kettering Cancer Center
NCT06733441 RECRUITING
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
Treeline Biosciences, Inc.
NCT05270057 ACTIVE NOT RECRUITING
Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies
Medical College of Wisconsin
NCT01815749 ACTIVE NOT RECRUITING
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT02153580 ACTIVE NOT RECRUITING
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
City of Hope Medical Center
NCT05878184 ACTIVE NOT RECRUITING
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
Sana Biotechnology
NCT05365659 RECRUITING
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Iksuda Therapeutics Ltd.
NCT04606433 ACTIVE NOT RECRUITING
Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05621096 ACTIVE NOT RECRUITING
Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma
University of Nebraska
NCT05705570 RECRUITING
Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies
Nelson Hamerschlak
NCT02935257 ACTIVE NOT RECRUITING
Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19
University College, London
NCT05794958 RECRUITING
Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel
Stanford University
NCT04993690 RECRUITING
A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
NCT04234048 RECRUITING
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
SciTech Development, Inc.
NCT06037018 RECRUITING
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
CytoCares Inc
NCT06709469 RECRUITING
Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults
Instituto de Investigación Hospital Universitario La Paz
NCT06743503 RECRUITING
UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
Nanjing IASO Biotechnology Co., Ltd.
NCT06792734 RECRUITING
Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
Bantam Pharmaceuticals
NCT06735664 RECRUITING
Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation
City of Hope Medical Center
NCT04162353 RECRUITING
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
iCell Gene Therapeutics
NCT04447716 ACTIVE NOT RECRUITING
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
Thomas Jefferson University
NCT07168486 ENROLLING BY INVITATION
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
University of Maryland, Baltimore
NCT05357651 RECRUITING
A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）
L & L Bio Co., Ltd., Ningbo, China
NCT02992522 ACTIVE NOT RECRUITING
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Beth Christian
NCT05107674 RECRUITING
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
NCT06383338 RECRUITING
A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.
Murdoch Childrens Research Institute
NCT04007029 ACTIVE NOT RECRUITING
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Jonsson Comprehensive Cancer Center
NCT03081910 RECRUITING
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
Baylor College of Medicine
NCT07109518 RECRUITING
uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Institute of Hematology & Blood Diseases Hospital, China
NCT03150329 ACTIVE NOT RECRUITING
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
City of Hope Medical Center
NCT05836896 RECRUITING
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
Technische Universität Dresden
NCT04464200 ACTIVE NOT RECRUITING
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
Memorial Sloan Kettering Cancer Center
NCT05798897 RECRUITING
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Marker Therapeutics, Inc.
NCT04468841 RECRUITING
Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
NCT06219356 RECRUITING
A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
Hangzhou GluBio Pharmaceutical Co., Ltd.
NCT06672705 RECRUITING
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
Timothy Voorhees
NCT06827782 ENROLLING BY INVITATION
Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT05934838 RECRUITING
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Weill Medical College of Cornell University
NCT07113496 NOT YET RECRUITING
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
The First Affiliated Hospital with Nanjing Medical University
NCT03684889 ACTIVE NOT RECRUITING
CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma
Seattle Children's Hospital
NCT05653271 RECRUITING
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Acepodia Biotech, Inc.
NCT05279300 RECRUITING
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
CStone Pharmaceuticals
NCT05824585 RECRUITING
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Dizal Pharmaceuticals
NCT06340737 RECRUITING
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Stanford University
NCT06977711 RECRUITING
Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
The University of Texas Health Science Center at San Antonio
NCT05659732 RECRUITING
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer
PharmaEngine
NCT02917083 RECRUITING
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Baylor College of Medicine
NCT04288726 RECRUITING
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
Baylor College of Medicine
NCT07073833 RECRUITING
The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma
Imbioray (Hangzhou) Biomedicine Co., Ltd.
NCT07072169 RECRUITING
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Ruijin Hospital
NCT05660395 RECRUITING
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
ADC Therapeutics S.A.
NCT07068906 NOT YET RECRUITING
A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
NCT01494103 ACTIVE NOT RECRUITING
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Baylor College of Medicine
NCT00710892 ACTIVE NOT RECRUITING
CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene
Baylor College of Medicine
NCT05857969 RECRUITING
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Florida International University
NCT00840853 ACTIVE NOT RECRUITING
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
Baylor College of Medicine
NCT06385522 NOT YET RECRUITING
A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System
Boston Immune Technologies and Therapeutics
NCT05625594 RECRUITING
Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma
City of Hope Medical Center
NCT04732845 ACTIVE NOT RECRUITING
Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies
Benjamin Tomlinson
NCT03843294 ACTIVE NOT RECRUITING
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma
Catherine Bollard
NCT05963217 RECRUITING
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
University Health Network, Toronto
NCT03713580 ACTIVE NOT RECRUITING
Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma
Case Comprehensive Cancer Center
NCT04892277 RECRUITING
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Mayo Clinic
NCT03774654 ACTIVE NOT RECRUITING
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
Baylor College of Medicine
NCT04827810 RECRUITING
A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer
Fox Chase Cancer Center
NCT07044050 RECRUITING
A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Emercell SAS
NCT05395533 ACTIVE NOT RECRUITING
A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.
Zhejiang Teruisi Pharmaceutical Inc.
NCT07032324 NOT YET RECRUITING
A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )
Qian Wenbin
NCT07024147 NOT YET RECRUITING
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
Peking University Cancer Hospital & Institute
NCT06830031 RECRUITING
Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
Shanghai Exuma Biotechnology Ltd.
NCT01430390 ACTIVE NOT RECRUITING
In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
Memorial Sloan Kettering Cancer Center
NCT01333046 ACTIVE NOT RECRUITING
Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
Baylor College of Medicine
NCT06541665 ACTIVE NOT RECRUITING
Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL
Ono Pharmaceutical Co., Ltd.
NCT05320809 ACTIVE NOT RECRUITING
Study of 3D189 in Patients With Hematologic Malignancies
3D Medicines
NCT04688151 ACTIVE NOT RECRUITING
Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.
National Health Research Institutes, Taiwan
NCT05418088 RECRUITING
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Sumithira Vasu
NCT02663297 ACTIVE NOT RECRUITING
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
UNC Lineberger Comprehensive Cancer Center
NCT05299164 ACTIVE NOT RECRUITING
GVM±R in Patients With Relapsed or Refractory Aggressive NHL
Institute of Hematology & Blood Diseases Hospital, China
NCT06447376 RECRUITING
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Taylor Brooks
NCT06730542 RECRUITING
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
Juan P. Alderuccio, MD
NCT06699771 RECRUITING
Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies
GC Cell Corporation
NCT03952078 ACTIVE NOT RECRUITING
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
Corvus Pharmaceuticals, Inc.
NCT05206357 ACTIVE NOT RECRUITING
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
Genmab
NCT05665062 ACTIVE NOT RECRUITING
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
Synthekine
NCT06879340 RECRUITING
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
University of Kansas Medical Center
NCT06914037 RECRUITING
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Tianjin Medical University Cancer Institute and Hospital
NCT06909474 RECRUITING
Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
Chongqing Precision Biotech Co., Ltd
NCT04088864 ACTIVE NOT RECRUITING
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies
Stanford University
NCT06894693 NOT YET RECRUITING
A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies
Guangdong Ruishun Biotech Co., Ltd
NCT06313957 RECRUITING
A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Peking University Cancer Hospital & Institute
NCT06251180 RECRUITING
Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
NCT04637763 RECRUITING
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Caribou Biosciences, Inc.
NCT06793956 RECRUITING
Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma
Sun Yat-sen University
NCT06060782 RECRUITING
Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine
Fifth Affiliated Hospital, Sun Yat-Sen University
NCT05472558 RECRUITING
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT06820268 RECRUITING
A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies
NovaOnco Therapeutics Co., Ltd.
NCT05607498 RECRUITING
First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
EpimAb Biotherapeutics (Suzhou)Co., Ltd.
NCT04072458 ACTIVE NOT RECRUITING
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
Bio-Path Holdings, Inc.
NCT05515406 ACTIVE NOT RECRUITING
A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL
Ono Pharmaceutical Co., Ltd.
NCT06622226 ACTIVE NOT RECRUITING
A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Ono Pharmaceutical Co., Ltd.
NCT06822868 RECRUITING
A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Kai Hu
NCT06464861 RECRUITING
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT03283137 ACTIVE NOT RECRUITING
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL
University of Chicago
NCT03212404 ACTIVE NOT RECRUITING
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
NCT05341557 RECRUITING
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Betta Pharmaceuticals Co., Ltd.
NCT06758713 RECRUITING
Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
The Third Affiliated Hospital of Southern Medical University
NCT05054257 RECRUITING
CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma
Institute of Hematology and Blood Transfusion, Czech Republic
NCT06734871 RECRUITING
A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma
Aibin Liang，MD，Ph.D.
NCT05967416 RECRUITING
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
SIRPant Immunotherapeutics, Inc.
NCT06731699 RECRUITING
A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS
Chengdu FenDi Pharmaceutical Co., Ltd.
NCT06732492 RECRUITING
RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT06725524 RECRUITING
A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma
Shanghai JMT-Bio Inc.
NCT05476770 RECRUITING
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
NCT06712173 NOT YET RECRUITING
Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)
Institute of Hematology & Blood Diseases Hospital, China
NCT05156203 RECRUITING
Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors
Taivex Therapeutics Corporation
NCT06395870 RECRUITING
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Tianjin Medical University Cancer Institute and Hospital
NCT05312801 RECRUITING
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma
Luminary Therapeutics
NCT05036577 ACTIVE NOT RECRUITING
A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL
Huashan Hospital
NCT06615193 RECRUITING
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
NCT06593145 RECRUITING
CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms
FamiCordTx
NCT05333302 RECRUITING
Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
NCT06047197 RECRUITING
Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma
Beijing Yongtai Ruike Biotechnology Company Ltd
NCT06567080 NOT YET RECRUITING
JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases
RenJi Hospital
NCT04049513 ACTIVE NOT RECRUITING
ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)
Malaghan Institute of Medical Research
NCT04682808 ACTIVE NOT RECRUITING
A Study of FCN-338 in Patients With Chronic CLL/SLL
Fochon Pharmaceuticals, Ltd.
NCT06547944 ACTIVE NOT RECRUITING
Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Institute of Hematology & Blood Diseases Hospital, China
NCT03245021 ACTIVE NOT RECRUITING
Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A
Dr. Eliza Hawkes
NCT06517004 RECRUITING
An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Fudan University
NCT05878691 ACTIVE NOT RECRUITING
A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.
Glenmark Specialty S.A.
NCT06503211 RECRUITING
On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma
The First Affiliated Hospital with Nanjing Medical University
NCT06494371 RECRUITING
A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma
Ruijin Hospital
NCT03422393 ACTIVE NOT RECRUITING
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
Michael Choi
NCT06445517 RECRUITING
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
InSilico Medicine Hong Kong Limited
NCT04443829 ACTIVE NOT RECRUITING
Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma
University College, London
NCT05650580 RECRUITING
TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors
Tarapeutics Science Inc.
NCT05052528 RECRUITING
Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Mehrdad Abedi, MD
NCT05758610 RECRUITING
A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients
Shengke Pharmaceuticals (Jiangsu) Limited, China
NCT05879744 ACTIVE NOT RECRUITING
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
Cullinan Therapeutics Inc.
NCT06318884 NOT YET RECRUITING
A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma
Sinocelltech Ltd.
NCT06314828 NOT YET RECRUITING
A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL
Guangdong Ruishun Biotech Co., Ltd
NCT06279611 RECRUITING
An Evaluation of LY007 Cell Injection for r/r B-NHL
Shanghai Longyao Biotechnology Inc., Ltd.
NCT06180174 RECRUITING
Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
Chongqing Precision Biotech Co., Ltd
NCT06136364 RECRUITING
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
Hebei Senlang Biotechnology Inc., Ltd.
NCT05631886 RECRUITING
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Chinese PLA General Hospital
NCT05900089 NOT YET RECRUITING
Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma
Henan Cancer Hospital
NCT04526834 ACTIVE NOT RECRUITING
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
Tessa Therapeutics
NCT05659628 RECRUITING
CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL
Ningbo No. 1 Hospital
NCT05528887 RECRUITING
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
NCT05528055 RECRUITING
A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
NCT04214886 ACTIVE NOT RECRUITING
CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies
Loyola University
NCT02477878 ACTIVE NOT RECRUITING
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
Bellicum Pharmaceuticals
NCT07586618 NOT YET RECRUITING
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
Allterum Therapeutics, Inc
NCT04301076 SUSPENDED
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
National Cancer Institute (NCI)
NCT07388563 SUSPENDED
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
National Cancer Institute (NCI)
NCT06254495 TERMINATED
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
Seagen, a wholly owned subsidiary of Pfizer
NCT06870487 TERMINATED
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
NCT07093086 WITHDRAWN
Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
NCT07453446 WITHDRAWN
Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
NCT01087294 COMPLETED
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
National Cancer Institute (NCI)
NCT02315612 COMPLETED
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
National Cancer Institute (NCI)
NCT02783625 COMPLETED
Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
Memorial Sloan Kettering Cancer Center
NCT05607199 TERMINATED
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
Aurigene Discovery Technologies Limited
NCT05605119 TERMINATED
First in Human, Dose Escalation, Dose Expansion Study of AUR105
Aurigene Discovery Technologies Limited
NCT05983965 TERMINATED
Study of Tazemetostat in Lymphoid Malignancies
University of Alabama at Birmingham
NCT04853329 TERMINATED
Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma
Conjupro Biotherapeutics, Inc.
NCT04488354 COMPLETED
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Calibr, a division of Scripps Research
NCT04049825 COMPLETED
A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL
Otsuka Pharmaceutical Co., Ltd.
NCT06824701 SUSPENDED
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
University of Utah
NCT05618366 TERMINATED
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Weill Medical College of Cornell University
NCT07049432 WITHDRAWN
N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
University of Utah
NCT04903197 TERMINATED
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
Novartis Pharmaceuticals
NCT04088890 COMPLETED
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Matthew Frank
NCT01846390 COMPLETED
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma
Canadian Cancer Trials Group
NCT03547115 TERMINATED
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
MEI Pharma, Inc.
NCT05994157 TERMINATED
Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
Y-mAbs Therapeutics
NCT06256484 TERMINATED
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Atara Biotherapeutics
NCT07454863 COMPLETED
A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15)
Dizal Pharmaceuticals
NCT03939026 COMPLETED
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma
Allogene Therapeutics
NCT05170828 WITHDRAWN
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
NCT03779113 TERMINATED
An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma
Hutchmed
NCT02909777 COMPLETED
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Dana-Farber Cancer Institute
NCT04067414 COMPLETED
Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
NCT04316624 COMPLETED
A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy
Institute of Hematology & Blood Diseases Hospital, China
NCT01625351 COMPLETED
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
NCT05694364 COMPLETED
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
H. Lee Moffitt Cancer Center and Research Institute
NCT04850495 SUSPENDED
Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
Yazeed Sawalha
NCT05149391 COMPLETED
A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma
Peking University
NCT00709033 COMPLETED
T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL
Baylor College of Medicine
NCT04447027 COMPLETED
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
National Cancer Institute (NCI)
NCT03703167 COMPLETED
Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)
Memorial Sloan Kettering Cancer Center
NCT06120504 TERMINATED
A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
Seagen, a wholly owned subsidiary of Pfizer
NCT05665530 COMPLETED
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Prelude Therapeutics
NCT05678998 COMPLETED
WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
Werewolf Therapeutics, Inc.
NCT01695005 COMPLETED
A Study of LY3039478 in Participants With Advanced Cancer
Eli Lilly and Company
NCT05025358 COMPLETED
A Study of LP-118 in Patients With Advanced Tumors
Guangzhou Lupeng Pharmaceutical Company LTD.
NCT04155710 COMPLETED
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
Iovance Biotherapeutics, Inc.
NCT02296918 COMPLETED
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
Acerta Pharma BV
NCT03985189 COMPLETED
Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Kyowa Kirin Co., Ltd.
NCT03573310 COMPLETED
A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS
Janssen Research & Development, LLC
NCT05336409 TERMINATED
A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies
Century Therapeutics, Inc.
NCT05065866 COMPLETED
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
H. Lee Moffitt Cancer Center and Research Institute
NCT05083208 TERMINATED
PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma
Henan Cancer Hospital
NCT05364424 COMPLETED
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
Hoffmann-La Roche
NCT06295549 TERMINATED
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
The First Affiliated Hospital with Nanjing Medical University
NCT02568553 COMPLETED
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
NCT05400122 SUSPENDED
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
David Wald
NCT03259503 COMPLETED
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
NCT02996773 COMPLETED
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
University of Arizona
NCT03010176 COMPLETED
Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)
Merck Sharp & Dohme LLC
NCT06248086 TERMINATED
A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas
Astellas Pharma Global Development, Inc.
NCT05075603 COMPLETED
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
NeoImmuneTech
NCT05169489 TERMINATED
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
Regeneron Pharmaceuticals
NCT04540796 COMPLETED
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Janssen Research & Development, LLC
NCT02290951 COMPLETED
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
Regeneron Pharmaceuticals
NCT04702425 TERMINATED
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
Novartis Pharmaceuticals
NCT04240704 TERMINATED
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL
Novartis Pharmaceuticals
NCT05526313 COMPLETED
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant
Chengdu Zenitar Biomedical Technology Co., Ltd
NCT04984356 COMPLETED
A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
Wugen, Inc.
NCT02512497 COMPLETED
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Ohio State University Comprehensive Cancer Center
NCT04372641 WITHDRAWN
Testing the Safety of CB-5339 in Patients With Cancer
National Cancer Institute (NCI)
NCT04500548 WITHDRAWN
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
National Cancer Institute (NCI)
NCT04018248 COMPLETED
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Boryung Pharmaceutical Co., Ltd
NCT05490043 TERMINATED
A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
Antengene (Hangzhou) Biologics Co., Ltd.
NCT04772989 COMPLETED
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
Arcus Biosciences, Inc.
NCT06027957 COMPLETED
CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia
Vinmec Research Institute of Stem Cell and Gene Technology
NCT04169321 COMPLETED
Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors
Cytosite Biopharma Inc.
NCT05390814 COMPLETED
[18F]-Fludarabine PET/MRI in Primary Central Nervous System Lymphoma
Assistance Publique - Hôpitaux de Paris
NCT05950334 COMPLETED
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
Fate Therapeutics
NCT04970992 COMPLETED
A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma
Da Zen Theranostics Inc
NCT04210219 COMPLETED
A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Janssen Research & Development, LLC
NCT04657224 COMPLETED
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Janssen Research & Development, LLC
NCT04876092 COMPLETED
A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL
Janssen Research & Development, LLC
NCT03039114 COMPLETED
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Incyte Corporation
NCT03424122 COMPLETED
INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Incyte Corporation
NCT02900651 TERMINATED
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
Novartis Pharmaceuticals
NCT06343376 TERMINATED
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies
Roswell Park Cancer Institute
NCT03013218 COMPLETED
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology Inc.
NCT03249792 TERMINATED
Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)
Merck Sharp & Dohme LLC
NCT04239092 TERMINATED
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Actuate Therapeutics Inc.
NCT01051635 COMPLETED
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas
National Cancer Institute (NCI)
NCT05153330 TERMINATED
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Biomea Fusion Inc.
NCT03884556 COMPLETED
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Trishula Therapeutics, Inc.
NCT03786926 TERMINATED
Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas
Hutchmed
NCT05121103 TERMINATED
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Epizyme, Inc.
NCT03900598 COMPLETED
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Janssen Research & Development, LLC
NCT03742258 COMPLETED
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
Northwestern University
NCT02303392 COMPLETED
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Jennifer Woyach
NCT04986865 TERMINATED
A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
Antengene Biologics Limited
NCT05290155 COMPLETED
Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT03448393 COMPLETED
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Cancer Institute (NCI)
NCT05318963 TERMINATED
Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
NCT03870945 COMPLETED
Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)
Miltenyi Biomedicine GmbH
NCT04696432 COMPLETED
A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma
Tianjin Medical University Cancer Institute and Hospital
NCT03432741 TERMINATED
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
NCT04317885 COMPLETED
A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects
Shanghai Tongji Hospital, Tongji University School of Medicine
NCT04436107 COMPLETED
Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeiGene
NCT04655677 COMPLETED
A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma
Peking Union Medical College Hospital
NCT04103905 COMPLETED
A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas
Beijing Mabworks Biotech Co., Ltd.
NCT04240808 COMPLETED
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)
University of Colorado, Denver
NCT04556266 WITHDRAWN
A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies
Memorial Sloan Kettering Cancer Center
NCT05038644 TERMINATED
XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia
Ehab L Atallah
NCT06290622 WITHDRAWN
PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL
University of Alabama at Birmingham
NCT02548468 WITHDRAWN
Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT04464798 TERMINATED
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
Celgene
NCT01352312 TERMINATED
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03939182 COMPLETED
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT04578600 COMPLETED
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
Joseph Tuscano
NCT02875223 TERMINATED
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Celgene
NCT04836195 COMPLETED
Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma
Pacylex Pharmaceuticals
NCT03755414 COMPLETED
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Washington University School of Medicine
NCT04317066 COMPLETED
A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)
Merck Sharp & Dohme LLC
NCT02616965 COMPLETED
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma
Fox Chase Cancer Center
NCT03894618 COMPLETED
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Shattuck Labs, Inc.
NCT04553692 TERMINATED
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
NCT06892119 COMPLETED
Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation
Hospital Universitario Dr. Jose E. Gonzalez
NCT01877382 COMPLETED
A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas
Daiichi Sankyo
NCT03440567 COMPLETED
Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
City of Hope Medical Center
NCT03792256 COMPLETED
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Children's Oncology Group
NCT02342782 COMPLETED
Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT05225584 COMPLETED
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
Kymera Therapeutics, Inc.
NCT05293912 TERMINATED
SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
Hangzhou Sumgen Biotech Co., Ltd.
NCT01497184 COMPLETED
Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood
M.D. Anderson Cancer Center
NCT03893682 TERMINATED
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
Aptose Biosciences Inc.
NCT04781855 WITHDRAWN
Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation
M.D. Anderson Cancer Center
NCT04052061 WITHDRAWN
QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
ImmunityBio, Inc.
NCT00788684 COMPLETED
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
AbbVie
NCT04537715 COMPLETED
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Epizyme, Inc.
NCT06210243 TERMINATED
C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
NCT03654716 COMPLETED
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
Dana-Farber Cancer Institute
NCT01638533 COMPLETED
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
NCT05096234 TERMINATED
18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
Stanford University
NCT03636503 TERMINATED
Rituximab + Immunotherapy in Follicular Lymphoma
Dana-Farber Cancer Institute
NCT04599634 COMPLETED
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
National Cancer Institute (NCI)
NCT01703481 COMPLETED
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma
Janssen Research & Development, LLC
NCT02743546 WITHDRAWN
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
Janssen Research & Development, LLC
NCT05665725 COMPLETED
Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma
Timothy Voorhees
NCT03467373 COMPLETED
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
Hoffmann-La Roche
NCT04774068 COMPLETED
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
Walter Hanel
NCT02323880 COMPLETED
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Children's Oncology Group
NCT04502446 TERMINATED
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)
CRISPR Therapeutics AG
NCT05205161 TERMINATED
A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma
AstraZeneca
NCT03189524 COMPLETED
A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma
BeiGene
NCT02112526 COMPLETED
Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
Acerta Pharma BV
NCT03922204 COMPLETED
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies
Merus B.V.
NCT03410901 COMPLETED
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
Ronald Levy
NCT03030417 COMPLETED
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
National Cancer Institute (NCI)
NCT05233033 COMPLETED
Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL
Kymera Therapeutics, Inc.
NCT02702492 TERMINATED
PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)
Karyopharm Therapeutics Inc
NCT05896774 COMPLETED
A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China
Pfizer
NCT02268851 COMPLETED
A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
Dana-Farber Cancer Institute
NCT04840875 COMPLETED
Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma
Beijing Boren Hospital
NCT02924402 COMPLETED
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
Xencor, Inc.
NCT03524235 COMPLETED
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Noah Merin
NCT06003179 WITHDRAWN
Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah
University Health Network, Toronto
NCT05567887 COMPLETED
A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies
Pfizer
NCT02383368 COMPLETED
A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma
Astellas Pharma Global Development, Inc.
NCT03450343 COMPLETED
Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Medical University of South Carolina
NCT03955783 COMPLETED
Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies
Sanjay Mohan
NCT03323034 COMPLETED
Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Children's Oncology Group
NCT05134740 WITHDRAWN
(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).
Baylor College of Medicine
NCT03340766 COMPLETED
Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Amgen
NCT03755154 TERMINATED
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Institut de Recherches Internationales Servier
NCT04134936 COMPLETED
Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL
MorphoSys AG
NCT04860466 TERMINATED
A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
Celgene
NCT03220347 TERMINATED
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
Celgene
NCT03936465 COMPLETED
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
Dana-Farber Cancer Institute
NCT04431635 TERMINATED
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
University of Michigan Rogel Cancer Center
NCT03136497 TERMINATED
A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Hackensack Meridian Health
NCT02509039 TERMINATED
A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)
Celgene
NCT05094206 TERMINATED
CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies
Medical College of Wisconsin
NCT04500587 COMPLETED
Phase 1 First in Human Study of ZN-d5 as a Single Agent
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
NCT02978235 TERMINATED
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
Taiho Oncology, Inc.
NCT03530683 TERMINATED
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Pfizer
NCT05219513 TERMINATED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
NCT02594384 COMPLETED
A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma
OrphAI Therapeutics
NCT04450069 COMPLETED
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Calibr, a division of Scripps Research
NCT02595866 COMPLETED
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
NCT02192021 COMPLETED
Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)
Falo, Louis, MD
NCT00848601 TERMINATED
Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma
Astex Pharmaceuticals, Inc.
NCT05965505 TERMINATED
Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas
Axter Therapeutics (Beijing) Co., Ltd
NCT01296555 TERMINATED
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Genentech, Inc.
NCT04806035 TERMINATED
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
TG Therapeutics, Inc.
NCT06527781 COMPLETED
A Study of PD5K3 in Healthy Adult Volunteers
Chongqing Peg-Bio Biopharm Co., Ltd.
NCT04434196 COMPLETED
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Celgene
NCT02576496 COMPLETED
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Mundipharma Research Limited
NCT02920697 COMPLETED
Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma
Institut de Recherches Internationales Servier
NCT03435250 TERMINATED
Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss
Institut de Recherches Internationales Servier
NCT03671590 TERMINATED
Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
TG Therapeutics, Inc.
NCT03198234 TERMINATED
Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders
Roncarolo, Maria Grazia, MD
NCT04790903 TERMINATED
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
NCT02110563 TERMINATED
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
NCT04933617 TERMINATED
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
National Cancer Institute (NCI)
NCT04555811 COMPLETED
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
Masonic Cancer Center, University of Minnesota
NCT03934814 COMPLETED
Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
I-Mab Biopharma US Limited
NCT03704298 TERMINATED
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma
Kite, A Gilead Company
NCT02631044 COMPLETED
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
Juno Therapeutics, a Subsidiary of Celgene
NCT03451825 TERMINATED
Phase I/II Study of Avelumab in Pediatric Cancer Participants
EMD Serono Research & Development Institute, Inc.
NCT04279405 COMPLETED
A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies
Shanghai YingLi Pharmaceutical Co. Ltd.
NCT03061188 COMPLETED
Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma
Northwestern University
NCT03424603 COMPLETED
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Sutro Biopharma, Inc.
NCT04036019 COMPLETED
A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy
Shanghai Tongji Hospital, Tongji University School of Medicine
NCT04231747 COMPLETED
A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Juno Therapeutics, a Subsidiary of Celgene
NCT04477772 COMPLETED
A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China
Shanghai Junshi Bioscience Co., Ltd.
NCT01949883 COMPLETED
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
Constellation Pharmaceuticals
NCT04167137 TERMINATED
Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants
Synlogic
NCT03892044 COMPLETED
Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma
David Bond, MD
NCT04995536 WITHDRAWN
CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL
City of Hope Medical Center
NCT04306224 COMPLETED
A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas
ImmuneOncia Therapeutics Inc.
NCT03103971 TERMINATED
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
Fred Hutchinson Cancer Center
NCT01588015 COMPLETED
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT05321147 COMPLETED
Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2
Innate Pharma
NCT03329950 COMPLETED
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
NCT04313608 COMPLETED
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma
Hoffmann-La Roche
NCT03010982 COMPLETED
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors
Epizyme, Inc.
NCT03571828 TERMINATED
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
Amgen
NCT03151057 TERMINATED
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04144140 TERMINATED
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
Eisai Inc.
NCT04548700 TERMINATED
Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NCT05602597 COMPLETED
HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI
Hutchmed
NCT04314843 TERMINATED
Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma
Kite, A Gilead Company
NCT03878524 TERMINATED
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
NCT04920383 TERMINATED
ALPN-202 With PD-1 Inhibition in Advanced Malignancies
Alpine Immune Sciences, Inc.
NCT05796271 WITHDRAWN
Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy
The University of Texas Health Science Center at San Antonio
NCT05078593 COMPLETED
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma
Shanghai Henlius Biotech
NCT03458546 COMPLETED
Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma
The University of Texas Health Science Center at San Antonio
NCT03964259 COMPLETED
Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia
Virginia Commonwealth University
NCT02168140 COMPLETED
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Wake Forest University Health Sciences
NCT02961881 COMPLETED
A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma
Amgen
NCT06010680 COMPLETED
A Study to Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Volunteers
Jiangsu HengRui Medicine Co., Ltd.
NCT05107856 TERMINATED
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Prelude Therapeutics
NCT04609579 TERMINATED
Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
Stingthera, Inc.
NCT04657302 COMPLETED
A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
NCT02031419 TERMINATED
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma
Celgene
NCT02658968 COMPLETED
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
Nordic Nanovector
NCT03833180 COMPLETED
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT01606878 COMPLETED
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Children's Oncology Group
NCT03864419 TERMINATED
Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
Fred Hutchinson Cancer Center
NCT03806179 COMPLETED
Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL
Nordic Nanovector
NCT03454451 COMPLETED
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
NCT00968760 COMPLETED
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
M.D. Anderson Cancer Center
NCT01421524 COMPLETED
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Celgene
NCT03229278 COMPLETED
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
NCT05321940 WITHDRAWN
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
Juan C. Ramos, MD
NCT04828174 SUSPENDED
Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT03072771 COMPLETED
Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Washington University School of Medicine
NCT00697684 COMPLETED
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
Beth Israel Deaconess Medical Center
NCT04812691 COMPLETED
CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
NCT01523223 COMPLETED
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
Robert Lowsky
NCT02543879 COMPLETED
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
Forma Therapeutics, Inc.
NCT04978779 TERMINATED
A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
Vincerx Pharma, Inc.
NCT05221385 TERMINATED
Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma
Changchun GeneScience Pharmaceutical Co., Ltd.
NCT02728531 COMPLETED
Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
Washington University School of Medicine
NCT04245722 TERMINATED
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Fate Therapeutics
NCT02417285 COMPLETED
A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.
Celgene
NCT02916979 COMPLETED
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
Dartmouth-Hitchcock Medical Center
NCT05867030 WITHDRAWN
Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma
Innovent Biologics (Suzhou) Co. Ltd.
NCT02780804 COMPLETED
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
NCT06082596 COMPLETED
Study of BEBT-908 in Subjects With Advanced Hematological Tumors
BeBetter Med Inc
NCT03188965 COMPLETED
First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
Bayer
NCT04840784 TERMINATED
First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML
Shengke Pharmaceuticals Pty Ltd
NCT03884972 WITHDRAWN
Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor
M.D. Anderson Cancer Center
NCT05698888 TERMINATED
Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors
Virtuoso BINco, Inc.
NCT01336920 COMPLETED
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
University of Nebraska
NCT05917964 COMPLETED
A Food Effect Study of LP-168 Tablets in Healthy Subjects
Guangzhou Lupeng Pharmaceutical Company LTD.
NCT05176873 COMPLETED
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
NCT04952584 WITHDRAWN
Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas
Baylor College of Medicine
NCT03144583 COMPLETED
Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy
Sara V. Latorre
NCT03314922 COMPLETED
A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)
Incyte Corporation
NCT03121677 TERMINATED
Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
Washington University School of Medicine
NCT02343718 COMPLETED
Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
Canadian Cancer Trials Group
NCT04214093 TERMINATED
A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
AstraZeneca
NCT03019055 COMPLETED
Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell
Medical College of Wisconsin
NCT01614197 COMPLETED
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
NCT03328104 COMPLETED
Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma
Emory University
NCT05244070 TERMINATED
A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Bristol-Myers Squibb
NCT05934097 WITHDRAWN
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
Fate Therapeutics
NCT03991884 COMPLETED
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
University of Washington
NCT04156828 TERMINATED
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
University of Washington
NCT03028103 COMPLETED
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
Epizyme, Inc.
NCT01029366 COMPLETED
CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
University of Pennsylvania
NCT05037669 WITHDRAWN
Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma
University of Pennsylvania
NCT04136756 COMPLETED
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
Nektar Therapeutics
NCT03003546 COMPLETED
Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial
Mayo Clinic
NCT05242146 TERMINATED
GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma
GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
NCT03733951 COMPLETED
KN046 in Subjects With Advanced Solid Tumors and Lymphoma
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NCT01682616 COMPLETED
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
AbbVie
NCT04502706 TERMINATED
Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma
Gilead Sciences
NCT04186637 TERMINATED
An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies
Alpine Immune Sciences, Inc.
NCT05127811 TERMINATED
A Phase I Study of ZN-d5 in Chinese Subjects With Non-Hodgkin Lymphoma
Zentera Therapeutics HK Limited
NCT03311412 COMPLETED
Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Symphogen A/S
NCT03236857 COMPLETED
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
AbbVie
NCT02309580 COMPLETED
Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT02914938 TERMINATED
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
MEI Pharma, Inc.
NCT01925131 COMPLETED
S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia
SWOG Cancer Research Network
NCT03841110 COMPLETED
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
NCT02431988 COMPLETED
Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation
University College, London
NCT03802955 COMPLETED
Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
Adagene (Suzhou) Limited
NCT02659943 COMPLETED
T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
National Cancer Institute (NCI)
NCT01191775 COMPLETED
A Study of PNT2258 in Patients With Advanced Solid Tumors
Sierra Oncology LLC - a GSK company
NCT01493453 TERMINATED
A Phase I Study of CD19 Specific T Cells in CD19 Positive Malignancy
The Christie NHS Foundation Trust
NCT03465540 TERMINATED
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Amgen
NCT04045028 TERMINATED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Genentech, Inc.
NCT01393509 COMPLETED
The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies
Memorial Sloan Kettering Cancer Center
NCT03886831 COMPLETED
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
Prelude Therapeutics
NCT04232826 COMPLETED
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma
Juventas Cell Therapy Ltd.
NCT01316146 WITHDRAWN
Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)
UNC Lineberger Comprehensive Cancer Center
NCT05354362 TERMINATED
A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Antengene Corporation
NCT01572493 COMPLETED
Continuous Infusion of rhIL-15 for Adults With Advanced Cancer
National Cancer Institute (NCI)
NCT05513612 WITHDRAWN
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
Shanghai Pudong Hospital
NCT02292225 TERMINATED
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
SecuraBio
NCT05176691 WITHDRAWN
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
Hutchmed
NCT02890758 COMPLETED
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Brenda Cooper, MD
NCT02960646 COMPLETED
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
M.D. Anderson Cancer Center
NCT03305445 COMPLETED
Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL
Icahn School of Medicine at Mount Sinai
NCT01768338 COMPLETED
Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma
Michael John Robertson
NCT04877080 WITHDRAWN
CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
NCT02257242 COMPLETED
Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma
Brown University
NCT03238651 TERMINATED
A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)
Calithera Biosciences, Inc
NCT03772288 WITHDRAWN
A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)
Calithera Biosciences, Inc
NCT03357627 COMPLETED
A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma
Calithera Biosciences, Inc
NCT03359733 WITHDRAWN
A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor
Calithera Biosciences, Inc
NCT04152148 COMPLETED
A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients
Bio-Thera Solutions
NCT04804254 TERMINATED
Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers
AbbVie
NCT03876028 TERMINATED
Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
Novartis Pharmaceuticals
NCT03049449 COMPLETED
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
National Cancer Institute (NCI)
NCT05228249 WITHDRAWN
Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma
Fred Hutchinson Cancer Center
NCT03798314 COMPLETED
Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma
Mayo Clinic
NCT04185220 COMPLETED
Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
National Cancer Institute (NCI)
NCT03815682 TERMINATED
RPTR-147 in Patients With Selected Solid Tumors and Lymphomas
Repertoire Immune Medicines
NCT03809767 COMPLETED
A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas
CStone Pharmaceuticals
NCT04543305 COMPLETED
A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies
Prelude Therapeutics
NCT03009344 COMPLETED
A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Eisai Co., Ltd.
NCT03019666 COMPLETED
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
Masonic Cancer Center, University of Minnesota
NCT04639843 WITHDRAWN
Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
National Cancer Institute (NCI)
NCT03707093 COMPLETED
Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
Adagene Inc
NCT02756247 COMPLETED
A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
Memorial Sloan Kettering Cancer Center
NCT04635683 WITHDRAWN
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Yazeed Sawalha
NCT04746131 SUSPENDED
Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
NCT01886859 COMPLETED
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
NCT03905135 COMPLETED
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
National Cancer Institute (NCI)
NCT02698189 TERMINATED
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)
Merck Sharp & Dohme LLC
NCT05156229 TERMINATED
A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).
Codiak BioSciences
NCT02706392 TERMINATED
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Fred Hutchinson Cancer Center
NCT03036904 COMPLETED
Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas
Weill Medical College of Cornell University
NCT02706405 TERMINATED
JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
NCT03778073 TERMINATED
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
TG Therapeutics, Inc.
NCT04219319 TERMINATED
LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
NCT04973527 TERMINATED
LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor
Beijing Boren Hospital
NCT03527147 COMPLETED
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
Acerta Pharma BV
NCT03630159 COMPLETED
Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients
Novartis Pharmaceuticals
NCT02414724 TERMINATED
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma
Roswell Park Cancer Institute
NCT03768310 WITHDRAWN
CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)
Baylor College of Medicine
NCT02795182 COMPLETED
Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies
BeiGene
NCT02049541 COMPLETED
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Kami Maddocks, MD
NCT02529813 COMPLETED
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
M.D. Anderson Cancer Center
NCT01991184 COMPLETED
A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.
Genentech, Inc.
NCT02877550 COMPLETED
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
Swiss Cancer Institute
NCT04836832 WITHDRAWN
Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Narendranath Epperla
NCT00634504 COMPLETED
Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze
BTG International Inc.
NCT03302728 COMPLETED
Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma
Peter MacCallum Cancer Centre, Australia
NCT03682796 COMPLETED
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
Triphase Research and Development III Corp.
NCT04844086 TERMINATED
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
Eden BioCell Ltd.
NCT02395601 COMPLETED
A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas
Constellation Pharmaceuticals
NCT01744912 TERMINATED
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
TG Therapeutics, Inc.
NCT02689453 COMPLETED
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
National Cancer Institute (NCI)
NCT02471911 COMPLETED
KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
Weill Medical College of Cornell University
NCT01791595 COMPLETED
A Phase I Trial of AZD3965 in Patients With Advanced Cancer
Cancer Research UK
NCT01655225 COMPLETED
A Study of LY3023414 in Participants With Advanced Cancer
Eli Lilly and Company
NCT03886649 TERMINATED
Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
Swiss Cancer Institute
NCT01187810 TERMINATED
Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL
South Plains Oncology Consortium
NCT04974996 WITHDRAWN
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)
ADC Therapeutics S.A.
NCT02519270 TERMINATED
Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects
Spectrum Pharmaceuticals, Inc
NCT02293109 COMPLETED
Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma
Mehrdad Abedi, MD
NCT04260932 COMPLETED
CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients
Hebei Yanda Ludaopei Hospital
NCT03925935 COMPLETED
Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation
Angiocrine Bioscience
NCT01328626 COMPLETED
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
AbbVie
NCT02954406 TERMINATED
A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
Millennium Pharmaceuticals, Inc.
NCT04955340 COMPLETED
A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat
4SC AG
NCT02086604 COMPLETED
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
Washington University School of Medicine
NCT04160195 TERMINATED
T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma
National Cancer Institute (NCI)
NCT04089527 COMPLETED
Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Celgene
NCT03255096 COMPLETED
A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6
Hoffmann-La Roche
NCT04073147 TERMINATED
Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma
Klinikum Stuttgart
NCT04176913 TERMINATED
Study of LUCAR-20S in Patients With R/R NHL
The First Affiliated Hospital with Nanjing Medical University
NCT05173545 COMPLETED
Clinical Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Recurrent/Refractory Lymphoma Subjects
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NCT02613598 COMPLETED
Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
University of Michigan Rogel Cancer Center
NCT02741388 COMPLETED
A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP
The Lymphoma Academic Research Organisation
NCT03797261 TERMINATED
A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
AbbVie
NCT03332121 COMPLETED
B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma
Shanghai Pharmaceuticals Holding Co., Ltd
NCT03639324 WITHDRAWN
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL
Virginia Commonwealth University
NCT01445535 COMPLETED
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
National Cancer Institute (NCI)
NCT03593109 TERMINATED
A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma
Second Affiliated Hospital of Xi'an Jiaotong University
NCT03685344 TERMINATED
Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma
ADC Therapeutics S.A.
NCT03263637 COMPLETED
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies
AstraZeneca
NCT04418141 COMPLETED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1
Curon Biopharmaceutical (Australia) Co Pty Ltd
NCT03181126 COMPLETED
A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
AbbVie
NCT03489343 COMPLETED
Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Symphogen A/S
NCT03588936 TERMINATED
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
Medical College of Wisconsin
NCT03189836 TERMINATED
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
Cogent Biosciences, Inc.
NCT04464889 WITHDRAWN
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Medigene AG
NCT03403725 TERMINATED
MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study
Menarini Group
NCT02374333 COMPLETED
Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy
University of Pennsylvania
NCT03018223 COMPLETED
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
H. Lee Moffitt Cancer Center and Research Institute
NCT01767766 COMPLETED
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
TG Therapeutics, Inc.
NCT01728207 TERMINATED
Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL
Gilead Sciences
NCT03383055 COMPLETED
CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig
Masonic Cancer Center, University of Minnesota
NCT01953692 COMPLETED
A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)
Merck Sharp & Dohme LLC
NCT01594229 COMPLETED
A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
AbbVie
NCT02594267 COMPLETED
A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)
Acrotech Biopharma Inc.
NCT03892525 TERMINATED
Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma
The Lymphoma Academic Research Organisation
NCT02973113 COMPLETED
Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)
Baylor College of Medicine
NCT02432235 COMPLETED
Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma
ADC Therapeutics S.A.
NCT00794638 COMPLETED
A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma
SymBio Pharmaceuticals
NCT01822509 COMPLETED
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
National Cancer Institute (NCI)
NCT03885947 COMPLETED
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
Alla Keyzner
NCT02669017 COMPLETED
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
ADC Therapeutics S.A.
NCT02129582 COMPLETED
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
NCT03205176 COMPLETED
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
AstraZeneca
NCT01742988 COMPLETED
Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma
Curis, Inc.
NCT03283202 COMPLETED
Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors
Celgene
NCT03212937 COMPLETED
Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma
National Cancer Centre, Singapore
NCT02187133 COMPLETED
Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
University of California, San Francisco
NCT03605589 WITHDRAWN
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
Children's Hospital Medical Center, Cincinnati
NCT04292626 COMPLETED
Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose
Tomsk National Research Medical Center of the Russian Academy of Sciences
NCT03003039 COMPLETED
A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma
Nanjing Yoko Biomedical Co., Ltd.
NCT03722186 SUSPENDED
Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies
Jiangsu HengRui Medicine Co., Ltd.
NCT02242045 COMPLETED
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
Gilead Sciences
NCT01088048 COMPLETED
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Gilead Sciences
NCT01659255 COMPLETED
Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL
Gilead Sciences
NCT03415399 COMPLETED
Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma
Eureka Therapeutics Inc.
NCT03381768 COMPLETED
Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma
Lars Møller Pedersen
NCT01169532 COMPLETED
Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma
Fox Chase Cancer Center
NCT03489369 COMPLETED
Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Symphogen A/S
NCT01878890 COMPLETED
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
Institut Bergonié
NCT01713582 COMPLETED
A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT03601819 TERMINATED
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
University of Michigan Rogel Cancer Center
NCT02593045 COMPLETED
Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)
Innate Pharma
NCT04702503 COMPLETED
Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)
Moleculin Biotech, Inc.
NCT02423915 COMPLETED
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention
M.D. Anderson Cancer Center
NCT04564040 COMPLETED
A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole
AstraZeneca
NCT00622258 COMPLETED
A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Novartis Pharmaceuticals
NCT01634763 COMPLETED
Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
Novartis Pharmaceuticals
NCT01854606 COMPLETED
Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
Novartis Pharmaceuticals
NCT01402440 TERMINATED
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Novartis Pharmaceuticals
NCT01772797 COMPLETED
Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer
Novartis Pharmaceuticals
NCT01643603 TERMINATED
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Barbara Ann Karmanos Cancer Institute
NCT01300611 TERMINATED
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation
Tarix Pharmaceuticals
NCT01275209 COMPLETED
Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma
Novartis Pharmaceuticals
NCT02900716 COMPLETED
Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas
Zhejiang DTRM Biopharma
NCT02581878 COMPLETED
Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma
Bayer
NCT02483000 TERMINATED
Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies
Fred Hutchinson Cancer Center
NCT02580552 COMPLETED
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL
miRagen Therapeutics, Inc.
NCT00691210 COMPLETED
Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies
Columbia University
NCT02181218 COMPLETED
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
Washington University School of Medicine
NCT03688152 COMPLETED
A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma
Incyte Corporation
NCT01943682 COMPLETED
Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma
Children's Hospital Medical Center, Cincinnati
NCT04230330 WITHDRAWN
Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma
National Cancer Centre, Singapore
NCT03538028 COMPLETED
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Biosciences International Sàrl
NCT02541565 COMPLETED
Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma
University of Washington
NCT01432951 COMPLETED
A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma
Eli Lilly and Company
NCT03316144 COMPLETED
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma
Shanghai Junshi Bioscience Co., Ltd.
NCT03888534 WITHDRAWN
Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)
Millennium Pharmaceuticals, Inc.
NCT03925428 WITHDRAWN
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas
National Cancer Institute (NCI)
NCT02945215 COMPLETED
A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients
Innovent Biologics (Suzhou) Co. Ltd.
NCT01593696 COMPLETED
Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
National Cancer Institute (NCI)
NCT02343536 COMPLETED
A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma
Celgene
NCT01953783 COMPLETED
Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB
Millennium Pharmaceuticals, Inc.
NCT03834584 TERMINATED
A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma
Agios Pharmaceuticals, Inc.
NCT02014129 COMPLETED
A Study of LY2835219 in Japanese Participants With Advanced Cancer
Eli Lilly and Company
NCT00674427 TERMINATED
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant
University of Pennsylvania
NCT04233697 WITHDRAWN
Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
Columbia University
NCT01561833 COMPLETED
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
Yale University
NCT01542918 COMPLETED
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
James Rubenstein
NCT01403948 COMPLETED
BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
Boehringer Ingelheim
NCT01388335 COMPLETED
A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin
Eli Lilly and Company
NCT01902225 COMPLETED
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
Weiyun Ai
NCT03027284 COMPLETED
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
Eli Lilly and Company
NCT02223052 COMPLETED
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
NCT01916135 COMPLETED
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
Memorial Sloan Kettering Cancer Center
NCT02603419 TERMINATED
Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)
Pfizer
NCT01155817 COMPLETED
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Stanford University
NCT00860171 TERMINATED
Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
NCT02776813 COMPLETED
Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma
Cogent Biosciences, Inc.
NCT01307267 COMPLETED
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Pfizer
NCT01609816 TERMINATED
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute
NCT02082626 TERMINATED
Study of Eribulin in Children With Cancer to Determine Safety
University of Oklahoma
NCT03483688 COMPLETED
A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects
Peking Union Medical College Hospital
NCT01491841 COMPLETED
IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma
Anne Beaven, MD
NCT01742793 TERMINATED
An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)
Yale University
NCT03106428 COMPLETED
A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies
MedImmune LLC
NCT02603445 COMPLETED
Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL
Novartis Pharmaceuticals
NCT04279938 WITHDRAWN
A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL
Royal Marsden NHS Foundation Trust
NCT03217253 WITHDRAWN
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
National Cancer Institute (NCI)
NCT02576665 TERMINATED
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Tocagen Inc.
NCT01447056 COMPLETED
Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases
Baylor College of Medicine
NCT04043845 WITHDRAWN
ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies
Dana-Farber Cancer Institute
NCT02800889 WITHDRAWN
Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer
CTI BioPharma
NCT02220842 COMPLETED
A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Hoffmann-La Roche
NCT01789723 WITHDRAWN
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
Acrotech Biopharma Inc.
NCT01887587 TERMINATED
Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia
Ehab L Atallah
NCT02274506 WITHDRAWN
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
M.D. Anderson Cancer Center
NCT01222780 COMPLETED
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
Acrotech Biopharma Inc.
NCT02567656 COMPLETED
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
Rhizen Pharmaceuticals SA
NCT03670888 TERMINATED
A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients
JHL Biotech, Inc.
NCT01839097 COMPLETED
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Acrotech Biopharma Inc.
NCT03119467 TERMINATED
Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas
Rhizen Pharmaceuticals SA
NCT01969695 COMPLETED
An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma
AbbVie
NCT01134341 COMPLETED
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Acrotech Biopharma Inc.
NCT01445522 COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer
National Cancer Institute (NCI)
NCT00973804 TERMINATED
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders
National Cancer Institute (NCI)
NCT00861510 COMPLETED
A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
National Heart, Lung, and Blood Institute (NHLBI)
NCT02391480 COMPLETED
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
AbbVie
NCT02228772 COMPLETED
Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults
Massachusetts General Hospital
NCT01324323 COMPLETED
Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
Celgene
NCT01324310 COMPLETED
Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
Celgene
NCT00674024 COMPLETED
Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function
National Cancer Institute (NCI)
NCT00652626 COMPLETED
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
Celgene
NCT02518958 COMPLETED
A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab
EpicentRx, Inc.
NCT01169298 COMPLETED
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma
Celgene
NCT01351935 COMPLETED
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Celgene
NCT00761722 COMPLETED
Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma
Celgene
NCT02006485 COMPLETED
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
TG Therapeutics, Inc.
NCT01729104 TERMINATED
Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
NCT02167958 COMPLETED
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Rafic Farah, MD
NCT01429025 COMPLETED
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
NCT00688415 COMPLETED
Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer
Celgene
NCT03575078 WITHDRAWN
ARQ761 + PARP Inhibitor in Refractory Solid Tumors
University of Texas Southwestern Medical Center
NCT02259010 COMPLETED
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Millennium Pharmaceuticals, Inc.
NCT02614508 TERMINATED
Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Emory University
NCT02453087 COMPLETED
A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
NCT01738594 TERMINATED
Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
Northwestern University
NCT01287104 COMPLETED
A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias
National Cancer Institute (NCI)
NCT01055496 COMPLETED
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Pfizer
NCT01363817 COMPLETED
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Bristol-Myers Squibb
NCT02950220 COMPLETED
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Kami Maddocks
NCT01699152 COMPLETED
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Tragara Pharmaceuticals, Inc.
NCT02809573 COMPLETED
Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients
Chipscreen Biosciences, Ltd.
NCT03074825 TERMINATED
Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma
Chipscreen Biosciences, Ltd.
NCT01722305 COMPLETED
Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma
Mayo Clinic
NCT01111188 TERMINATED
Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma
Weill Medical College of Cornell University
NCT01898078 COMPLETED
Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas
Millennium Pharmaceuticals, Inc.
NCT02106091 TERMINATED
Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL
Affimed GmbH
NCT00880815 COMPLETED
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
NCT00697346 COMPLETED
Study of MLN8237 in Participants With Advanced Hematological Malignancies
Millennium Pharmaceuticals, Inc.
NCT01800838 COMPLETED
Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma
Kevin Cooper MD
NCT01164709 COMPLETED
Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
Swiss Cancer Institute
NCT01962532 COMPLETED
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma
Janssen Research & Development, LLC
NCT03373305 WITHDRAWN
Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas
City of Hope Medical Center
NCT03558750 TERMINATED
Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma
Vanderbilt-Ingram Cancer Center
NCT02145559 COMPLETED
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
University of Chicago
NCT01844583 COMPLETED
Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
Millennium Pharmaceuticals, Inc.
NCT01370694 TERMINATED
Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)
Merck Sharp & Dohme LLC
NCT00724971 COMPLETED
Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab
Pfizer
NCT02745769 COMPLETED
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
Eli Lilly and Company
NCT02269085 TERMINATED
Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
NCT02549651 COMPLETED
MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)
MedImmune LLC
NCT01588678 COMPLETED
A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
Daiichi Sankyo
NCT02076451 COMPLETED
Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas
Daiichi Sankyo
NCT02679196 COMPLETED
The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma
Karus Therapeutics Limited
NCT01897012 COMPLETED
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
National Cancer Institute (NCI)
NCT01634217 COMPLETED
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation
Masonic Cancer Center, University of Minnesota
NCT02976857 COMPLETED
A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects
Shanghai AbelZeta Ltd.
NCT02963389 COMPLETED
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients
Dong-A ST Co., Ltd.
NCT02657447 WITHDRAWN
Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
Nordic Nanovector
NCT02240719 COMPLETED
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
University of California, Davis
NCT02378922 WITHDRAWN
Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
Fred Hutchinson Cancer Center
NCT01078649 COMPLETED
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas
Debiopharm International SA
NCT02061449 TERMINATED
Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
NYU Langone Health
NCT02454270 TERMINATED
A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies
Janssen Research & Development, LLC
NCT03349346 WITHDRAWN
Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents
Gilead Sciences
NCT00923520 COMPLETED
A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies
National Cancer Institute (NCI)
NCT01401530 COMPLETED
E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Eisai Co., Ltd.
NCT02343666 WITHDRAWN
HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection
Fred Hutchinson Cancer Center
NCT02214147 COMPLETED
Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function
Millennium Pharmaceuticals, Inc.
NCT01714947 COMPLETED
Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib
Millennium Pharmaceuticals, Inc.
NCT01185548 TERMINATED
A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma
Eli Lilly and Company
NCT01240577 COMPLETED
An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients With Advanced Solid Tumors and Lymphomas
National Cancer Institute (NCI)
NCT01342289 COMPLETED
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01900496 TERMINATED
Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02055924 TERMINATED
Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas
The Lymphoma Academic Research Organisation
NCT01986426 COMPLETED
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab
Lytix Biopharma AS
NCT01794104 COMPLETED
Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas
National Cancer Institute (NCI)
NCT01590732 COMPLETED
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma
M.D. Anderson Cancer Center
NCT02602067 TERMINATED
131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients
sigma-tau i.f.r. S.p.A.
NCT02728700 TERMINATED
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
Stanford University
NCT01950273 COMPLETED
Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma
Boehringer Ingelheim
NCT00779584 COMPLETED
A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248)
Merck Sharp & Dohme LLC
NCT02702141 TERMINATED
A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma
Seagen Inc.
NCT02780011 WITHDRAWN
Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies
Eric Bernicker, MD
NCT01933516 COMPLETED
GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma
Sandoz
NCT01484015 COMPLETED
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Wake Forest University Health Sciences
NCT02071888 COMPLETED
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
Calithera Biosciences, Inc
NCT01910428 TERMINATED
L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL
ERYtech Pharma
NCT02168907 TERMINATED
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Wake Forest University Health Sciences
NCT01129193 COMPLETED
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma
Amir Mortazavi
NCT00963274 COMPLETED
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Virginia Commonwealth University
NCT01567709 COMPLETED
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
National Cancer Institute (NCI)
NCT01729806 COMPLETED
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
National Cancer Institute (NCI)
NCT03369964 WITHDRAWN
A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Hoffmann-La Roche
NCT01832922 COMPLETED
BR in Patients With CLL With Comorbidities and/or Renal Dysfunction
Dartmouth-Hitchcock Medical Center
NCT00909948 TERMINATED
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
Massachusetts General Hospital
NCT01766583 COMPLETED
A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma
The Lymphoma Academic Research Organisation
NCT03168035 COMPLETED
Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma
NanoCarrier Co., Ltd.
NCT02578511 WITHDRAWN
Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)
Ehab L Atallah
NCT03422874 WITHDRAWN
Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
Dartmouth-Hitchcock Medical Center
NCT01805375 COMPLETED
A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies
Cancer Research UK
NCT01460134 COMPLETED
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
Celldex Therapeutics
NCT01838434 COMPLETED
Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
NCT01644799 COMPLETED
Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
Alliance for Clinical Trials in Oncology
NCT02219737 COMPLETED
Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
National Cancer Institute (NCI)
NCT01400685 COMPLETED
Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL
Massachusetts General Hospital
NCT02142530 COMPLETED
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
Massachusetts General Hospital
NCT03205891 WITHDRAWN
Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas
M.D. Anderson Cancer Center
NCT01929941 TERMINATED
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
Incyte Corporation
NCT02200848 TERMINATED
Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Georgetown University
NCT00787969 COMPLETED
Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
NCT01534715 COMPLETED
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
ImmunoGen, Inc.
NCT02130869 COMPLETED
A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas
St. Jude Children's Research Hospital
NCT02875002 WITHDRAWN
Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas
Yale University
NCT02057445 COMPLETED
3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma
New York Medical College
NCT00889408 COMPLETED
DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma
Masonic Cancer Center, University of Minnesota
NCT00725062 TERMINATED
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
NCT00667082 COMPLETED
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Celgene
NCT01969669 COMPLETED
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199
AbbVie
NCT02700022 TERMINATED
A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas
UNC Lineberger Comprehensive Cancer Center
NCT00742144 COMPLETED
Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia
GlaxoSmithKline
NCT01454076 COMPLETED
Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma
Millennium Pharmaceuticals, Inc.
NCT01473095 COMPLETED
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCT01581541 TERMINATED
PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment
National Cancer Institute (NCI)
NCT00659425 COMPLETED
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
MedImmune LLC
NCT01254578 COMPLETED
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
National Cancer Institute (NCI)
NCT01926665 COMPLETED
Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)
M.D. Anderson Cancer Center
NCT01399840 COMPLETED
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Pfizer
NCT01569750 COMPLETED
A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma
Janssen Research & Development, LLC
NCT01334502 COMPLETED
Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma
Alliance for Clinical Trials in Oncology
NCT01362452 COMPLETED
Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells
M.D. Anderson Cancer Center
NCT01551628 TERMINATED
A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma
Bio-Cancer Treatment International Limited
NCT01236586 WITHDRAWN
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
National Cancer Institute (NCI)
NCT00644072 COMPLETED
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas
National Cancer Institute (NCI)
NCT01132911 COMPLETED
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
National Cancer Institute (NCI)
NCT01309789 COMPLETED
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
Seagen Inc.
NCT01317901 COMPLETED
A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma
Aptevo Therapeutics
NCT00614042 COMPLETED
Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma
Aptevo Therapeutics
NCT01290549 COMPLETED
A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma
Genentech, Inc.
NCT00513474 COMPLETED
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Massachusetts General Hospital
NCT03057418 COMPLETED
Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim
Biointegrator LLC
NCT02595242 WITHDRAWN
Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NCT01610999 TERMINATED
Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation
Tufts Medical Center
NCT01471067 COMPLETED
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
M.D. Anderson Cancer Center
NCT01226849 COMPLETED
Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma
Singapore General Hospital
NCT01900509 COMPLETED
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies
St. Jude Children's Research Hospital
NCT01831505 COMPLETED
Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents
Presage Biosciences
NCT02598570 COMPLETED
Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma
AbbVie
NCT01991938 TERMINATED
Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
Verastem, Inc.
NCT02697552 COMPLETED
Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma
HUYABIO International, LLC.
NCT01032148 TERMINATED
Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Roswell Park Cancer Institute
NCT00741403 COMPLETED
A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
Cornerstone Pharmaceuticals
NCT01555853 TERMINATED
Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma
Washington University School of Medicine
NCT01908413 TERMINATED
Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma
Curis, Inc.
NCT01745354 TERMINATED
Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)
Robert Lowsky
NCT00825149 COMPLETED
A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
Hoffmann-La Roche
NCT00930514 COMPLETED
A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma
Hoffmann-La Roche
NCT00854152 COMPLETED
A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma
Genentech, Inc.
NCT00876122 COMPLETED
A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
Genentech, Inc.
NCT00854126 COMPLETED
A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma
Genentech, Inc.
NCT00901069 COMPLETED
Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma
Shams Shakil
NCT01829971 TERMINATED
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
Mirna Therapeutics, Inc.
NCT02780830 WITHDRAWN
AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
AstraZeneca
NCT01527838 COMPLETED
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit
Fate Therapeutics
NCT00891592 COMPLETED
Umbilical Cord Blood Transplant for Hematological Malignancies
University of Pennsylvania
NCT02640833 WITHDRAWN
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
AbbVie
NCT01871675 COMPLETED
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
SCRI Development Innovations, LLC
NCT01284192 COMPLETED
Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)
Astellas Pharma Inc
NCT02017613 COMPLETED
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies
Rhizen Pharmaceuticals SA
NCT01535989 COMPLETED
Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma
Cristiana Sessa
NCT01950364 COMPLETED
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Millennium Pharmaceuticals, Inc.
NCT01212380 COMPLETED
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
Ohio State University Comprehensive Cancer Center
NCT00644124 COMPLETED
Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma
Sanofi
NCT01680991 COMPLETED
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
Hoffmann-La Roche
NCT01410513 COMPLETED
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
Sanofi
NCT01433731 COMPLETED
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
TetraLogic Pharmaceuticals
NCT01169584 COMPLETED
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
Jennerex Biotherapeutics
NCT01748721 COMPLETED
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Morphotek
NCT02532192 WITHDRAWN
A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma
M.D. Anderson Cancer Center
NCT01049113 TERMINATED
Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia
Traws Pharma, Inc.
NCT01276717 COMPLETED
Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma
University of Rochester
NCT01045928 TERMINATED
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Case Comprehensive Cancer Center
NCT01321346 COMPLETED
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
NCT01421173 COMPLETED
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
M.D. Anderson Cancer Center
NCT01076556 TERMINATED
Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
NCT00893464 COMPLETED
A Study of IXAZOMIB in Adult Patients With Lymphoma
Millennium Pharmaceuticals, Inc.
NCT01126502 TERMINATED
Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
National Cancer Institute (NCI)
NCT01588548 COMPLETED
Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma
AstraZeneca
NCT00671112 TERMINATED
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Brian Hill, MD, PhD
NCT02258555 TERMINATED
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
Gilead Sciences
NCT00916630 COMPLETED
Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)
Massachusetts General Hospital
NCT02109224 TERMINATED
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
National Cancer Institute (NCI)
NCT01658319 COMPLETED
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
Case Comprehensive Cancer Center
NCT01435863 COMPLETED
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)
Solasia Pharma K.K.
NCT01908387 TERMINATED
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
Celgene Corporation
NCT01403415 COMPLETED
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
NCT00608361 COMPLETED
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
National Cancer Institute (NCI)
NCT00963495 TERMINATED
Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy
University Health Network, Toronto
NCT00720135 COMPLETED
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT00800150 TERMINATED
Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment
City of Hope Medical Center
NCT01602289 COMPLETED
A Study of LY2875358 in Japanese Participants With Advanced Cancer
Eli Lilly and Company
NCT01344876 COMPLETED
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
Otsuka Pharmaceutical Co., Ltd.
NCT01846429 TERMINATED
Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain
H. Lee Moffitt Cancer Center and Research Institute
NCT00771472 COMPLETED
Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)
Merck Sharp & Dohme LLC
NCT00735930 COMPLETED
Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
NCT00694590 COMPLETED
Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Genzyme, a Sanofi Company
NCT00864942 COMPLETED
Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
Georgetown University
NCT01120457 COMPLETED
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
Bristol-Myers Squibb
NCT01650727 COMPLETED
A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)
Merck Sharp & Dohme LLC
NCT01015911 COMPLETED
A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma
Seagen Inc.
NCT00655837 COMPLETED
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
Seagen Inc.
NCT00649584 TERMINATED
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
Seagen Inc.
NCT00968656 COMPLETED
Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1
Washington University School of Medicine
NCT01158274 COMPLETED
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
NCT01088763 TERMINATED
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
National Cancer Institute (NCI)
NCT00891137 COMPLETED
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Cellerant Therapeutics
NCT01504776 COMPLETED
Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)
Anand Jillella
NCT01689220 COMPLETED
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea
Solasia Pharma K.K.
NCT02095574 WITHDRAWN
A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma
AbbVie
NCT01005979 TERMINATED
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)
Emory University
NCT02206308 COMPLETED
Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.
Sinocelltech Ltd.
NCT01292135 COMPLETED
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
Pharmacyclics LLC.
NCT01534949 TERMINATED
Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial
Celltrion
NCT00933985 TERMINATED
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
National Cancer Institute (NCI)
NCT01231919 COMPLETED
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
National Cancer Institute (NCI)
NCT00640796 COMPLETED
Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors
St. Jude Children's Research Hospital
NCT01161511 COMPLETED
Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia
Xencor, Inc.
NCT00890747 COMPLETED
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
National Cancer Institute (NCI)
NCT00791011 COMPLETED
Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat
Amgen
NCT01168752 COMPLETED
Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma
Debiopharm International SA
NCT01273090 COMPLETED
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
Children's Oncology Group
NCT00978523 COMPLETED
Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma
Arno Therapeutics
NCT00769288 COMPLETED
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
NCT01068301 COMPLETED
A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation
St. Jude Children's Research Hospital
NCT01479023 TERMINATED
Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors
Washington University School of Medicine
NCT01129180 COMPLETED
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
Pierluigi Porcu
NCT00722488 COMPLETED
Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma
Millennium Pharmaceuticals, Inc.
NCT01205737 COMPLETED
A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects
Teva Branded Pharmaceutical Products R&D, Inc.
NCT00996359 TERMINATED
Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation
University of Medicine and Dentistry of New Jersey
NCT00947388 TERMINATED
Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
Case Comprehensive Cancer Center
NCT00871702 COMPLETED
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease
Washington University School of Medicine
NCT00807677 COMPLETED
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
Millennium Pharmaceuticals, Inc.
NCT00994500 COMPLETED
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
National Cancer Institute (NCI)
NCT01149668 COMPLETED
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
Pharmacyclics LLC.
NCT00659568 COMPLETED
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
London Health Sciences Centre
NCT00944905 COMPLETED
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
Bristol-Myers Squibb
NCT00849654 COMPLETED
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Pharmacyclics LLC.
NCT00962507 COMPLETED
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
City of Hope Medical Center
NCT01345357 COMPLETED
Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma
Cephalon
NCT00891072 COMPLETED
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT01568632 WITHDRAWN
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma
National Cancer Institute (NCI)
NCT00710528 COMPLETED
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
Gilead Sciences
NCT01139359 WITHDRAWN
Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma
Alaunos Therapeutics
NCT00796731 COMPLETED
SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma
Sanofi
NCT00779337 COMPLETED
Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas
Queensland Institute of Medical Research
NCT00647764 COMPLETED
Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas
Esanex Inc.
NCT00741871 COMPLETED
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
S*BIO
NCT00734890 COMPLETED
Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
NCT01452334 WITHDRAWN
Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy
Bristol-Myers Squibb
NCT00935844 COMPLETED
Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma
Millennium Pharmaceuticals, Inc.
NCT00880867 TERMINATED
Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma
Nevada Cancer Institute
NCT00651443 TERMINATED
Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma
Biogen
NCT01021358 COMPLETED
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).
Abbott
NCT01116154 TERMINATED
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT06289673 RECRUITING
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
St. Jude Children's Research Hospital
NCT07218341 RECRUITING
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Eli Lilly and Company
NCT06049134 ACTIVE NOT RECRUITING
Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
M.D. Anderson Cancer Center
NCT06876662 RECRUITING
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Eli Lilly and Company
NCT06876649 RECRUITING
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Eli Lilly and Company
NCT05170399 RECRUITING
Vaccine Responses in Patients With B Cell Malignancies
National Heart, Lung, and Blood Institute (NHLBI)
NCT07355699 RECRUITING
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
Beijing Tongren Hospital
NCT07270835 RECRUITING
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
The First Affiliated Hospital of Soochow University
NCT07264894 NOT YET RECRUITING
ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial
Zhengzhou University
NCT03229200 ACTIVE NOT RECRUITING
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Pharmacyclics Switzerland GmbH
NCT06285370 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy
Kyowa Kirin China Pharmaceutical Co., Ltd.
NCT07016165 RECRUITING
Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
Gadjah Mada University
NCT07046182 ACTIVE NOT RECRUITING
Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight
Zhengzhou University
NCT04460235 RECRUITING
Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma
Poitiers University Hospital
NCT06956092 NOT YET RECRUITING
Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
Zhengzhou University
NCT06665737 NOT YET RECRUITING
Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients
Department of Medical Services Ministry of Public Health of Thailand
NCT05806580 RECRUITING
Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma
Ruijin Hospital
NCT06609304 RECRUITING
Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
Zhengzhou University
NCT05525338 RECRUITING
Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels
University Medical Center Groningen
NCT05814848 NOT YET RECRUITING
A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma
Changhai Hospital
NCT05518383 RECRUITING
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
NCT02858804 COMPLETED
EDOCH Alternating With DHAP for New Diagnosed Younger MCL
Institute of Hematology & Blood Diseases Hospital, China
NCT01909934 COMPLETED
Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Takeda
NCT05442554 COMPLETED
A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma
Takeda
NCT03190330 COMPLETED
A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
Johnson & Johnson Private Limited
NCT05108805 COMPLETED
Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
Vanderbilt-Ingram Cancer Center
NCT01804166 COMPLETED
A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
Janssen Scientific Affairs, LLC
NCT03817853 COMPLETED
An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma
Hoffmann-La Roche
NCT01088750 COMPLETED
Surgery Alone or With CYC VBL and PRED or CVP Alone in Stage IA or IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Christine Mauz-Körholz
NCT03677596 COMPLETED
A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients
Pfizer
NCT04003012 COMPLETED
Pain Control in Pediatric Oncology: Utility of EMLA Cream vs Lidocaine Injection in Lumbar Punctures
CAMC Health System
NCT04349306 COMPLETED
Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia
Sanofi
NCT02323659 TERMINATED
Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas
Polish Lymphoma Research Group
NCT03649334 COMPLETED
Ketamine-ketorolac Versus Fentanyl- Ketorolac I.M in Children During Bone Marrow Biopsy
Mansoura University
NCT01007448 COMPLETED
Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)
Bausch Health Americas, Inc.
NCT03376958 COMPLETED
Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma
Zhengzhou University
NCT01180049 COMPLETED
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Pfizer
NCT02095951 COMPLETED
Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection
Children's Hospital of Michigan
NCT01569724 COMPLETED
Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma
Rennes University Hospital
NCT02487316 WITHDRAWN
A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib
Jun Zhu
NCT01841814 WITHDRAWN
Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy
Centre Hospitalier Universitaire, Amiens
NCT02805218 COMPLETED
PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
NCT01658280 COMPLETED
Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration for the Diagnosis of Hilar/Mediastinal Lymphadenopathies
Azienda Ospedaliero, Universitaria Ospedali Riuniti
NCT00808171 COMPLETED
Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture
Federal University of Minas Gerais
NCT01164475 COMPLETED
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms
Genzyme, a Sanofi Company
NCT00969462 COMPLETED
Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma
Meir Medical Center
NCT00926757 COMPLETED
Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B
Taipei Veterans General Hospital, Taiwan
Full Non-Hodgkin Lymphoma Pipeline
Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.
Unlock with ProData: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only